View Filing Data

Portions of the registrant’s proxy statement pursuant to Regulation 14A relating to its 2020 Annual General Meeting, to be filed with the Securities and Exchange Commission subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the conclusion of the registrant’s fiscal year ended December 31, 2019.

Amendment Flag

false

Document Fiscal Year Focus

2019

Document Fiscal Period Focus

Entity Central Index Key

0001593034

Current Fiscal Year End Date

--12-31

Entity Public Float

$ 670,135,609

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 1,454,531	$ 1,149,113
Restricted cash and cash equivalents	247,457	305,368
Accounts receivable, net	467,953	470,570
Inventories, net	327,865	322,179
Prepaid expenses and other current assets	40,845	56,139
Income taxes receivable	47,567	39,781
Total current assets	2,586,218	2,343,150
PROPERTY, PLANT AND EQUIPMENT, NET	504,865	498,892
OPERATING LEASE ASSETS	51,700	0
GOODWILL	3,595,184	3,764,636
OTHER INTANGIBLES, NET	2,571,267	3,457,306
DEFERRED INCOME TAXES	2,192	678
OTHER ASSETS	78,101	67,731
TOTAL ASSETS	9,389,527	10,132,393
CURRENT LIABILITIES:
Accounts payable and accrued expenses	899,949	1,009,200
Current portion of legal settlement accrual	513,005	905,085
Current portion of operating lease liabilities	10,763	0
Current portion of long-term debt	34,150	34,150
Income taxes payable	2,422	1,661
Total current liabilities	1,460,289	1,950,096
DEFERRED INCOME TAXES	31,703	34,487
LONG-TERM DEBT, LESS CURRENT PORTION, NET	8,359,899	8,224,269
OPERATING LEASE LIABILITIES, LESS CURRENT PORTION	48,299	0
OTHER LIABILITIES	355,881	421,824
COMMITMENTS AND CONTINGENCIES (NOTE 15)
SHAREHOLDERS' DEFICIT:
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both December 31, 2019 and December 31, 2018	45	46
Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 226,802,609 and 224,382,791 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively	23	22
Additional paid-in capital	8,904,692	8,855,810
Accumulated deficit	(9,552,214)	(9,124,932)
Accumulated other comprehensive loss	(219,090)	(229,229)
Total equity	(866,544)	(498,283)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 9,389,527	$ 10,132,393

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Euro deferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Euro deferred shares, shares authorized (in shares)	4,000,000	4,000,000
Euro deferred shares, shares issued (in shares)	4,000,000	4,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	226,802,609	224,382,791
Common stock, shares outstanding (in shares)	226,802,609	224,382,791

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
TOTAL REVENUES, NET	$ 2,914,364	$ 2,947,078	$ 3,468,858
COSTS AND EXPENSES:
Cost of revenues	1,569,338	1,631,682	2,228,530
Selling, general and administrative	632,420	646,037	629,874
Research and development	130,732	185,826	172,067
Litigation-related and other contingencies, net	11,211	13,809	185,990
Asset impairment charges	526,082	916,939	1,154,376
Acquisition-related and integration items, net	(46,098)	21,914	58,086
Interest expense, net	538,734	521,656	488,228
(Gain) loss on extinguishment of debt	(119,828)	0	51,734
Other expense (income), net	16,677	(51,953)	(17,023)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX	(344,904)	(938,832)	(1,483,004)
INCOME TAX EXPENSE (BENEFIT)	15,680	22,935	(250,293)
LOSS FROM CONTINUING OPERATIONS	(360,584)	(961,767)	(1,232,711)
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3)	(62,052)	(69,702)	(802,722)
NET LOSS	$ (422,636)	$ (1,031,469)	$ (2,035,433)
NET LOSS PER SHARE—BASIC:
Continuing operations (in dollars per share)	$ (1.60)	$ (4.29)	$ (5.52)
Discontinued operations (in dollars per share)	(0.27)	(0.32)	(3.60)
Basic (in dollars per share)	(1.87)	(4.61)	(9.12)
NET LOSS PER SHARE—DILUTED:
Continuing operations (in dollars per share)	(1.60)	(4.29)	(5.52)
Discontinued operations (in dollars per share)	(0.27)	(0.32)	(3.60)
Diluted (in dollars per share)	$ (1.87)	$ (4.61)	$ (9.12)
WEIGHTED AVERAGE SHARES:
Basic (in shares)	226,050	223,960	223,198
Diluted (in shares)	226,050	223,960	223,198

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net loss	$ (422,636)	$ (1,031,469)	$ (2,035,433)
Net unrealized loss on securities:
Unrealized loss arising during the period			(515)
Less: reclassification adjustments for gain realized in net loss	0	0	0
Unrealized loss on securities	0	0	(515)
Net unrealized gain (loss) on foreign currency:
Foreign currency translation gain (loss) arising during the period	10,139	(19,408)	31,202
Less: reclassification adjustments for loss realized in net loss	0	0	112,926
Foreign currency translation gain (loss)	10,139	(19,408)	144,128
OTHER COMPREHENSIVE INCOME (LOSS)	10,139	(19,408)	143,613
COMPREHENSIVE LOSS	$ (412,497)	$ (1,050,877)	$ (1,891,820)

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Ordinary Shares	Euro Deferred Shares	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	$ 2,701,589	$ 22	$ 42	$ 8,743,240	$ (5,688,281)	$ (353,434)
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2016		222,954,175	4,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	484,880	$ 22	$ 48	8,791,170	(8,096,539)	(209,821)
Net loss	(2,035,433)				(2,035,433)
Other comprehensive income (loss)	143,613					143,613
Compensation related to share-based awards	50,149			50,149
Ordinary shares issued (in shares)		377,531
Ordinary shares issued	0
Tax withholding for restricted shares	(2,078)			(2,078)
Other	(135)		$ 6	(141)
Shareholders' equity, ending balance (in shares) at Dec. 31, 2017		223,331,706	4,000,000
Shareholders' equity, ending balance at Dec. 31, 2017	484,880	$ 22	$ 48	8,791,170	(8,096,539)	(209,821)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	484,880	22	48	8,791,170	(8,096,539)	(209,821)
Shareholders' equity, beginning balance	(498,283)	$ 22	46	8,855,810	(9,124,932)	(229,229)
Net loss	(1,031,469)				(1,031,469)
Other comprehensive income (loss)	(19,408)					(19,408)
Compensation related to share-based awards	$ 54,071			54,071
Exercise of options (in shares)	94,392	94,392
Exercise of options	$ 933			933
Ordinary shares issued (in shares)		956,693
Ordinary shares issued	0
LTCI modification	14,936			14,936
Tax withholding for restricted shares	(5,375)			(5,375)
Other	73		$ (2)	75
Shareholders' equity, ending balance (in shares) at Dec. 31, 2018		224,382,791	4,000,000
Shareholders' equity, ending balance at Dec. 31, 2018	(498,283)	$ 22	$ 46	8,855,810	(9,124,932)	(229,229)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	(498,283)	22	46	8,855,810	(9,124,932)	(229,229)
Shareholders' equity, beginning balance	(866,544)	$ 23	45	8,904,692	(9,552,214)	(219,090)
Net loss	(422,636)				(422,636)
Other comprehensive income (loss)	10,139					10,139
Compensation related to share-based awards	$ 59,142			59,142
Exercise of options (in shares)	557	557
Exercise of options	$ 4			4
Ordinary shares issued (in shares)		2,419,261
Ordinary shares issued	0
Tax withholding for restricted shares	(10,156)			(10,156)
Other	(108)	$ 1	$ (1)	(108)		0
Shareholders' equity, ending balance (in shares) at Dec. 31, 2019		226,802,609	4,000,000
Shareholders' equity, ending balance at Dec. 31, 2019	(866,544)	$ 23	$ 45	8,904,692	(9,552,214)	(219,090)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shareholders' equity, beginning balance	$ (866,544)	$ 23	$ 45	$ 8,904,692	$ (9,552,214)	$ (219,090)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
OPERATING ACTIVITIES:
Net loss	$ (422,636)	$ (1,031,469)	$ (2,035,433)
Adjustments to reconcile Net loss to Net cash provided by operating activities:
Depreciation and amortization	612,862	723,707	983,765
Inventory step-up	0	261	390
Share-based compensation	59,142	54,071	50,149
Amortization of debt issuance costs and discount	18,107	20,514	22,694
Deferred income taxes	(5,561)	5,557	(156,129)
Change in fair value of contingent consideration	(46,098)	19,910	49,949
(Gain) loss on extinguishment of debt	(119,828)	0	51,734
Asset impairment charges	526,082	916,939	1,154,376
Gain on sale of business and other assets	(6,367)	(45,155)	(13,809)
Changes in assets and liabilities which provided (used) cash:
Accounts receivable	19,158	17,090	484,710
Inventories	(27,139)	67,269	147,189
Prepaid and other assets	11,370	(12,797)	5,345
Accounts payable, accrued expenses and other liabilities	(525,746)	(425,336)	(87,944)
Income taxes payable/receivable, net	4,706	(43,291)	(103,001)
Net cash provided by operating activities	98,052	267,270	553,985
INVESTING ACTIVITIES:
Purchases of property, plant and equipment, excluding capitalized interest	(63,854)	(83,398)	(125,654)
Capitalized interest payments	(3,833)	(3,549)	0
Decrease in notes receivable	0	0	7,000
Product acquisition costs and license fees	0	(3,000)	0
Proceeds from sale of business and other assets, net	6,577	70,369	223,237
Other investing activities	912	1,678	0
Net cash (used in) provided by investing activities	(60,198)	(17,900)	104,583
FINANCING ACTIVITIES:
Proceeds from issuance of notes, net	1,483,125	0	300,000
Proceeds from issuance of term loans	0	0	3,415,000
Repayments of notes	(1,501,788)	0	0
Repayments of term loans	(34,152)	(34,150)	(3,730,951)
Proceeds from draw of revolving debt	300,000	0	0
Repayments of other indebtedness	(9,196)	(5,222)	(6,154)
Payments for debt issuance and extinguishment costs	(6,414)	0	(57,773)
Payments for contingent consideration	(16,822)	(37,758)	(85,037)
Payments of tax withholding for restricted shares	(10,156)	(5,375)	(2,078)
Proceeds from exercise of options	4	933	0
Net cash provided by (used in) financing activities	204,601	(81,572)	(166,993)
Effect of foreign exchange rate	1,096	(1,975)	2,515
Movement in cash held for sale	0	0	11,744
NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	243,551	165,823	505,834
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	1,476,837	1,311,014	805,180
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	1,720,388	1,476,837	1,311,014
SUPPLEMENTAL INFORMATION:
Cash paid for interest, excluding capitalized interest	559,528	515,042	467,017
Cash paid for income taxes	14,875	17,639	28,675
Cash paid into Qualified Settlement Funds for mesh legal settlements	253,520	336,648	668,306
Cash paid out of Qualified Settlement Funds for mesh legal settlements	314,266	353,032	632,176
Other cash distributions for mesh legal settlements	$ 15,330	$ 25,222	$ 19,243

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1. DESCRIPTION OF BUSINESS Endo International plc is an Ireland-domiciled specialty branded and generics pharmaceutical company that conducts business through its operating subsidiaries. Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our” or “us” refer to financial information and transactions of Endo International plc and its subsidiaries. The accompanying Consolidated Financial Statements of Endo International plc and its subsidiaries have been prepared in accordance with U.S. GAAP.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Significant Accounting Policies

Consolidation and Basis of Presentation. The Consolidated Financial Statements include the accounts of wholly-owned subsidiaries after the elimination of intercompany accounts and transactions.

Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

Use of Estimates. The preparation of our Consolidated Financial Statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts and disclosures in our Consolidated Financial Statements, including the notes thereto, and elsewhere in this report. For example, we are required to make significant estimates and assumptions related to revenue recognition, including sales deductions, long-lived assets, goodwill, other intangible assets, income taxes, contingencies, financial instruments and share-based compensation, among others. Some of these estimates can be subjective and complex. Although we believe that our estimates and assumptions are reasonable, there may be other reasonable estimates or assumptions that differ significantly from ours. Further, our estimates and assumptions are based upon information available at the time they were made. Actual results may differ significantly from our estimates.

We regularly evaluate our estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Market conditions, such as illiquid credit markets, volatile equity markets, dramatic fluctuations in foreign currency rates and economic downturn, can increase the uncertainty already inherent in our estimates and assumptions. We also are subject to other risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our Consolidated Financial Statements on a prospective basis.

Customer, Product and Supplier Concentration. We primarily sell our branded and generic products to wholesalers, retail drug store chains, supermarket chains, mass merchandisers, distributors, mail order accounts, hospitals and government agencies. Our wholesalers and distributors purchase products from us and, in turn, supply products to retail drug store chains, independent pharmacies and MCOs. Customers in the managed care market include health maintenance organizations, nursing homes, hospitals, clinics, pharmacy benefit management companies and mail order customers. Total revenues from direct customers that accounted for 10% or more of our total consolidated revenues during the years ended December 31, 2019, 2018 and 2017 are as follows:



	2019		2018		2017
AmerisourceBergen Corporation	34	%	32	%	25	%
McKesson Corporation	26	%	27	%	25	%
Cardinal Health, Inc.	25	%	26	%	25	%

Revenues from these customers are included within each of our segments.

VASOSTRICT^® accounted for 18%, 15% and 12% of our 2019, 2018 and 2017 total revenues, respectively. XIAFLEX^® accounted for 11% of our 2019 total revenues. No other products accounted for 10% or more of our total revenues during the years ended December 31, 2019, 2018 or 2017.

We have agreements with certain third parties for the manufacture, supply and processing of certain of our existing pharmaceutical products. See Note 15. Commitments and Contingencies for information on material manufacturing, supply and other service agreements.

We are subject to risks and uncertainties associated with these concentrations that could have a material adverse effect on our business, financial condition, results of operations and cash flows in future periods, including in the near term.

Revenue Recognition and Sales Deductions. The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. ASC 606 applies to contracts with commercial substance that establish the payment terms and each party’s rights regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. Under ASC 606, we recognize revenue for contracts meeting these criteria when (or as) we satisfy our performance obligations for such contracts by transferring control of the underlying promised goods or services to our customers. The amount of revenue we recognize reflects our estimate of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for such goods or services. This amount is referred to as the transaction price.

Our revenue consists almost entirely of sales of our products to customers, whereby we ship products to a customer pursuant to a purchase order. For contracts such as these, revenue is recognized when our contractual performance obligations have been fulfilled and control has been transferred to the customer pursuant to the contract’s terms, which is generally upon delivery to the customer. The amount of revenue we recognize is equal to the fixed amount of the transaction price, adjusted for our estimates of a number of significant variable components including, but not limited to, estimates for chargebacks, rebates, sales incentives and allowances, DSA and other fees for services, returns and allowances, which we collectively refer to as sales deductions. The Company utilizes the expected value method when estimating the amount of variable consideration to include in the transaction price with respect to each of the foregoing variable components and the most likely amount method when estimating the amount of variable consideration to include in the transaction price with respect to future potential milestone payments that do not qualify for the sales- and usage-based royalty exception. Variable consideration is included in the transaction price only to the extent that it is probable that a significant revenue reversal will not occur when the uncertainty associated with the variable consideration is resolved. Payment terms for these types of contracts generally fall within 30 to 90 days of invoicing.

At December 31, 2019 and 2018, our reserves for sales deductions totaled $660.3 million and $772.3 million, respectively. These amounts relate primarily to our estimates of unsettled obligations for returns and allowances, rebates and chargebacks. The most significant sales deductions relate to rebates paid under Medicaid and Medicare for the Branded Pharmaceuticals segment, wholesaler chargebacks and rebates for the Sterile Injectables and Generic Pharmaceuticals segments and sales returns for each of these three segments. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below.

Returns and Allowances—Consistent with industry practice, we maintain a return policy that allows our customers to return products within a specified period of time both subsequent to and, in certain cases, prior to the products’ expiration dates. Our return policy generally allows customers to receive credit for expired products within six months prior to expiration and within one year after expiration. Our provision for returns and allowances consists of our estimates for future product returns, pricing adjustments and delivery errors.

Rebates—Our provision for rebates, sales incentives and other allowances can generally be categorized into the following four types:


•	direct rebates;


•	indirect rebates;


•	governmental rebates, including those for Medicaid, Medicare and TRICARE, among others; and


•	managed-care rebates.

We establish contracts with wholesalers, chain stores and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described above. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us.

We are subject to rebates on sales made under governmental and managed-care pricing programs based on relevant statutes with respect to governmental pricing programs and contractual sales terms with respect to managed-care providers and GPOs. For example, we are required to provide a discount on our brand-name products to patients who fall within the Medicare Part D coverage gap, also referred to as the donut hole.

We participate in various federal and state government-managed programs whereby discounts and rebates are provided to participating government entities. For example, Medicaid rebates are amounts owed based upon contractual agreements or legal requirements with public sector (Medicaid) benefit providers after the final dispensing of the product by a pharmacy to a benefit plan participant.

Chargebacks—We market and sell products to both: (i) direct customers including wholesalers, distributors, warehousing pharmacy chains and other direct purchasing groups and (ii) indirect customers including independent pharmacies, non-warehousing chains, MCOs, GPOs and government entities. We enter into agreements with certain of our indirect customers to establish contract pricing for certain products. These indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, we may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, we provide credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler’s invoice price. Such credit is called a chargeback.

Prior to the adoption of ASC 606, the Company accounted for revenue recognition and sales deductions under Accounting Standards Codification Topic 605, Revenue Recognition (ASC 605).

Contract Assets and Contract Liabilities. Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred when that right is conditioned on something other than the passage of time. The Company records revenue and a corresponding contract asset when it fulfills a contractual performance obligation, but must also fulfill one or more additional performance obligations before being entitled to payment. Once the Company’s right to consideration becomes unconditional, the contract asset amount is reclassified as Accounts receivable.

Contract liabilities represent the Company’s obligation to transfer goods or services to a customer. The Company records a contract liability generally upon receipt of consideration in advance of fulfilling one or more of its contractual performance obligations. Upon completing each performance obligation, the corresponding contract liability amount is reversed and revenue is recognized.

Contract assets and liabilities related to rights and obligations arising from a single contract, or a series of contracts combined and accounted for as a single contract, are generally presented on a net basis. Contract assets and liabilities are further described in Note 12. Contract Assets and Liabilities.

R&D. Expenditures for R&D are expensed as incurred. Total R&D expenses include, among other things, the costs of discovery research, preclinical development, early- and late-clinical development and drug formulation, clinical trials, materials, medical support of marketed products and certain upfront and milestone payments. R&D spending also includes enterprise-wide costs which support our overall R&D infrastructure. Property, plant and equipment that are acquired or constructed for R&D activities and that have alternate future uses are capitalized and depreciated over their estimated useful lives on a straight-line basis. Contractual upfront and milestone payments made to third parties are generally: (i) expensed as incurred up to the point of regulatory approval and (ii) capitalized and amortized over the related product’s remaining useful life subsequent to regulatory approval. Amounts capitalized for such payments are included in Other intangibles, net in the Consolidated Balance Sheets.

Cash and Cash Equivalents. The Company considers all highly liquid money market instruments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2019 and 2018, cash equivalents were deposited in financial institutions and consisted almost entirely of immediately available fund balances. The Company maintains its cash deposits and cash equivalents with financial institutions it believes to be well-known and stable.

Restricted Cash and Cash Equivalents. Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are excluded from Cash and cash equivalents in the Consolidated Balance Sheets. For additional information see Note 6. Fair Value Measurements.

Accounts Receivable. Accounts receivable are stated at their net realizable value and the Company maintains an allowance for doubtful accounts against gross accounts receivable. The allowance is not material to the Company’s Consolidated Financial Statements at December 31, 2019 or 2018. In addition, our accounts receivable balance is reduced by certain sales deduction reserves where we have the right of offset with the customer.

Concentrations of Credit Risk. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents, restricted cash equivalents and accounts receivable. From time to time, we invest our excess cash in high-quality, liquid money market instruments maintained by major banks and financial institutions. We have not experienced any losses on our cash equivalents.

We perform ongoing credit evaluations of our customers and generally do not require collateral. We have no history of significant losses from uncollectible accounts. Approximately 88% and 87% of our gross trade accounts receivable balances represent amounts due from three customers (Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen Corporation) at December 31, 2019 and 2018, respectively.

We do not expect our current or future exposures to credit risk to have a significant impact on our operations. However, there can be no assurance that any of these risks will not have an adverse effect on our business.

Inventories. Inventories consist of raw materials, work-in-process and finished goods. Inventory that is in excess of the amount expected to be sold within one year is classified as long-term inventory and is recorded in Other assets in the Consolidated Balance Sheets. The Company capitalizes inventory costs associated with certain products prior to regulatory approval and product launch when it is reasonably certain, based on management’s judgment of future commercial use and net realizable value, that the pre-launch inventories will be saleable. The determination to capitalize is made on a product-by-product basis. The Company could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, a denial or delay of approval by regulatory bodies, a delay in commercialization or other potential factors. Our inventories are stated at the lower of cost or net realizable value.

Cost is determined by the first-in, first-out method. It includes materials, direct labor and an allocation of overhead, but excludes certain period charges and unallocated overheads that are charged to expense in the period in which they are incurred. Unallocated overheads can occur as a consequence of abnormally low production or idle facilities.

Net realizable value is determined by the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. When necessary, we write-down inventories to net realizable value based on forecasted demand and market and regulatory conditions, which may differ from actual results.

Property, Plant and Equipment. Property, plant and equipment is generally stated at cost less accumulated depreciation. Major improvements are capitalized, while routine maintenance and repairs are expensed as incurred. Costs incurred during the construction or development of property, plant and equipment are capitalized as assets under construction. Once an asset has been placed into service, depreciation expense is taken on a straight-line basis over the estimated useful life of the related assets or, in the case of leasehold improvements and finance lease assets, over the shorter of the estimated useful life and the lease term. Depreciation is based on the following estimated useful lives, as of December 31, 2019:



	Range of Useful Lives, from:
Buildings	10 years	to	30 years
Machinery and equipment	1 year	to	15 years
Computer equipment and software	1 year	to	10 years
Furniture and fixtures	1 year	to	10 years

Depreciation expense is not recorded on assets held for sale. Gains and losses on disposals are included in Other expense (income), net in the Consolidated Statements of Operations. As further described below under the heading “Long-Lived Asset Impairment Testing,” our property plant and equipment assets are also subject to impairment reviews.

Computer Software. The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including external direct costs of material and services, and payroll costs for employees directly involved with the software development. Capitalized software costs are included in Property, plant and equipment, net in the Consolidated Balance Sheets and depreciated beginning when the software project is substantially complete and the asset is ready for its intended use. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.

Lease Accounting. The Company adopted ASC 842 on January 1, 2019. For further discussion of the adoption, refer to the “Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2019” section below. ASC 842 applies to a number of arrangements to which the Company is party.

Whenever the Company enters into a new arrangement, it must determine, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset.

If a lease exists, the Company must then determine the separate lease and nonlease components of the arrangement. Each right to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: (i) can benefit the Company without depending on other resources not readily available to the Company and (ii) does not significantly affect and is not significantly affected by other rights of use conveyed by the lease. Aspects of a lease arrangement that transfer other goods or services to the Company but do not meet the definition of lease components are considered nonlease components. The consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and nonlease component for accounting purposes. However, the Company has elected, for all of its leases, to not separate lease and nonlease components. Each lease component is accounted for separately from other lease components, but together with the associated nonlease components.

For each lease, the Company must then determine the lease term, the present value of lease payments and the classification of the lease as either an operating or finance lease.

The lease term is the period of the lease not cancellable by the Company, together with periods covered by: (i) renewal options the Company is reasonably certain to exercise, (ii) termination options the Company is reasonably certain not to exercise and (iii) renewal or termination options that are controlled by the lessor.

The present value of lease payments is calculated based on:

•

Lease payments—Lease payments include fixed and certain variable payments, less lease incentives, together with amounts probable of being owed by the Company under residual value guarantees and, if reasonably certain of being paid, the cost of certain renewal options and early termination penalties set forth in the lease arrangement. Lease payments exclude consideration that is not related to the transfer of goods and services to the Company.

•

Discount rate—The discount rate must be determined based on information available to the Company upon the commencement of a lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; however, as the implicit rate in the Company’s leases is generally not readily determinable, the Company generally uses the hypothetical incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a collateralized basis, over a timeframe similar to the lease term.

In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors, including the lessee's and lessor's rights, obligations and economic incentives over the term of the lease.

Generally, upon the commencement of a lease, the Company will record a lease liability and a right-of-use (ROU) asset. However, the Company has elected, for all underlying assets with initial lease terms of twelve months or less (known as short-term leases), to not recognize a lease liability or ROU asset. Lease liabilities are initially recorded at lease commencement as the present value of future lease payments. ROU assets are initially recorded at lease commencement as the initial amount of the lease liability, together with the following, if applicable: (i) initial direct costs incurred by the lessee and (ii) lease payments made by the lessor, net of lease incentives received, prior to lease commencement.

Over the lease term, the Company generally increases its lease liabilities using the effective interest method and decreases its lease liabilities for lease payments made. For finance leases, amortization expense and interest expense are recognized separately in the Consolidated Statements of Operations, with amortization expense generally recorded on a straight-line basis over the lease term and interest expense recorded using the effective interest method. For operating leases, a single lease cost is generally recognized in the Consolidated Statements of Operations on a straight-line basis over the lease term unless an impairment has been recorded with respect to a leased asset. Lease costs for short-term leases not recognized in the Consolidated Balance Sheets are recognized in the Consolidated Statements of Operations on a straight-line basis over the lease term. Variable lease costs not initially included in the lease liability and ROU asset impairment charges are expensed as incurred. ROU assets are assessed for impairment, similar to other long-lived assets.

Prior to the adoption of ASC 842, the Company accounted for leases under Accounting Standards Codification Topic 840, Leases (ASC 840).

Cloud Computing Arrangements. The Company may from time to time incur costs in connection with hosting arrangements that are service contracts. Subsequent to the Company’s January 1, 2019 adoption of Accounting Standards Update (ASU) No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (ASU 2018-15), which is further described below, the Company capitalizes any such implementation costs, expenses them over the terms of the respective hosting arrangements and subjects them to impairment testing consistent with other long-lived assets.

Finite-Lived Intangible Assets. Our finite-lived intangible assets consist of license rights and developed technology. Upon acquisition, intangible assets are generally initially recorded at fair value if acquired in a business combination, or at cost if otherwise. There are several methods that can be used to determine fair value. For intangible assets, we typically use an income approach. This approach starts with our forecast of all of the expected future net cash flows. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and, if applicable, the life of any estimated period of marketing exclusivity, such as that granted by a patent. The pricing, margins and expense levels of similar products are considered if available. For certain licensed assets, our estimates of future cash flows consider periods covered by renewal options to the extent we have the intent and ability, at the date of the estimate, to renew the underlying license agreements. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.

To the extent an intangible asset is deemed to have a finite life, it is then amortized over its estimated useful life using either the straight-line method or, in the case of certain developed technology assets, an accelerated amortization model. The values of these various assets are subject to continuing scientific, medical and marketplace uncertainty. Factors giving rise to our initial estimate of useful lives are subject to change. Significant changes to any of these factors may result in a reduction in the useful life of the asset and an acceleration of related amortization expense, which could cause our net income and net income per share to decrease. Amortization expense is not recorded on assets held for sale.

As further described below under the heading “Long-Lived Asset Impairment Testing,” our finite-lived intangible assets are also subject to impairment reviews.

Developed Technology. Our developed technology assets subject to amortization have useful lives ranging from 4 years to 20 years, with a weighted average useful life of approximately 11 years. We determine amortization periods and methods of amortization for developed technology assets based on our assessment of various factors impacting estimated useful lives and the timing and extent of estimated cash flows of the acquired assets, including the strength of the intellectual property protection of the product (if applicable), contractual terms and various other competitive and regulatory issues.

License Rights. Our license rights subject to amortization have useful lives ranging from 12 years to 15 years, with a weighted average useful life of approximately 14 years. We determine amortization periods for licenses based on our assessment of various factors including the expected launch date of the product, the strength of the intellectual property protection of the product (if applicable), contractual terms and various other competitive, developmental and regulatory issues.

Long-Lived Asset Impairment Testing. Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are assessed for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. Recoverability of an asset that will continue to be used in our operations is measured by comparing the carrying amount of the asset to the forecasted undiscounted future cash flows related to the asset. In the event the carrying amount of the asset exceeds its undiscounted future cash flows and the carrying amount is not considered recoverable, impairment may exist. An impairment loss, if any, is measured as the excess of the asset’s carrying amount over its fair value, generally based on a discounted future cash flow method, independent appraisals or offers from prospective buyers. An impairment loss would be recognized in the Consolidated Statements of Operations in the period that the impairment occurs.

In-Process Research and Development Assets. In-process research and development acquired in an asset acquisition is expensed in the period it is acquired, assuming the assets have no alternative future use to the Company. Otherwise, acquired in-process research and development is generally recognized as an indefinite-lived intangible asset. Such assets are generally initially recorded at fair value if acquired in a business combination, or at cost if otherwise. Indefinite-lived intangible assets are not subject to amortization. Instead, they are tested for impairment annually and when events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1. If the fair value of the intangible assets is less than its carrying amount, an impairment loss is recognized for the difference. For those assets that reach commercialization, the assets are reclassified and accounted for as finite-lived intangible assets.

Goodwill. Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. While amortization expense is not recorded on goodwill, goodwill is subject to impairment reviews. An impairment assessment is conducted as of October 1, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired.

We perform the goodwill impairment test by comparing the fair value and carrying amount of each reporting unit. Any goodwill impairment charge we recognize for a reporting unit is equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value.

Contingencies. The Company is subject to various patent challenges, product liability claims, government investigations and other legal proceedings in the ordinary course of business. Contingent accruals and legal settlements are recorded in the Consolidated Statements of Operations as Litigation-related and other contingencies, net (or as Discontinued operations, net of tax in the case of vaginal mesh matters) when the Company determines that a loss is both probable and reasonably estimable. Legal fees and other expenses related to litigation are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations (or as Discontinued operations, net of tax in the case of vaginal mesh matters).

Due to the fact that legal proceedings and other contingencies are inherently unpredictable, our estimates of the probability and amount of any such liabilities involve significant judgment regarding future events. The Company records receivables from its insurance carriers only when the realization of the potential claim for recovery is considered probable.

Contingent Consideration. Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the occurrence of a future event, such as (i) the achievement of specified regulatory, operational and/or commercial milestones or (ii) royalty payments, such as those relating to future product sales. Contingent consideration liabilities related to an asset acquisition are initially recorded when considered probable and reasonably estimable, which may occur subsequent to the acquisition date. Subsequent changes in the recorded amounts are recorded as adjustments to the cost of the acquired assets. Contingent consideration liabilities related to a business combination are initially recorded at fair value on the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the Company remeasures its contingent consideration liabilities to their current estimated fair values, with changes recorded in earnings. Changes to any of the inputs used in determining fair value may result in fair value adjustments that differ significantly from the actual remeasurement adjustments recognized.

Share Repurchases. The Company accounts for the repurchase of ordinary shares, if any, at par value. Under applicable Irish law, ordinary shares repurchased are retired and not displayed separately as treasury stock. Upon retirement of the ordinary shares, the Company records the difference between the weighted average cost of such ordinary shares and the par value of the ordinary shares as an adjustment to Accumulated deficit in the Consolidated Balance Sheets.

Advertising Costs. Advertising costs are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations. Advertising costs amounted to $63.1 million, $49.6 million and $42.0 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Cost of Revenues. Cost of revenues includes all costs directly related to bringing both purchased and manufactured products to their final selling destination. Amounts include purchasing and receiving costs, direct and indirect costs to manufacture products including direct materials, direct labor and direct overhead expenses necessary to acquire and convert purchased materials and supplies into finished goods, royalties paid or owed by Endo on certain in-licensed products, inspection costs, depreciation of certain property, plant and equipment, amortization of intangible assets, lease costs, warehousing costs, freight charges, costs to operate our equipment and other shipping and handling costs, among others.

Share-Based Compensation. The Company grants share-based compensation awards to certain employees and non-employee directors. Generally, the grant-date fair value of each award is recognized as expense over the requisite service period. However, expense recognition differs in the case of certain performance share units where the ultimate payout is performance-based. For these awards, at each reporting period, the Company estimates the ultimate payout and adjusts the cumulative expense based on its estimate and the percent of the requisite service period that has elapsed. Share-based compensation expense is reduced for estimated future forfeitures. These estimates are revised in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation expense in the period in which the change in estimate occurs. New ordinary shares are generally issued upon the exercise of stock options or vesting of stock awards by employees and non-employee directors. Refer to Note 18. Share-based Compensation for additional discussion, including the accounting treatment for long-term cash incentive awards that will be settled in ordinary shares.

Foreign Currency. The Company operates in various jurisdictions both inside and outside of the U.S. While the Company’s reporting currency is the U.S. dollar, the Company has concluded that certain of its distinct and separable operations have functional currencies other than the U.S. dollar. Further, certain of the Company’s operations hold assets and liabilities and recognize income and expenses denominated in various local currencies, which may differ from their functional currencies.

Assets and liabilities are first remeasured from local currency to functional currency, generally using end-of-period exchange rates. Foreign currency income and expenses are generally remeasured using average exchange rates in effect during the year. In the case of nonmonetary assets and liabilities such as inventories, prepaid expenses, property, plant and equipment, goodwill and other intangible assets, and related income statement amounts, such as depreciation expense, historical exchange rates are used for remeasurement. The net effect of remeasurement is included in Other expense (income), net in the Consolidated Statements of Operations.

As part of the Company’s consolidation process, assets and liabilities of entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at end-of-period exchange rates. Income and expenses are translated using average exchange rates in effect during the year. The net effect of translation, as well as any foreign currency gains or losses on intercompany transactions considered to be of a long-term investment nature, are recognized as foreign currency translation, a component of Other comprehensive income (loss). Upon the sale or liquidation of an investment in a foreign operation, the Company records a reclassification adjustment out of Other comprehensive income (loss) for the corresponding accumulated amount of foreign currency translation gain or loss.

Income Taxes. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. In making such a determination, the Company considers all available positive and negative evidence, including projected future taxable income, tax-planning strategies and results of recent operations. In the event that the Company were to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income tax.

The Company records uncertain tax positions on the basis of a two-step process whereby the Company first determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and then measures those tax positions that meet the more-likely-than-not recognition threshold. The Company recognizes the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within the Income tax expense (benefit) line in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related tax liability line in the Consolidated Balance Sheets.

Comprehensive Income. Comprehensive income or loss includes all changes in equity during a period except those that resulted from investments by or distributions to a company’s shareholders. Other comprehensive income or loss refers to revenues, expenses, gains and losses that are included in comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted at December 31, 2019

In June 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13, together with a series of subsequently-issued related ASUs, establishes new requirements for companies to estimate expected credit losses when measuring certain assets, including accounts receivables. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. With certain exceptions, this guidance requires adoption using a modified retrospective approach. This guidance is not expected to have a material impact on the Company’s consolidated results of operations, financial position or disclosures.

In November 2018, the FASB issued ASU No. 2018-18, Clarifying the Interaction Between Topic 808 and Topic 606 (ASU 2018-18). The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606, which was January 1, 2018 for the Company. Early adoption is permitted. ASU 2018-18 is not expected to have a material impact on the Company’s consolidated results of operations, financial position or disclosures.

Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2019

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (ASU 2016-02) to establish a comprehensive new accounting standard for leases. ASU 2016-02, together with a series of subsequently-issued related ASUs, has been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in ASC 840 and requires lessees to, among other things, recognize on the balance sheet ROU assets and ROU lease liabilities, representing the present value of future minimum lease payments, for most leases.

The Company adopted ASC 842 using the modified retrospective approach with an effective date of January 1, 2019 for leases that existed on that date.

The Company has elected to apply certain practical expedients permitted under the transition guidance within ASC 842 to leases that commenced before January 1, 2019, including the package of practical expedients, as well as the practical expedient permitting the Company to not assess whether certain land easements contain leases. Due to the Company's election of these practical expedients, the Company has carried forward certain historical conclusions for existing contracts, including conclusions relating to initial direct costs and to the existence and classification of leases.

On January 1, 2019, as a result of adopting ASC 842, the Company recognized new ROU assets, current lease liabilities and noncurrent lease liabilities associated with operating leases of $59.4 million, $11.0 million and $57.3 million, respectively, which were recorded in the Consolidated Balance Sheets as Operating lease assets, Current portion of operating lease liabilities and Operating lease liabilities, less current portion, respectively. The Company also derecognized certain assets and liabilities related to existing build-to-suit lease arrangements for which construction was completed prior to the date of transition and recognized new finance lease ROU assets and lease liabilities related to those lease arrangements. The net effect of the Company’s adoption of ASC 842 resulted in a net increase to Accumulated deficit of $4.6 million.

In August 2018, the FASB issued ASU 2018-15. ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (including hosting arrangements where a software license is deemed to exist). ASU 2018-15 also requires the customer to expense any such capitalized implementation costs over the term of the hosting arrangement and to apply the existing impairment guidance for long-lived assets to such capitalized costs. Additionally, ASU 2018-15 sets forth required disclosures and guidance on financial statement classification for expenses, cash flows and balances related to implementation costs within the scope of ASU 2018-15. The Company early adopted this guidance during the first quarter of 2019 on a prospective

Discontinued Operations and Divestitures

12 Months Ended

Dec. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS AND DIVESTITURES

NOTE 3. DISCONTINUED OPERATIONS AND DIVESTITURES

Astora

The operating results of the Company’s Astora business, which the Board resolved to wind-down in 2016, are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented.

The following table provides the operating results of Astora Discontinued operations, net of tax, for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019			2018			2017
Litigation-related and other contingencies, net	$	30,400		$	34,000		$	775,474
Loss from discontinued operations before income taxes	$	(62,052	)	$	(69,702	)	$	(816,426	)
Income tax benefit	$	—		$	—		$	(13,704	)
Discontinued operations, net of tax	$	(62,052	)	$	(69,702	)	$	(802,722	)

Loss from discontinued operations before income taxes includes Litigation-related and other contingencies, net, mesh-related legal defense costs and certain other items.

The cash flows from discontinued operating activities related to Astora included the impact of net losses of $62.1 million, $69.7 million and $802.7 million for the years ended December 31, 2019, 2018 and 2017, respectively, and the impact of cash activity related to vaginal mesh cases. There were no material net cash flows related to Astora discontinued investing activities during the years ended December 31, 2019, 2018 and 2017. There was no depreciation or amortization during the years ended December 31, 2019, 2018 and 2017 related to Astora.

Litha

During the fourth quarter of 2016, the Company initiated a process to sell Litha and, on February 27, 2017, the Company entered into a definitive agreement to sell Litha to Acino Pharma AG. The sale closed on July 3, 2017 and the Company received net cash proceeds of approximately $94.2 million, after giving effect to cash and net working capital purchase price adjustments, as well as a short-term receivable of $4.4 million, which was subsequently collected in October 2017. No additional gain or loss was recognized upon sale. However, in December 2017, Acino Pharma AG became obligated to pay $10.1 million of additional consideration to the Company related to the settlement of certain contingencies set forth in the purchase agreement, which was subsequently paid to the Company in January 2018. In December 2017, the Company recorded a short-term receivable and a gain on the sale of Litha for this amount. The gain was recorded in Other expense (income), net in the Consolidated Statements of Operations. Litha was part of the Company’s International Pharmaceuticals segment. Litha did not meet the requirements for treatment as a discontinued operation.

Somar

On June 30, 2017, the Company entered into a definitive agreement to sell Somar and all of the securities thereof, to AI Global Investments (Netherlands) PCC Limited acting for and on behalf of the Soar Cell (the purchaser). The sale closed on October 25, 2017 and the Soar Cell paid an aggregate purchase price of approximately $124 million in cash, after giving effect to estimated cash, debt and net working capital purchase price adjustments. The Company recognized a $1.3 million loss upon sale. Somar was part of the Company’s International Pharmaceuticals segment. Somar did not meet the requirements for treatment as a discontinued operation.

Restructuring

12 Months Ended

Dec. 31, 2019

Restructuring and Related Activities [Abstract]

RESTRUCTURING

NOTE 4. RESTRUCTURING

Set forth below are disclosures relating to restructuring initiatives that resulted in material expenses or cash expenditures during any of the years ended December 31, 2019, 2018 or 2017 or had material restructuring liabilities at either December 31, 2019 or December 31, 2018. Employee separation benefits provided under an established severance plan are expensed when a liability is considered both probable and estimable. One-time employee separation benefits, retention and certain other employee benefit-related costs are expensed ratably over the requisite service period. Other restructuring costs are generally expensed as incurred.

2016 Generic Pharmaceuticals Restructuring Initiative

As part of the Generic Pharmaceuticals integration efforts initiated in connection with the acquisition of Par Pharmaceutical Companies, Inc. in September 2015, the Company announced a restructuring initiative in May 2016 to optimize its product portfolio and rationalize its manufacturing sites to expand product margins (the 2016 Generic Pharmaceuticals Restructuring Initiative). This initiative included certain cost savings measures, including a reduction in headcount and the disposal of our Charlotte, North Carolina manufacturing facility. On October 31, 2016, we entered into a definitive agreement to sell the Charlotte facility for cash proceeds of $14 million. The transaction closed in January 2017.

The Company did not incur any material pre-tax charges as a result of the 2016 Generic Pharmaceuticals Restructuring Initiative during any of the years ended December 31, 2019, 2018 or 2017 and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all related cash payments were made by the end of 2017. Payments made in 2017 included $10.7 million for previously-accrued employee separation and other benefit-related costs.

2016 Branded Pharmaceuticals Restructuring Initiative

In December 2016, the Company announced that it was terminating its worldwide license and development agreement with BioDelivery Sciences International, Inc. (BDSI) for BELBUCA™ and returning the product to BDSI. This termination was completed on January 6, 2017. As a result of this announcement and a comprehensive assessment of its product portfolio, the Company restructured its Branded Pharmaceuticals segment sales organization during the fourth quarter of 2016 (the 2016 Branded Pharmaceuticals Restructuring Initiative), which included the elimination of an approximate 375-member Branded Pharmaceuticals pain field sales force and the termination of certain contracts.

The Company did not incur any material pre-tax charges as a result of the 2016 Branded Pharmaceuticals Restructuring Initiative during any of the years ended December 31, 2019, 2018 or 2017 and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative. Substantially all related cash payments were made by the end of 2017. Payments made in 2017 included $16.5 million for previously-accrued employee separation and other benefit-related costs and $5.2 million for previously-accrued contract termination charges.

January 2017 Restructuring Initiative

On January 26, 2017, the Company announced a restructuring initiative implemented as part of an organizational review (the January 2017 Restructuring Initiative). This restructuring was intended to further integrate, streamline and optimize the Company’s operations by aligning certain corporate and R&D functions with its recently restructured U.S. generics and U.S. branded business units in order to create efficiencies and cost savings. As part of this restructuring, the Company undertook certain cost reduction initiatives, including a reduction of approximately 90 positions of its workforce, primarily related to corporate and branded R&D functions in Malvern, Pennsylvania and Chestnut Ridge, New York, a streamlining of general and administrative expenses, an optimization of commercial spend and a refocusing of R&D efforts.

During the year ended December 31, 2017, the Company incurred total pre-tax charges of approximately $15.1 million related to employee separation and other benefit-related costs. Of the total charges incurred, $6.9 million was included in the Branded Pharmaceuticals segment, $4.9 million was included in Corporate unallocated costs and $3.3 million was included in the Generic Pharmaceuticals segment. These charges were included in Selling, general and administrative expenses in the Consolidated Statements of Operations. Of these amounts, $12.4 million was paid in 2017 and $2.7 million was paid in 2018.

The Company did not incur any other material pre-tax charges as a result of the January 2017 Restructuring Initiative and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative.

2017 Generic Pharmaceuticals Restructuring Initiative

On July 21, 2017, the Company announced that, after completing a comprehensive review of its manufacturing network, it would be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama (the 2017 Generic Pharmaceuticals Restructuring Initiative). The closure of the facilities was completed in June 2018 and the facilities were sold in the fourth quarter of 2018 for net cash proceeds of $23.1 million, resulting in a net gain on disposal of $12.5 million, which is included in Other expense (income), net in the Consolidated Statements of Operations.

As a result of the 2017 Generic Pharmaceuticals Restructuring Initiative, the Company incurred pre-tax charges of $61.6 million and $286.7 million during the years ended December 31, 2018 and 2017, respectively. The 2018 amount does not include the $12.5 million gain on sale of the Huntsville facilities described above.

During the year ended December 31, 2018, the expenses consisted of charges relating to accelerated depreciation of $35.2 million, employee separation, retention and other benefit-related costs of $9.1 million, asset impairment charges of $2.6 million and certain other charges of $14.7 million.

During the year ended December 31, 2017, the expenses included accelerated depreciation charges of $123.3 million, employee separation, retention and other benefit-related costs of $29.6 million, certain intangible asset and property, plant and equipment impairment charges of $104.7 million, charges to increase excess inventory reserves of $12.1 million and certain other charges of $17.0 million.

These charges are included in the Generic Pharmaceuticals segment. Accelerated depreciation, employee separation, retention and other benefit-related costs and charges to increase excess inventory reserves are primarily included in Cost of revenues in the Consolidated Statements of Operations. Impairment charges are included in Asset impairment charges. Certain other charges are included in both Cost of revenues and Selling, general and administrative expenses.

The Company did not incur any other material pre-tax charges as a result of the 2017 Generic Pharmaceuticals Restructuring Initiative and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative.

The liability related to the 2017 Generic Pharmaceuticals Restructuring Initiative is primarily included in Accounts payable and accrued expenses in the Consolidated Balance Sheets. Changes to this liability during the years ended December 31, 2019 and 2018 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2018	$	22,975		$	1,610		$	24,585
Expenses	9,090			11,294			20,384
Cash distributions	(27,826		)	(12,856		)	(40,682		)
Liability balance as of December 31, 2018	$	4,239		$	48		$	4,287
Cash distributions	(4,239		)	(48		)	(4,287		)
Liability balance as of December 31, 2019	$	—		$	—		$	—

January 2018 Restructuring Initiative

In January 2018, the Company initiated a restructuring initiative that included a reorganization of its Generic Pharmaceuticals segment’s R&D network, a further simplification of the Company’s manufacturing networks and a company-wide unification of certain corporate functions (the January 2018 Restructuring Initiative).

As a result of the January 2018 Restructuring Initiative, the Company incurred pre-tax charges of $23.5 million and $2.6 million during the years ended December 31, 2018 and 2017, respectively.

The expenses in 2018 consisted primarily of employee separation, retention and other benefit-related costs of $21.7 million and certain other charges of $1.8 million. Of the total charges incurred, $10.6 million are included in the Generic Pharmaceuticals segment, $5.2 million are included in Corporate unallocated costs, $3.9 million are included in the Sterile Injectables segment, $3.1 million are included in the International Pharmaceuticals segment and $0.7 million are included in the Branded Pharmaceuticals segment.

The expenses in 2017 consisted of certain property, plant and equipment impairment charges of $2.0 million and certain other charges of $0.6 million. These charges are primarily included in the Generic Pharmaceuticals segment.

Employee separation, retention and other benefit-related costs are included in Cost of revenues, Selling, general and administrative and R&D expenses in the Consolidated Statements of Operations. Certain other charges are primarily included in Selling, general and administrative expenses. Impairment charges are included in Asset impairment charges.

The Company did not incur any other material pre-tax charges as a result of the January 2018 Restructuring Initiative and does not expect to incur additional material pre-tax restructuring-related expenses related to this initiative.

The liability related to the January 2018 Restructuring Initiative is primarily included in Accounts payable and accrued expenses in the Consolidated Balance Sheets. Changes to this liability during the years ended December 31, 2019 and 2018 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2018	$	—		$	650		$	650
Expenses	21,754			1,764			23,518
Cash distributions	(20,925		)	(2,094		)	(23,019		)
Liability balance as of December 31, 2018	$	829		$	320		$	1,149
Cash distributions	(829		)	(320		)	(1,149		)
Liability balance as of December 31, 2019	$	—		$	—		$	—

Segment Results

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

SEGMENT RESULTS

NOTE 5. SEGMENT RESULTS

During the first quarter of 2019, the Company changed the names of its reportable segments. This change, which was intended to simplify the segments’ names, had no impact on the Company’s Consolidated Financial Statements or segment results for any of the periods presented. Following this change, the Company’s four reportable business segments are Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. These segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.

We evaluate segment performance based on segment adjusted income from continuing operations before income tax, which we define as Loss from continuing operations before income tax and before certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs and changes in the fair value of contingent consideration; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company’s operations; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; litigation-related and other contingent matters; certain legal costs; gains or losses from early termination of debt; gains or losses from the sales of businesses and other assets; foreign currency gains or losses on intercompany financing arrangements; and certain other items.

Certain of the corporate expenses incurred by the Company are not directly attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as “Corporate unallocated costs.” Interest income and expense are also considered corporate items and not allocated to any of the Company’s segments. The Company’s total segment adjusted income from continuing operations before income tax is equal to the combined results of each of its segments.

Branded Pharmaceuticals

Our Branded Pharmaceuticals segment includes a variety of branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The products in this segment include XIAFLEX^®, SUPPRELIN^®LA, NASCOBAL^® Nasal Spray, AVEED^®, PERCOCET^®, TESTOPEL^®, LIDODERM^®, EDEX^® and VOLTAREN^®Gel, among others.

Sterile Injectables

Our Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT^®, ADRENALIN^® and APLISOL^®, among others, and certain generic sterile injectable products, including ertapenem for injection, the authorized generic of Merck’s Invanz^®, ephedrine sulfate injection and treprostinil for injection, among others.

Generic Pharmaceuticals

Our Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health and cardiovascular disease markets, among others.

International Pharmaceuticals

Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin. The key products of this segment serve growing therapeutic areas, including attention deficit hyperactivity disorder, pain, women’s health and oncology. This segment also included Litha and Somar, which were sold in the second half of 2017.

The following represents selected information for the Company’s reportable segments for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019		2018		2017
Net revenues from external customers:
Branded Pharmaceuticals	$	855,402	$	862,832	$	957,525
Sterile Injectables	1,063,131		929,566		750,471
Generic Pharmaceuticals	879,882		1,012,215		1,530,530
International Pharmaceuticals (1)	115,949		142,465		230,332
Total net revenues from external customers	$	2,914,364	$	2,947,078	$	3,468,858
Segment adjusted income from continuing operations before income tax:
Branded Pharmaceuticals	$	362,711	$	368,790	$	485,515
Sterile Injectables	780,799		695,363		563,103
Generic Pharmaceuticals	158,400		317,892		501,249
International Pharmaceuticals	44,758		59,094		58,308
Total segment adjusted income from continuing operations before income tax	$	1,346,668	$	1,441,139	$	1,608,175

__________


(1)	Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha in July 2017 and Somar in October 2017, South Africa and Latin America.

There were no material revenues from external customers attributed to an individual country outside of the U.S. during any of the periods presented. There were no material tangible long-lived assets in an individual country other than the U.S. as of December 31, 2019 or December 31, 2018.

The table below provides reconciliations of our Total consolidated loss from continuing operations before income tax, which is determined in accordance with U.S. GAAP, to our total segment adjusted income from continuing operations before income tax for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019			2018			2017
Total consolidated loss from continuing operations before income tax	$	(344,904	)	$	(938,832	)	$	(1,483,004	)
Interest expense, net	538,734			521,656			488,228
Corporate unallocated costs (1)	168,136			200,592			165,298
Amortization of intangible assets	543,862			622,339			773,766
Inventory step-up	—			261			390
Upfront and milestone payments to partners	6,623			45,108			9,483
Retention and separation benefits and other cost reduction initiatives (2)	34,598			86,295			212,448
Certain litigation-related and other contingencies, net (3)	11,211			13,809			185,990
Asset impairment charges (4)	526,082			916,939			1,154,376
Acquisition-related and integration items, net (5)	(46,098		)	21,914			58,086
(Gain) loss on extinguishment of debt	(119,828		)	—			51,734
Foreign currency impact related to the remeasurement of intercompany debt instruments	4,362			(5,486		)	(1,403		)
Other, net (6)	23,890			(43,456		)	(7,217		)
Total segment adjusted income from continuing operations before income tax	$	1,346,668		$	1,441,139		$	1,608,175

__________


(1)	Amounts include certain corporate overhead costs, such as headcount, facility and corporate litigation expenses and certain other income and expenses.

(2)

Amounts in 2019 include $14.7 million of costs associated with retention bonuses awarded to certain senior management of the Company. Other amounts in 2019 related primarily to our restructuring and other cost reduction initiatives. Such amounts included employee separation costs of $8.9 million and other charges of $11.0 million. Amounts in 2018 primarily relate to employee separation costs of $31.7 million, accelerated depreciation of $35.2 million, charges to increase excess inventory reserves of $2.9 million and other charges of $16.5 million, each of which related primarily to our restructuring initiatives. Amounts in 2017 primarily relate to employee separation costs of $53.0 million, accelerated depreciation of $123.7 million, charges to increase excess inventory reserves of $13.7 million and other charges of $22.0 million. These charges were related primarily to the 2017 Generic Pharmaceuticals Restructuring Initiative. See Note 4. Restructuring for discussion of our material restructuring initiatives.


(3)	Amounts include adjustments to our accruals for litigation-related settlement charges and certain settlement proceeds related to suits filed by our subsidiaries. Our material legal proceedings and other contingent matters are described in more detail in Note 15. Commitments and Contingencies.


(4)	Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 10. Goodwill and Other Intangibles as well as charges to write down certain property, plant and equipment as further described in Note 4. Restructuring, Note 6. Fair Value Measurements and Note 9. Property, Plant and Equipment.


(5)	Amounts primarily relate to changes in the fair value of contingent consideration.

(6)

Amounts in 2019 include $17.5 million for contract termination costs incurred as a result of certain product discontinuation activities in our International Pharmaceuticals segment and $14.1 million for a premium associated with an extended reporting period endorsement on an expiring insurance program. The remaining amounts in 2019 and 2018 primarily relate to gains on sales of businesses and other assets, as further described in Note 19. Other Expense (Income), Net.

During the years ended December 31, 2019, 2018 and 2017, the Company disaggregated its revenue from contracts with customers into the categories included in the table below (in thousands). The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.



	2019		2018		2017
Branded Pharmaceuticals:
Specialty Products:
XIAFLEX®	$	327,638	$	264,638	$	213,378
SUPPRELIN® LA	86,797		81,707		86,211
Other Specialty (1)	105,241		98,230		84,161
Total Specialty Products	$	519,676	$	444,575	$	383,750
Established Products:
PERCOCET®	$	116,012	$	122,901	$	125,231
TESTOPEL®	55,244		58,377		69,223
Other Established (2)	164,470		236,979		379,321
Total Established Products	$	335,726	$	418,257	$	573,775
Total Branded Pharmaceuticals (3)	$	855,402	$	862,832	$	957,525
Sterile Injectables:
VASOSTRICT®	$	531,737	$	453,767	$	399,909
ADRENALIN®	179,295		143,489		76,523
Ertapenem for injection	104,679		57,668		—
APLISOL®	61,826		64,913		66,286
Other Sterile Injectables (4)	185,594		209,729		207,753
Total Sterile Injectables (3)	$	1,063,131	$	929,566	$	750,471
Total Generic Pharmaceuticals (5)	$	879,882	$	1,012,215	$	1,530,530
Total International Pharmaceuticals (6)	$	115,949	$	142,465	$	230,332
Total revenues, net	$	2,914,364	$	2,947,078	$	3,468,858

__________


(1)	Products included within Other Specialty are NASCOBAL^®Nasal Spray and AVEED^®. Beginning with our first-quarter 2019 reporting, TESTOPEL^®, which was previously included in Other Specialty, has been reclassified and is now included in the Established Products portfolio for all periods presented.


(2)	Products included within Other Established include, but are not limited to, LIDODERM^®, EDEX^® and VOLTAREN^® Gel.


(3)	Individual products presented above represent the top two performing products in each product category for the year ended December 31, 2019 and/or any product having revenues in excess of $100 million during any of the years ended December 31, 2019, 2018 or 2017 or $25 million during any quarterly period in 2019 or 2018.


(4)	Products included within Other Sterile Injectables include ephedrine sulfate injection, treprostinil for injection and others.

(5)

The Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have no intellectual property protection and are sold within the U.S. During 2019, colchicine tablets, which launched in July 2018, made up 6% of consolidated total revenue. During 2017, combined sales of ezetimibe tablets and quetiapine ER tablets, for which we lost temporary marketing exclusivity during the second quarter of 2017, made up 7% of consolidated total revenue. No other individual product within this segment has exceeded 5% of consolidated total revenues for the periods presented.


(6)	The International Pharmaceuticals segment, which accounted for 4%, 5% and 7% of consolidated total revenues in 2019, 2018 and 2017, respectively, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin. This segment also included Litha, which was sold in July 2017, and Somar, which was sold in October 2017.

The following represents depreciation expense for our reportable segments for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019		2018		2017
Branded Pharmaceuticals	$	12,573	$	14,542	$	16,957
Sterile Injectables	14,287		10,500		8,411
Generic Pharmaceuticals	32,689		66,016		174,652
International Pharmaceuticals	4,234		4,925		3,332
Corporate unallocated	5,217		5,385		6,647
Total depreciation expense	$	69,000	$	101,368	$	209,999

Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.

Fair Value Measurements

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 6. FAIR VALUE MEASUREMENTS

Financial Instruments

The financial instruments recorded in our Consolidated Balance Sheets include cash and cash equivalents (including money market funds), restricted cash and cash equivalents, accounts receivable, equity method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds pay dividends that generally reflect short-term interest rates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds), accounts receivable, accounts payable and accrued expenses approximate their fair values.

The following table presents current and noncurrent restricted cash and cash equivalent balances at December 31, 2019 and December 31, 2018 (in thousands):



	December 31, 2019		December 31, 2018
Restricted cash and cash equivalents—current portion (1)	$	247,457	$	305,368
Restricted cash and cash equivalents—noncurrent portion (2)	18,400		22,356
Restricted cash and cash equivalents—total (3)	$	265,857	$	327,724

__________


(1)	These amounts are reported in our Consolidated Balance Sheets as Restricted cash and cash equivalents.


(2)	These amounts are reported in our Consolidated Balance Sheets as Other assets.


(3)	Approximately $242.8 million and $299.7 million of our restricted cash and cash equivalents are held in QSFs for mesh-related matters at December 31, 2019 and December 31, 2018, respectively. The remaining restricted cash and cash equivalents primarily relates to other litigation-related matters. See Note 15. Commitments and Contingencies for further information.

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:


•	Level 1—Quoted prices in active markets for identical assets or liabilities.


•	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.


•	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Acquisition-Related Contingent Consideration

The fair value of contingent consideration liabilities is determined using unobservable inputs; hence, these instruments represent Level 3 measurements within the above-defined fair value hierarchy. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. Changes in any of these estimated inputs used as of the date of this report could have resulted in significant adjustments to fair value. See the “Recurring Fair Value Measurements” section below for additional information on acquisition-related contingent consideration.

Recurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a recurring basis at December 31, 2019 and 2018 were as follows (in thousands):



	Fair Value Measurements at December 31, 2019 using:
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total
Assets:
Money market funds	$	427,033	$	—	$	—	$	427,033
Liabilities:
Acquisition-related contingent consideration—current	$	—	$	—	$	6,534	$	6,534
Acquisition-related contingent consideration—noncurrent	$	—	$	—	$	23,123	$	23,123



	Fair Value Measurements at December 31, 2018 using:
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total
Assets:
Money market funds	$	137,215	$	—	$	—	$	137,215
Liabilities:
Acquisition-related contingent consideration—current	$	—	$	—	$	36,514	$	36,514
Acquisition-related contingent consideration—noncurrent	$	—	$	—	$	80,189	$	80,189

At December 31, 2019 and December 31, 2018, money market funds include $70.2 million and $86.9 million, respectively, in QSFs to be disbursed to mesh-related or other product liability claimants. Amounts in QSFs are considered restricted cash equivalents. See Note 15. Commitments and Contingencies for further discussion of our product liability cases. At December 31, 2019 and December 31, 2018, the differences between the amortized cost and the fair value of our money market funds were not material, individually or in the aggregate.

Fair Value Measurements Using Significant Unobservable Inputs

The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3), for the years ended December 31, 2019 and 2018 (in thousands):



	2019			2018
Beginning of period	$	116,703		$	190,442
Amounts settled	(41,448		)	(92,627		)
Changes in fair value recorded in earnings	(46,098		)	19,910
Effect of currency translation	500			(1,022		)
End of period	$	29,657		$	116,703

At December 31, 2019, the fair value measurements of the contingent consideration obligations were determined using risk-adjusted discount rates ranging from approximately 9.5% to 15.0% (weighted average rate of approximately 10.9%). Changes in fair value recorded in earnings related to acquisition-related contingent consideration are included in our Consolidated Statements of Operations as Acquisition-related and integration items, net. Amounts recorded for the current and noncurrent portions of acquisition-related contingent consideration are included in Accounts payable and accrued expenses and Other liabilities, respectively, in our Consolidated Balance Sheets.

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2019 by acquisition (in thousands):



	Balance as of December 31, 2018		Changes in Fair Value Recorded in Earnings			Amounts Settled and Other			Balance as of December 31, 2019
Auxilium acquisition	$	14,157	$	777		$	(1,727	)	$	13,207
Lehigh Valley Technologies, Inc. acquisitions	34,700		(8,614		)	(19,286		)	6,800
VOLTAREN® Gel acquisition (1)	56,240		(37,184		)	(18,870		)	186
Other	11,606		(1,077		)	(1,065		)	9,464
Total	$	116,703	$	(46,098	)	$	(40,948	)	$	29,657

__________


(1)	The change in fair value recorded in earnings includes the impact of certain competitive events occurring during 2019.

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2018 by acquisition (in thousands):



	Balance as of December 31, 2017		Changes in Fair Value Recorded in Earnings			Amounts Settled and Other			Balance as of December 31, 2018
Auxilium acquisition	$	13,061	$	2,941		$	(1,845	)	$	14,157
Lehigh Valley Technologies, Inc. acquisitions	63,001		19,146			(47,447		)	34,700
VOLTAREN® Gel acquisition	98,124		9			(41,893		)	56,240
Other	16,256		(2,186		)	(2,464		)	11,606
Total	$	190,442	$	19,910		$	(93,649	)	$	116,703

Nonrecurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the years ended December 31, 2019 and 2018 were as follows (in thousands):



	Fair Value Measurements during the Year Ended December 31, 2019 (1) using:						Total Expense for the Year Ended December 31, 2019
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total Expense for the Year Ended December 31, 2019
Intangible assets, excluding goodwill (Note 10)	$	—	$	—	$	229,680	$	(347,706	)
Certain property, plant and equipment (Note 9)	—		—		—		(6,468		)
Total	$	—	$	—	$	229,680	$	(354,174	)



	Fair Value Measurements during the Year Ended December 31, 2018 (1) using:						Total Expense for the Year Ended December 31, 2018
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total Expense for the Year Ended December 31, 2018
Intangible assets, excluding goodwill (Note 10)	$	—	$	—	$	239,857	$	(230,418	)
Certain property, plant and equipment (Note 9)	—		—		—		(6,521		)
Total	$	—	$	—	$	239,857	$	(236,939	)

__________


(1)	The fair value amounts are presented as of the date of the fair value measurement as these assets are not measured at fair value on a recurring basis. Such measurements generally occur in connection with our quarter-end financial reporting close procedures.

The Company also performed fair value measurements in connection with its goodwill impairment tests. Refer to Note 10. Goodwill and Other Intangibles for additional information, including the valuation methodologies utilized.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventories

12 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 7. INVENTORIES

Inventories consist of the following at December 31, 2019 and December 31, 2018 (in thousands):



	December 31, 2019		December 31, 2018
Raw materials (1)	$	124,171	$	122,825
Work-in-process (1)	65,392		70,458
Finished goods (1)	138,302		128,896
Total	$	327,865	$	322,179

__________

(1) The components of inventory shown in the table above are net of allowance for obsolescence.

Inventory that is in excess of the amount expected to be sold within one year is classified as noncurrent inventory and is not included in the table above. At December 31, 2019 and December 31, 2018, $29.0 million and $8.1 million, respectively, of noncurrent inventory was included in Other assets in the Consolidated Balance Sheets. As of December 31, 2019 and December 31, 2018, the Company’s Consolidated Balance Sheets included approximately $17.6 million and $12.5 million, respectively, of capitalized pre-launch inventories related to products that were not yet available to be sold.

Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

LEASES

NOTE 8. LEASES

We have entered into contracts with third parties to lease a variety of assets, including certain real estate, machinery, equipment, automobiles and other assets.

Our leases frequently allow for lease payments that could vary based on factors such as inflation or the degree of utilization of the underlying asset and the incurrence of contractual charges such as those for common area maintenance or utilities.

Renewal and/or early termination options are common in our lease arrangements, particularly with respect to our real estate leases. Our ROU assets and lease liabilities generally exclude periods covered by renewal options and include periods covered by early termination options (based on our conclusion that it is not reasonably certain that we will exercise such options).

Our most significant lease is for our Malvern, Pennsylvania location. The initial term of the lease is through 2024 and includes three renewal options, each for an additional 60-month period. These renewal options are not considered reasonably certain of exercise and are therefore excluded from the ROU asset and lease liability.

We are party to certain sublease arrangements, primarily related to our real estate leases, where we act as the lessee and intermediate lessor. For example, we sublease portions of our Malvern, Pennsylvania facility to multiple tenants through sublease arrangements ending in 2024, with certain limited renewal and early termination options.

The following table presents information about the Company's ROU assets and lease liabilities at December 31, 2019 (in thousands):



	Consolidated Balance Sheets Line Items	December 31, 2019
ROU assets:
Operating lease ROU assets	Operating lease assets	$	51,700
Finance lease ROU assets	Property, plant and equipment, net	56,793
Total ROU assets		$	108,493
Operating lease liabilities:
Current operating lease liabilities	Current portion of operating lease liabilities	$	10,763
Noncurrent operating lease liabilities	Operating lease liabilities, less current portion	48,299
Total operating lease liabilities		$	59,062
Finance lease liabilities:
Current finance lease liabilities	Accounts payable and accrued expenses	$	5,672
Noncurrent finance lease liabilities	Other liabilities	31,312
Total finance lease liabilities		$	36,984

At December 31, 2018, our lease assets and liabilities determined in accordance with ASC 840, which related primarily to our Malvern, Pennsylvania lease that was accounted for as a build-to-suit lease arrangement, totaled $49.0 million and $36.1 million, respectively. Lease assets had a cost basis of $98.3 million and accumulated depreciation of $49.3 million and were reflected as Property, plant and equipment, net in the Consolidated Balance Sheets. Lease liabilities consisted of current liabilities of $5.3 million included in Accounts payable and accrued expenses and noncurrent liabilities of $30.8 million included in Other liabilities.

The following table presents information about lease costs and expenses and sublease income for the year ended December 31, 2019 (in thousands):



	Consolidated Statements of Operations Line Items	2019
Operating lease cost	Various (1)	$	13,648
Finance lease cost:
Amortization of ROU assets	Various (1)	$	9,407
Interest on lease liabilities	Interest expense, net	$	1,986
Other lease costs and income:
Variable lease costs (2)	Various (1)	$	9,653
Sublease income	Various (1)	$	(3,689	)

__________


(1)	Amounts are included in the Consolidated Statements of Operations based on the function that the underlying leased asset supports. The following table presents the components of such aggregate amounts for the year ended December 31, 2019 (in thousands):



	2019
Cost of revenues	$	11,168
Selling, general and administrative	$	17,648
Research and development	$	203


(2)	Amounts represent variable lease costs incurred that were not included in the initial measurement of the lease liability such as common area maintenance and utilities costs associated with leased real estate and certain costs associated with our automobile leases.

Expenses incurred under operating leases, determined in accordance with ASC 840, were $18.7 million in both 2018 and 2017.

The following table provides the undiscounted amount of future cash flows included in our lease liabilities at December 31, 2019 for each of the five years subsequent to December 31, 2019 and thereafter, as well as a reconciliation of such undiscounted cash flows to our lease liabilities at December 31, 2019 (in thousands):



	Operating Leases		Finance Leases
2020	$	14,103	$	7,446
2021	13,262		7,593
2022	12,688		7,743
2023	10,017		7,897
2024	5,176		8,054
Thereafter	15,332		13,483
Total future lease payments	$	70,578	$	52,216
Less: amount representing interest	11,516		15,232
Present value of future lease payments (lease liability)	$	59,062	$	36,984

The Company’s future minimum lease commitments as of December 31, 2018, as determined in accordance with ASC 840 and reported in the Annual Report on Form 10-K for the year ended December 31, 2018, were as follows:



	Capital Leases (1)		Operating Leases
2019	$	6,884	$	15,800
2020	6,819		14,519
2021	6,921		12,883
2022	7,072		12,454
2023	7,225		9,945
Thereafter	9,127		20,573
Total minimum lease payments	$	44,048	$	86,174
Less: Amount representing interest	4,084
Total present value of minimum payments	$	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$	34,119

__________


(1)	The Malvern, Pennsylvania location’s lease arrangement is included under Capital Leases.

The following table provides the weighted average remaining lease term and weighted average discount rates for our leases as of December 31, 2019:



	December 31, 2019
Weighted average remaining lease term (years), weighted based on lease liability balances:
Operating leases	5.9 years
Finance leases	9.5 years
Weighted average discount rate (percentages), weighted based on the remaining balance of lease payments:
Operating leases	5.8	%
Finance leases	5.5	%

The following table provides certain cash flow and supplemental noncash information related to our lease liabilities for the year ended December 31, 2019 (in thousands):



	2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$	14,940
Operating cash payments for finance leases	$	2,000
Financing cash payments for finance leases	$	9,196
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	623
Finance leases	$	5,953

LEASES

NOTE 8. LEASES

We have entered into contracts with third parties to lease a variety of assets, including certain real estate, machinery, equipment, automobiles and other assets.

The following table presents information about the Company's ROU assets and lease liabilities at December 31, 2019 (in thousands):



	Consolidated Balance Sheets Line Items	December 31, 2019
ROU assets:
Operating lease ROU assets	Operating lease assets	$	51,700
Finance lease ROU assets	Property, plant and equipment, net	56,793
Total ROU assets		$	108,493
Operating lease liabilities:
Current operating lease liabilities	Current portion of operating lease liabilities	$	10,763
Noncurrent operating lease liabilities	Operating lease liabilities, less current portion	48,299
Total operating lease liabilities		$	59,062
Finance lease liabilities:
Current finance lease liabilities	Accounts payable and accrued expenses	$	5,672
Noncurrent finance lease liabilities	Other liabilities	31,312
Total finance lease liabilities		$	36,984

The following table presents information about lease costs and expenses and sublease income for the year ended December 31, 2019 (in thousands):



	Consolidated Statements of Operations Line Items	2019
Operating lease cost	Various (1)	$	13,648
Finance lease cost:
Amortization of ROU assets	Various (1)	$	9,407
Interest on lease liabilities	Interest expense, net	$	1,986
Other lease costs and income:
Variable lease costs (2)	Various (1)	$	9,653
Sublease income	Various (1)	$	(3,689	)

__________


(1)	Amounts are included in the Consolidated Statements of Operations based on the function that the underlying leased asset supports. The following table presents the components of such aggregate amounts for the year ended December 31, 2019 (in thousands):



	2019
Cost of revenues	$	11,168
Selling, general and administrative	$	17,648
Research and development	$	203


(2)	Amounts represent variable lease costs incurred that were not included in the initial measurement of the lease liability such as common area maintenance and utilities costs associated with leased real estate and certain costs associated with our automobile leases.

Expenses incurred under operating leases, determined in accordance with ASC 840, were $18.7 million in both 2018 and 2017.



	Operating Leases		Finance Leases
2020	$	14,103	$	7,446
2021	13,262		7,593
2022	12,688		7,743
2023	10,017		7,897
2024	5,176		8,054
Thereafter	15,332		13,483
Total future lease payments	$	70,578	$	52,216
Less: amount representing interest	11,516		15,232
Present value of future lease payments (lease liability)	$	59,062	$	36,984



	Capital Leases (1)		Operating Leases
2019	$	6,884	$	15,800
2020	6,819		14,519
2021	6,921		12,883
2022	7,072		12,454
2023	7,225		9,945
Thereafter	9,127		20,573
Total minimum lease payments	$	44,048	$	86,174
Less: Amount representing interest	4,084
Total present value of minimum payments	$	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$	34,119

__________


(1)	The Malvern, Pennsylvania location’s lease arrangement is included under Capital Leases.

The following table provides the weighted average remaining lease term and weighted average discount rates for our leases as of December 31, 2019:



	December 31, 2019
Weighted average remaining lease term (years), weighted based on lease liability balances:
Operating leases	5.9 years
Finance leases	9.5 years
Weighted average discount rate (percentages), weighted based on the remaining balance of lease payments:
Operating leases	5.8	%
Finance leases	5.5	%

The following table provides certain cash flow and supplemental noncash information related to our lease liabilities for the year ended December 31, 2019 (in thousands):



	2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$	14,940
Operating cash payments for finance leases	$	2,000
Financing cash payments for finance leases	$	9,196
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	623
Finance leases	$	5,953

Property, Plant And Equipment

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

NOTE 9. PROPERTY, PLANT AND EQUIPMENT

Changes in the amount of Property, plant and equipment for the year ended December 31, 2019 are set forth in the table below (in thousands).



Cost:	Land and Buildings			Machinery and Equipment			Leasehold Improvements			Computer Equipment and Software			Furniture and Fixtures			Assets under Construction			Total
At January 1, 2019	$	230,035		$	211,491		$	69,256		$	117,134		$	12,495		$	121,024		$	761,435
Additions (1)	49,716			56,888			9,934			8,359			954			(46,715		)	79,136
Disposals, transfers, impairments and other (2)	6,115			(6,394		)	(8,926		)	(8,951		)	(515		)	(1,096		)	(19,767		)
Effect of currency translation	—			71			60			495			509			—			1,135
At December 31, 2019	$	285,866		$	262,056		$	70,324		$	117,037		$	13,443		$	73,213		$	821,939
Accumulated Depreciation:
At January 1, 2019	$	(69,656	)	$	(83,906	)	$	(30,600	)	$	(71,437	)	$	(6,944	)	$	—		$	(262,543	)
Additions	(17,670		)	(22,012		)	(7,337		)	(20,696		)	(1,285		)	—			(69,000		)
Disposals, transfers and other (2)	2,850			1,605			1,110			8,617			515			—			14,697
Effect of currency translation	—			(44		)	(31		)	(142		)	(11		)	—			(228		)
At December 31, 2019	$	(84,476	)	$	(104,357	)	$	(36,858	)	$	(83,658	)	$	(7,725	)	$	—		$	(317,074	)
Net Book Amount:
At December 31, 2019	$	201,390		$	157,699		$	33,466		$	33,379		$	5,718		$	73,213		$	504,865
At December 31, 2018	$	160,379		$	127,585		$	38,656		$	45,697		$	5,551		$	121,024		$	498,892

__________


(1)	Costs incurred during the construction or development of property, plant and equipment are initially recorded as additions to Assets under Construction. Once an asset has been placed into service, the cost of that asset is transferred from Assets under Construction to one of the other classes of assets.


(2)	Amounts include the effect of the Company’s January 1, 2019 adoption of ASC 842, which is further described in Note 2. Summary of Significant Accounting Policies.

Depreciation expense was $69.0 million, $101.4 million and $210.0 million for the years ended December 31, 2019, 2018 and 2017, respectively.

During the years ended December 31, 2019, 2018 and 2017, the Company recorded property, plant and equipment impairment charges totaling $6.5 million, $6.5 million and $65.7 million, respectively. These charges are included in the Asset impairment charges line item in our Consolidated Statement of Operations.

In 2019 and 2018, impairment charges reflect the write-off of certain property, plant and equipment, including amounts that were abandoned or sold as part of our ongoing efforts to improve our operating efficiency and consolidate certain locations.

In 2017, impairment charges primarily relate to an aggregate charge of $47.2 million recorded in connection with the 2017 Generic Pharmaceuticals Restructuring Initiative, which is described further in Note 4. Restructuring, and $11.9 million recorded following the initiation of held-for-sale accounting resulting from the Company’s June 30, 2017 definitive agreement to sell Somar, which is described in Note 3. Discontinued Operations and Divestitures.

Goodwill and Other Intangibles

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLES

NOTE 10. GOODWILL AND OTHER INTANGIBLES

Goodwill

Changes in the carrying amount of our goodwill for the years ended December 31, 2019 and 2018 were as follows (in thousands):



	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals			International Pharmaceuticals			Total
Goodwill as of December 31, 2017	$	828,818	$	—	$	3,531,301		$	89,963		$	4,450,082
Allocation to current segments (1)	—		2,731,193		(2,731,193		)	—			—
Effect of currency translation	—		—		—			(5,446		)	(5,446		)
Goodwill impairment charges	—		—		(649,000		)	(31,000		)	(680,000		)
Goodwill as of December 31, 2018	$	828,818	$	2,731,193	$	151,108		$	53,517		$	3,764,636
Effect of currency translation	—		—		—			2,456			2,456
Goodwill impairment charges	—		—		(151,108		)	(20,800		)	(171,908		)
Goodwill as of December 31, 2019	$	828,818	$	2,731,193	$	—		$	35,173		$	3,595,184

__________


(1)	This allocation relates to the change in segments described below under the heading “Impairments.” The amount of goodwill allocated was determined using a relative fair value methodology in accordance with U.S. GAAP.

The carrying amounts of goodwill at December 31, 2019 and December 31, 2018 are net of the following accumulated impairments (in thousands):



	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2018	$	855,810	$	—	$	2,991,549	$	456,408	$	4,303,767
Accumulated impairment losses as of December 31, 2019	$	855,810	$	—	$	3,142,657	$	500,417	$	4,498,884

Other Intangible Assets

Changes in the amount of other intangible assets from December 31, 2018 to December 31, 2019 are set forth in the table below (in thousands).



Cost basis:	Balance as of December 31, 2018			Acquisitions			Impairments			Other (1)			Effect of Currency Translation			Balance as of December 31, 2019
Indefinite-lived intangibles:
In-process research and development	$	93,900		$	—		$	—		$	—		$	—		$	93,900
Total indefinite-lived intangibles	$	93,900		$	—		$	—		$	—		$	—		$	93,900
Finite-lived intangibles:
Licenses (weighted average life of 14 years)	$	457,402		$	—		$	—		$	—		$	—		$	457,402
Tradenames	6,409			—			—			—			—			6,409
Developed technology (weighted average life of 11 years)	6,182,015			—			(347,706		)	(2,197		)	12,327			5,844,439
Total finite-lived intangibles (weighted average life of 11 years)	$	6,645,826		$	—		$	(347,706	)	$	(2,197	)	$	12,327		$	6,308,250
Total other intangibles	$	6,739,726		$	—		$	(347,706	)	$	(2,197	)	$	12,327		$	6,402,150

Accumulated amortization:	Balance as of December 31, 2018			Amortization			Impairments			Other (1)			Effect of Currency Translation			Balance as of December 31, 2019
Finite-lived intangibles:
Licenses	$	(398,182	)	$	(12,154	)	$	—		$	—		$	—		$	(410,336	)
Tradenames	(6,409		)	—			—			—			—			(6,409		)
Developed technology	(2,877,829		)	(531,708		)	—			2,197			(6,798		)	(3,414,138		)
Total other intangibles	$	(3,282,420	)	$	(543,862	)	$	—		$	2,197		$	(6,798	)	$	(3,830,883	)
Net other intangibles	$	3,457,306														$	2,571,267

__________


(1)	Other adjustments relate to the removal of certain fully amortized intangible assets.

Amortization expense for the years ended December 31, 2019, 2018 and 2017 totaled $543.9 million, $622.3 million and $773.8 million, respectively. Amortization expense is included in Cost of revenues in the Consolidated Statements of Operations. Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2019 is as follows (in thousands):



2020	$	437,420
2021	$	396,864
2022	$	381,312
2023	$	351,805
2024	$	308,986

Impairments

Goodwill and indefinite-lived intangible assets are tested for impairment annually and when events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1.

As part of our goodwill and intangible asset impairment assessments, we estimate the fair values of our reporting units and our intangible assets using an income approach that utilizes a discounted cash flow model or, where appropriate, a market approach.

The discounted cash flow models are dependent upon our estimates of future cash flows and other factors including estimates of (i) future operating performance, including future sales, long-term growth rates, operating margins, discount rates, variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows and (ii) future economic conditions. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows for the Company’s October 1, 2019, 2018 and 2017 annual goodwill and indefinite-lived intangible assets impairment tests ranged from 9.5% to 13.5%, from 9.5% to 11.5% and from 9.5% to 12.5%, respectively, depending on the overall risk associated with the particular assets and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use. Any impairment charges resulting from annual or interim goodwill and intangible asset impairment assessments are recorded to Asset impairment charges in our Consolidated Statements of Operations.

During the years ended December 31, 2019, 2018 and 2017, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):



	2019		2018		2017
Goodwill impairment charges	$	171,908	$	680,000	$	288,745
Other intangible asset impairment charges	$	347,706	$	230,418	$	799,955

A summary of significant goodwill and other intangible asset impairment tests and related charges is included below. Except as described below, pre-tax non-cash intangible asset impairment charges related primarily to certain in-process research and development and/or developed technology intangible assets that were tested for impairment following changes in market conditions and certain other factors impacting recoverability.

Annual Goodwill Impairment Tests

As a result of our annual test performed as of October 1, 2019, the Company determined that the estimated carrying amount of the Paladin reporting unit exceeded its fair value; therefore, the Company recorded a pre-tax non-cash goodwill impairment charge of $20.8 million during the fourth quarter of 2019. The Paladin impairment was primarily a result of certain anticipated product discontinuation activities. The impairment also reflects the estimated impact of Canadian pricing regulations that were issued in the second half of 2019 and that we expect will become effective as early as July 2020. We did not record goodwill impairment charges for the other reporting units as a result of the 2019 annual tests.

As a result of our annual test performed as of October 1, 2018, the Company determined that the estimated carrying amounts of the Generic Pharmaceuticals and Paladin reporting units exceeded their respective fair values; therefore, the Company recorded pre-tax non-cash goodwill impairment charges of $258.0 million and $31.0 million, respectively, during the fourth quarter of 2018. The Generic Pharmaceuticals impairment can be primarily attributed to an increase in the discount rate used in the determination of fair value and unfavorable underlying business outlook assumption changes. The Paladin impairment was primarily a result of increased competition and slower than expected product launches in our Canadian market. We did not record goodwill impairment charges for the other reporting units as a result of the 2018 annual tests.

As a result of our annual test performed as of October 1, 2017, the Company determined that the estimated fair values of its Branded, Generics and Paladin reporting units exceeded their carrying amounts; therefore, no related goodwill impairment charges were required.

Other Impairment Tests

As a result of certain competitive events that occurred during the first quarter of 2019, we tested the goodwill of our Generic Pharmaceuticals reporting unit for impairment as of March 31, 2019. The fair value of the reporting unit was estimated using an income approach that utilized a discounted cash flow model. The discount rate utilized in this test was 10.5%. This goodwill impairment test resulted in a pre-tax non-cash goodwill impairment charge of $86.0 million during the three months ended March 31, 2019, representing the excess of this reporting unit’s carrying amount over its estimated fair value. This Generic Pharmaceuticals impairment can be primarily attributed to the impact of the competitive events referenced above and an increase in the discount rate used in the determination of fair value.

During the second quarter of 2019, unfavorable competitive and pricing events occurred that caused us to update certain assumptions from those used in our first-quarter 2019 Generic Pharmaceuticals goodwill impairment test. The Company considered these events, together with the fact that this reporting unit’s carrying amount equaled its fair value immediately subsequent to the first-quarter 2019 goodwill impairment charge, as part of its qualitative assessment of goodwill triggering events for the second quarter of 2019. As a result, we concluded that it was more likely than not that the fair value of this reporting unit was below its carrying amount as of June 30, 2019 and a goodwill impairment test was required. After performing this quantitative test, we determined that this reporting unit’s carrying amount exceeded its estimated fair value. The fair value of the reporting unit was estimated using an income approach that utilized a discounted cash flow model. The discount rate utilized in this test was 10.5%. Based on the excess of this reporting unit’s carrying amount over its estimated fair value, we recorded a pre-tax non-cash goodwill impairment charge of $65.1 million during the three months ended June 30, 2019, representing the entire remaining amount of this reporting unit’s goodwill.

During the first quarter of 2018, a change in segments resulted in changes to our reporting units for goodwill impairment testing purposes, including the creation of a new Sterile Injectables reporting unit, which was previously part of our Generics reporting unit. As a result of these changes, under U.S. GAAP, we tested the goodwill of the former Generics reporting unit immediately before the segment realignment and the goodwill of both the new Sterile Injectables and Generic Pharmaceuticals reporting units immediately after the segment realignment. These goodwill tests were performed using an income approach that utilized a discounted cash flow model. The results of these goodwill impairment tests were as follows:


•	The former Generics reporting unit’s estimated fair value exceeded its carrying amount, resulting in no related goodwill impairment charge.


•	The new Sterile Injectables reporting unit’s estimated fair value exceeded its carrying amount, resulting in no related goodwill impairment charge.


•	The new Generic Pharmaceuticals reporting unit’s carrying amount exceeded its estimated fair value, resulting in a pre-tax non-cash goodwill impairment charge of $391.0 million.

In March 2017, we announced that the FDA’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted that the benefits of reformulated OPANA^®ER (oxymorphone hydrochloride extended release) no longer outweigh its risks. In June 2017, we became aware of the FDA’s request that we voluntarily withdraw OPANA^®ER from the market and, in July 2017, after careful consideration and consultation with the FDA, we decided to voluntarily remove OPANA^®ER from the market. As a result of our decision, the Company determined that the carrying amount of its OPANA^® ER intangible asset was no longer recoverable, resulting in a pre-tax, non-cash impairment charge of $20.6 million in the second quarter of 2017, representing the remaining carrying amount.

As a result of the withdrawal of OPANA^® ER from the market and the continued erosion of our Branded Pharmaceuticals segment’s Established Products portfolio, we initiated an interim goodwill impairment analysis of our Branded reporting unit during the second quarter of 2017. We recorded a pre-tax, non-cash goodwill impairment charge of $180.4 million during the three months ended June 30, 2017 for the amount by which the reporting unit’s carrying amount exceeded its fair value. We estimated the fair value of the Branded reporting unit using an income approach that utilized a discounted cash flow model.

Following the announcement of the 2017 Generic Pharmaceuticals Restructuring Initiative, which is further described in Note 4. Restructuring, the Company assessed the recoverability of certain products that were discontinued as part of this initiative, resulting in pre-tax, non-cash intangible asset impairment charges of approximately $57.5 million during the second quarter of 2017.

Pursuant to an existing agreement with a wholly-owned subsidiary of Novartis, Paladin licensed the Canadian rights to commercialize serelaxin, an investigational drug for the treatment of acute heart failure (AHF). In March 2017, Novartis announced that a Phase 3 study of serelaxin in patients with AHF failed to meet its primary endpoints. As a result, we concluded that the full carrying amount of our serelaxin in-process research and development intangible asset was impaired, resulting in a $45.5 million pre-tax non-cash impairment charge during the three months ended March 31, 2017. In addition, and as a result of the serelaxin impairment, we assessed the recoverability of our Paladin goodwill balance and determined that the estimated fair value of the Paladin reporting unit was below its carrying amount. We recorded a pre-tax, non-cash goodwill impairment charge of $82.6 million during the three months ended March 31, 2017 for the amount by which the carrying amount exceeded the reporting unit’s fair value. We estimated the fair value of the Paladin reporting unit using an income approach that utilized a discounted cash flow model.

As further discussed in Note 3. Discontinued Operations and Divestitures, we entered into a definitive agreement to sell Somar on June 30, 2017, which resulted in Somar’s assets and liabilities being classified as held for sale. The initiation of held-for-sale accounting, together with the agreed upon sale price, triggered an impairment review. Accordingly, we performed an impairment analysis using a market approach and determined that impairment charges were required. We recorded pre-tax, non-cash impairment charges of $25.7 million and $89.5 million related to Somar’s goodwill and other intangible assets, respectively, during the second quarter of 2017, each of which represented the remaining carrying amounts of the corresponding assets.

License and Collaboration Agreements	12 Months Ended
License and Collaboration Agreements	Dec. 31, 2019
License And Collaboration Agreements [Abstract]
LICENSE AND COLLABORATION AGREEMENTS	NOTE 11. LICENSE AND COLLABORATION AGREEMENTS Our subsidiaries have entered into certain license, collaboration and discovery agreements with third parties for product development. These agreements require our subsidiaries to share in the development costs of such products and the third parties grant marketing rights to our subsidiaries for such products. Generally, under these agreements: (i) we are required to make upfront payments and other payments upon successful completion of regulatory or sales milestones and/or (ii) we are required to pay royalties on sales of the products arising from these agreements. BioSpecifics Technologies Corp. (BioSpecifics) The Company, through an affiliate, is party to a development and license agreement, as amended (the BioSpecifics Agreement) with BioSpecifics. The BioSpecifics Agreement was originally entered into in June 2004 to obtain exclusive worldwide rights to develop, market and sell certain products containing BioSpecifics’ enzyme CCH, which is included in our XIAFLEX^® product. The Company’s licensed rights concern the development and commercialization of products, other than dermal formulations labeled for topical administration, and currently, the Company’s licensed rights cover the indications of DC, Dupuytren’s nodules, PD, adhesive capsulitis, cellulite, plantar fibromatosis, lateral hip fat and other potential indications. The Company may further expand the BioSpecifics Agreement, at its option, to cover other indications as they are developed by the Company or BioSpecifics. Under the BioSpecifics Agreement, we are responsible, at our own cost and expense, for developing the formulation and finished dosage form of products and arranging for the clinical supply of products. BioSpecifics may from time to time conduct exploratory clinical trials evaluating CCH as a treatment for a number of conditions, including uterine fibroids. In certain cases, the Company has the option to license development and marketing rights to future indications based on a full analysis of the data from the clinical trials, which would transfer responsibility for the future development costs to the Company and trigger opt-in payments and potential future milestone and royalty payments to BioSpecifics. The BioSpecifics Agreement extends, on a country-by-country and product-by-product basis, for the longer of the patent life, the expiration of any regulatory exclusivity period or twelve years from the effective date. Either party may terminate the BioSpecifics Agreement as a result of the other party’s breach or bankruptcy. We may terminate the BioSpecifics Agreement with 90 days’ written notice. We must pay BioSpecifics on a country-by-country and product-by-product basis a specified percentage within a range of 5% to 15% of net sales for products covered by the BioSpecifics Agreement. This royalty applies to net sales by the Company and/or any of its sublicensees. We are also obligated to pay a percentage of any future regulatory or commercial milestone payments received from any sublicensees. In addition, the Company and its affiliates pay BioSpecifics an amount equal to a specified mark-up on certain cost of goods related to supply of XIAFLEX^® (which mark-up is capped at a specified percentage within the range of 5% to 15% of the cost of goods of XIAFLEX^®) for products sold by the Company and its affiliates. Nevakar, Inc. During the second quarter of 2018, we entered into a development, license and commercialization agreement with Nevakar, Inc. related to five sterile injectable product candidates. Pursuant to this agreement, Nevakar, Inc. will generally be responsible, at its expense, to develop and seek regulatory approval for these product candidates, and the Company will generally be responsible, at its expense, to launch and distribute any products that are approved. The Company will have exclusive license rights to all of these products launched in the U.S. and a first right of refusal for the Canadian territory. Upon entering into this agreement, the Company became obligated to make an upfront payment, which was recorded as R&D expense in the Consolidated Statements of Operations during the three months ended June 30, 2018. The Company could become obligated to make additional payments based on certain potential future milestones being achieved.

Contract Assets and Liabilities

12 Months Ended

Dec. 31, 2019

Contract with Customer, Asset and Liability [Abstract]

CONTRACT ASSETS AND LIABILITIES

NOTE 12. CONTRACT ASSETS AND LIABILITIES

Our revenue consists almost entirely of sales of our pharmaceutical products to customers, whereby we ship products to a customer pursuant to a purchase order. Revenue contracts such as these do not generally give rise to contract assets or contract liabilities because: (i) the underlying contracts generally have only a single performance obligation and (ii) we do not generally receive consideration until the performance obligation is fully satisfied. At December 31, 2019, the unfulfilled performance obligations for these types of contracts relate to ordered but undelivered products. We generally expect to fulfill the performance obligations and recognize revenue within one week of entering into the underlying contract. Based on the short-term initial contract duration, additional disclosure about the remaining performance obligations is not required.

Certain of our other revenue-generating contracts, including license and collaboration agreements, may result in contract assets and/or contract liabilities. For example, we may recognize contract liabilities upon receipt of certain upfront and milestone payments from customers when there are remaining performance obligations.

The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):



	December 31, 2019		December 31, 2018		$ Change			% Change
Contract assets, net (1)	$	—	$	12,065	$	(12,065	)	(100	)%
Contract liabilities, net (2)	$	6,592	$	19,217	$	(12,625	)	(66	)%

__________

(1)

At December 31, 2018, approximately $9.3 million of the contract asset amount is classified as a current asset and is included in Prepaid expenses and other current assets in the Company’s Consolidated Balance Sheets. The remaining amount is classified as noncurrent and is included in Other assets. The net decrease in contract assets during the year ended December 31, 2019 was primarily due to reclassifications to accounts receivable following the resolution of certain conditions other than the passage of time affecting the Company’s rights to consideration for the sale of certain goods, as well as certain product discontinuation activities in our International Pharmaceuticals segment.

(2)

At December 31, 2019 and December 31, 2018, approximately $1.4 million and $1.7 million, respectively, of these contract liability amounts are classified as current liabilities and are included in Accounts payable and accrued expenses in the Company’s Consolidated Balance Sheets. The remaining amounts are classified as noncurrent and are included in Other liabilities. During the year ended December 31, 2019, the Company entered into new contracts resulting in an increase to contract liabilities of approximately $4.0 million. This increase was more than offset by approximately $14.9 million in reductions following certain product discontinuation activities in our International Pharmaceuticals segment and approximately $1.2 million in revenue recognized during the period.

During the year ended December 31, 2019, we recognized revenue of $10.8 million relating to performance obligations satisfied, or partially satisfied, in prior periods. Such revenue generally relates to changes in estimates with respect to our variable consideration.

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2019

Accounts Payable and Accrued Liabilities, Current [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 13. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses include the following at December 31, 2019 and December 31, 2018 (in thousands):



	December 31, 2019		December 31, 2018
Trade accounts payable	$	101,532	$	96,024
Returns and allowances	206,248		236,946
Rebates	129,056		144,860
Chargebacks	1,594		2,971
Accrued interest	112,860		130,182
Accrued payroll and related benefits	79,869		89,895
Accrued royalties and other distribution partner payables	115,816		122,028
Acquisition-related contingent consideration—current	6,534		36,514
Other	146,440		149,780
Total	$	899,949	$	1,009,200

Debt

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

DEBT

NOTE 14. DEBT

The following table presents information about the Company’s total indebtedness at December 31, 2019 and December 31, 2018 (dollars in thousands):



	December 31, 2019						December 31, 2018
	Effective Interest Rate		Principal Amount		Carrying Amount		Effective Interest Rate		Principal Amount		Carrying Amount
7.25% Senior Notes due 2022	7.25	%	$	8,294	$	8,294	7.91	%	$	400,000	$	392,947
5.75% Senior Notes due 2022	5.75	%	182,479		182,479		6.04	%	700,000		694,464
5.375% Senior Notes due 2023	5.62	%	210,440		209,018		5.62	%	750,000		743,438
6.00% Senior Notes due 2023	6.28	%	1,439,840		1,426,998		6.28	%	1,635,000		1,616,817
5.875% Senior Secured Notes due 2024	6.14	%	300,000		296,647		6.14	%	300,000		296,062
6.00% Senior Notes due 2025	6.27	%	1,200,000		1,185,726		6.27	%	1,200,000		1,183,415
7.50% Senior Secured Notes due 2027	7.71	%	1,500,000		1,482,212				—		—
Term Loan Facility	6.21	%	3,329,625		3,302,675		7.02	%	3,363,775		3,331,276
Revolving Credit Facility	4.25	%	300,000		300,000				—		—
Total long-term debt, net			$	8,470,678	$	8,394,049			$	8,348,775	$	8,258,419
Less current portion, net			34,150		34,150				34,150		34,150
Total long-term debt, less current portion, net			$	8,436,528	$	8,359,899			$	8,314,625	$	8,224,269

The Company and its subsidiaries, with certain customary exceptions, guarantee or serve as issuers or borrowers of the debt instruments representing substantially all of the Company’s indebtedness at December 31, 2019. The obligations under (i) all of the senior secured notes and (ii) the Credit Agreement (as defined below) and related loan documents are secured on a pari passu basis by a perfected first priority (subject to certain permitted liens) lien on the collateral securing such instruments, which collateral represents substantially all of the assets of the issuers or borrowers and the guarantors party thereto (subject to customary exceptions). Our senior unsecured notes are unsecured and effectively subordinated in right of priority to the Credit Agreement and our senior secured notes, in each case to the extent of the value of the collateral securing such instruments.

The aggregate estimated fair value of the Company’s long-term debt, which was estimated using inputs based on quoted market prices for the same or similar debt issuances, was $7.4 billion and $7.2 billion at December 31, 2019 and December 31, 2018, respectively. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.

Credit Facilities

The Company and certain of its subsidiaries are party to a credit agreement (the Credit Agreement), which provides for (i) a $1,000.0 million senior secured revolving credit facility (the Revolving Credit Facility) and (ii) a senior secured term loan facility in an initial principal amount of $3,415.0 million (the Term Loan Facility and, together with the Revolving Credit Facility, the Credit Facilities). Current amounts outstanding under the Credit Facilities are set forth in the table above. After giving effect to borrowings under the Revolving Credit Facility and previously issued and outstanding letters of credit, approximately $696.8 million of remaining credit is available under the Revolving Credit Facility as of December 31, 2019. The Company’s outstanding debt agreements contain a number of restrictive covenants, including certain limitations on the Company’s ability to incur additional indebtedness.

The Credit Agreement contains affirmative and negative covenants that the Company believes to be usual and customary for a senior secured credit facility of this type. The negative covenants include, among other things, limitations on asset sales, mergers and acquisitions, indebtedness, liens, dividends and other restricted payments, investments and transactions with the Company’s affiliates. As of December 31, 2019 and December 31, 2018, we were in compliance with all such covenants.

In addition, after each fiscal year-end, the Company is required to perform a calculation of Excess Cash Flow (as defined in the Credit Agreement), which could result in certain pre-payments of the principal relating to the Term Loan Facility in accordance with the terms of the Credit Agreement. No such payment is required at December 31, 2019.

The commitments under the Revolving Credit Facility generally mature in 2024, with the exception of $76.0 million of commitments that mature in 2022. Principal payments on the Term Loan Facility equal to 0.25% of the initial principal amount are generally payable quarterly until the Term Loan Facility’s ultimate maturity date in 2024, at which time the remaining principal amount outstanding will be payable. However, with certain exceptions set forth in the Credit Agreement, maturities under the Credit Facilities will be accelerated if any of the following of our senior notes are not refinanced or repaid in full at least 91 days prior to the respective maturity dates thereof:



Instrument		Maturity Date
7.25% Senior Notes Due 2022		January 15, 2022
5.75% Senior Notes Due 2022		January 15, 2022
5.375% Senior Notes Due 2023		January 15, 2023
6.00% Senior Notes Due 2023		July 15, 2023

Borrowings under the Revolving Credit Facility bear interest, at the borrower’s election, at a rate equal to (i) an applicable margin between 1.50% and 3.00% depending on the Company’s Total Net Leverage Ratio plus LIBOR or (ii) an applicable margin between 0.50% and 2.00% depending on the Company’s Total Net Leverage Ratio plus the Alternate Base Rate (as defined in the Credit Agreement). In addition, borrowings under our Term Loan Facility bear interest, at the borrower’s election, at a rate equal to (i) 4.25% plus LIBOR, subject to a LIBOR floor of 0.75%, or (ii) 3.25% plus the Alternate Base Rate, subject to an Alternate Base Rate floor of 1.75%.

Senior Notes and Senior Secured Notes

Our various senior notes and senior secured notes mature between 2022 and 2027. The indentures governing these notes generally allow for redemption prior to maturity, in whole or in part, subject to certain restrictions and limitations described therein, in the following ways:

•

Until a date specified in each indenture (the Non-Call Period), the notes may be redeemed, in whole or in part, by paying the sum of: (i) 100% of the principal amount being redeemed, (ii) an applicable make-whole premium as described in each indenture and (iii) accrued and unpaid interest. As of December 31, 2019, the Non-Call Period has expired for each of our notes except for the 5.875% Senior Secured Notes due 2024, the 6.00% Senior Notes due 2025 and the 7.50% Senior Secured Notes due 2027.

•

After the Non-Call Period specified in each indenture, the notes may be redeemed, in whole or in part, at redemption prices set forth in each indenture, plus accrued and unpaid interest. The redemption prices for each of our notes vary over time. The redemption prices pursuant to this clause range from 100.000% to 105.625% of principal at December 31, 2019; however, these redemption prices generally decrease to 100% of the principal amount of the applicable notes over time as the notes approach maturity pursuant to a step-down schedule set forth in each of the indentures.

•

Until a date specified in each indenture, the notes may be redeemed, in part (up to 35% of the principal amount outstanding), with the net cash proceeds from specified equity offerings at redemption prices set forth in each indenture, plus accrued and unpaid interest. As of December 31, 2019, this clause has expired for each of our notes except for the 5.875% Senior Secured Notes due 2024 and the 7.50% Senior Secured Notes due 2027, for which the specified redemption premiums are 105.875% and 107.500%, respectively.

The indentures governing our various senior notes contain affirmative and negative covenants that the Company believes to be usual and customary for similar indentures. Under the senior secured notes indentures, the negative covenants, among other things, restrict the Company’s ability and the ability of its restricted subsidiaries (as defined in the indentures) to incur certain additional indebtedness and issue preferred stock; make certain dividends, distributions, investments and other restricted payments; sell certain assets; enter into sale and leaseback transactions; agree to certain restrictions on the ability of restricted subsidiaries to make certain payments to the Company or any of its restricted subsidiaries; create certain liens; merge, consolidate or sell all or substantially all of the Company’s assets; enter into certain transactions with affiliates or designate subsidiaries as unrestricted subsidiaries. Under the senior unsecured notes indentures, the negative covenants, among other things, restrict the ability of Endo Designated Activity Company and its restricted subsidiaries (as defined in the indentures) to incur certain additional indebtedness and issue preferred stock; make certain dividends, distributions, investments and other restricted payments; sell certain assets; enter into sale and leaseback transactions; agree to certain restrictions on the ability of restricted subsidiaries to make certain payments to the issuer or any of the restricted subsidiaries; create certain liens; merge, consolidate or sell all or substantially all of Endo Designated Activity Company’s, its co-issuers’ or guarantors’ assets; enter into certain transactions with affiliates or designate subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions and qualifications, including the fall away or revision of certain of these covenants and release of collateral in the case of the senior secured notes, upon the notes receiving investment grade credit ratings. As of December 31, 2019 and December 31, 2018, we were in compliance with all such covenants. Additionally, pursuant to the terms of the indentures governing certain of our senior unsecured notes, the restricted subsidiaries of Endo International plc, whose assets comprise substantially all of the Company’s consolidated total assets after intercompany eliminations, are subject to various restrictions limiting their ability to transfer assets in excess of certain thresholds to Endo International plc.

Debt Financing Transactions

Set forth below are certain disclosures relating to debt financing transactions that occurred during the years ended December 31, 2019, 2018 and 2017.

April 2017 Refinancing

In April 2017, the Company executed certain transactions (the April 2017 Refinancing Transactions) that included entry into a credit agreement, which provided for a term loan facility and a revolving credit facility, and the issuance of $300.0 million of 5.875% Senior Secured Notes due 2024 (the 2024 Notes). The Company used the net proceeds from this term loan facility, the 2024 Notes and cash on hand to refinance certain of its prior indebtedness and to pay related fees and expenses.

In connection with the April 2017 Refinancing Transactions, the Company incurred new debt issuance costs of approximately $56.7 million, which were allocated among the new debt instruments as follows: (i) $41.3 million to the new term loan facility, (ii) $10.5 million to the new revolving credit facility and (iii) $4.9 million to the 2024 Notes. These costs, together with $10.1 million of the previously deferred debt issuance costs associated with our prior revolving credit facility, were deferred to be amortized as interest expense over the terms of the respective instruments. The remaining $51.7 million of deferred debt issuance costs associated with our prior revolving and term loan facilities were charged to expense in the second quarter of 2017. These net expenses were included in the (Gain) loss on extinguishment of debt line item in the Consolidated Statements of Operations.

March 2019 Refinancing

In March 2019, the Company executed certain transactions (the March 2019 Refinancing Transactions) that included:


•	entry into an amendment (the Revolving Credit Facility Amendment) to the Company’s existing credit agreement, which was originally dated April 27, 2017 (the amended credit agreement is described above under the heading “Credit Agreement”);


•	issuance of $1,500.0 million of 7.50% Senior Secured Notes due 2027 (the 2027 Notes);


•	repurchase of $1,642.2 million aggregate principal amount of certain of the Company’s senior unsecured notes for $1,500.0 million in cash, excluding accrued interest (the Notes Repurchases); and


•	solicitation of consents from the holders of the existing 7.25% Senior Notes due 2022 and 5.75% Senior Notes due 2022 (together, the Consent Notes) to certain amendments to the indentures governing such notes, which eliminated substantially all of the restrictive covenants, certain events of default and other provisions contained in each such indenture.

The Revolving Credit Facility Amendment amended the Credit Agreement to, among other things, (i) extend the maturity of the commitments under the Revolving Credit Facility from April 2022 to March 2024 (with the exception of $76.0 million of commitments that were not extended), (ii) provide greater covenant flexibility by increasing the maximum Secured Net Leverage Ratio described in the Financial Covenant (as defined in the Credit Agreement) from 3.50 to 1.00 to 4.50 to 1.00 and (iii) limit the scenarios under which such Financial Covenant will be tested.

The 2027 Notes were issued by PPI, a wholly-owned indirect subsidiary of the Company, in a private offering to “qualified institutional buyers” (as defined in Rule 144A under the Securities Act) and outside the U.S. to non-U.S. persons in compliance with Regulation S under the Securities Act. The 2027 Notes are guaranteed on a senior secured basis by the Company and its subsidiaries that also guarantee the Credit Agreement (collectively, the Guarantors). The 2027 Notes are senior secured obligations of PPI and the Guarantors and are secured by the same collateral that secures the Credit Agreement and the Company’s existing senior secured notes. Interest on the 2027 Notes is payable semiannually in arrears on April 1 and October 1 of each year, beginning on October 1, 2019.

The 2027 Notes will mature on April 1, 2027; however, the indenture governing these notes generally allow for redemption prior to maturity, in whole or in part, subject to certain restrictions and limitations described therein, in the following ways:


•	Before April 1, 2022, the 2027 Notes may be redeemed, in whole or in part, by paying the sum of: (i) 100% of the principal amount being redeemed, (ii) an applicable make-whole premium as described in the indenture and (iii) accrued and unpaid interest.


•	On or after April 1, 2022, the 2027 Notes may be redeemed, in whole or in part, at redemption prices set forth in the indenture, plus accrued and unpaid interest. The redemption prices for the 2027 Notes vary over time pursuant to a step-down schedule set forth in the indenture, beginning at 105.625% of the principal amount redeemed and decreasing to 100% by April 1, 2025.


•	Before April 1, 2022, the 2027 Notes may be redeemed, in part (up to 35% of the principal amount outstanding), with the net cash proceeds from specified equity offerings at 107.500% of the principal amount redeemed, plus accrued and unpaid interest.

The Company used the net proceeds from the 2027 Notes and cash on hand primarily to fund the Notes Repurchases and to pay certain premiums, fees and expenses related thereto. The Notes Repurchases were completed by Endo Finance LLC (Endo Finance), a wholly-owned subsidiary of the Company, pursuant to a tender offer to repurchase portions of the Company’s outstanding 7.25% Senior Notes due 2022, 5.75% Senior Notes due 2022, 5.375% Senior Notes due 2023 and 6.00% Senior Notes due 2023. In connection with the Notes Repurchases, Endo Finance repurchased $1,642.2 million of senior unsecured note indebtedness, representing the aggregate principal amount repurchased, for $1,500.0 million in cash (including certain cash premiums related thereto). The $1,642.2 million aggregate repurchase amount consisted of (i) $389.9 million aggregate principal amount of the 7.25% Senior Notes due 2022, (ii) $517.5 million aggregate principal amount of the 5.75% Senior Notes due 2022, (iii) $539.6 million aggregate principal amount of the 5.375% Senior Notes due 2023 and (iv) $195.2 million aggregate principal amount of the 6.00% Senior Notes due 2023. The aggregate carrying amount of notes repurchased was $1,624.0 million. In conjunction with the Notes Repurchases, Endo Finance also solicited consents from holders of the Consent Notes to certain proposed amendments to the applicable indentures under which each series of Consent Notes were issued, which would eliminate substantially all restrictive covenants, certain events of default and certain other provisions contained in each such indenture. The proposed amendments were effected pursuant to a supplemental indenture to each such indenture executed by Endo Finance and the guarantors of the Consent Notes, which became operative upon the repurchase of at least the requisite consent amount of the applicable series of Consent Notes tendered.

The difference between the cash paid and the carrying amount of notes repurchased in the Notes Repurchases resulted in a $124.0 million gain. In connection with the March 2019 Refinancing Transactions, we also incurred costs and fees totaling $26.2 million, of which $4.2 million related to the Notes Repurchases, $19.1 million related to the 2027 Notes issuance and $2.9 million related to the Revolving Credit Facility Amendment. The costs incurred in connection with the Notes Repurchases were charged to expense in the first quarter of 2019 and recorded as a partial offset to the gain. The costs incurred in connection with the 2027 Notes issuance and the Revolving Credit Facility Amendment, together with previously deferred debt issuance costs associated with the Revolving Credit Facility, have been deferred to be amortized as interest expense over the terms of the respective instruments. The net gain resulting from the March 2019 Refinancing Transactions was included in the (Gain) loss on extinguishment of debt line item in the Consolidated Statements of Operations.

June 2019 Revolving Credit Facility Borrowing

In June 2019, the Company borrowed $300.0 million under the Revolving Credit Facility. These proceeds will be used for purposes consistent with the Company’s capital allocation priorities, including for general corporate purposes.

Maturities

The following table presents the maturities on our long-term debt for each of the five fiscal years subsequent to December 31, 2019 (in thousands):



	Maturities (1)
2020	$	34,150
2021	$	34,150
2022 (2)	$	247,723
2023	$	1,684,430
2024 (2)	$	3,770,225

__________

(1)

Certain amounts borrowed pursuant to the Credit Facilities will immediately mature if certain of our senior notes are not refinanced or repaid in full prior to the date that is 91 days prior to the respective stated maturity dates thereof. Accordingly, we may seek to repay or refinance certain senior notes prior to their stated maturity dates. The amounts in this maturities table do not reflect any such early repayment or refinancing; rather, they reflect stated maturity dates.

(2)

Based on the Company’s borrowings under the Revolving Credit Facility that were outstanding at December 31, 2019, $22.8 million will mature in 2022, with the remainder maturing in 2024.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 15. COMMITMENTS AND CONTINGENCIES

Manufacturing, Supply and Other Service Agreements

Our subsidiaries contract with various third party manufacturers, suppliers and service providers to provide raw materials used in our subsidiaries’ products and semi-finished and finished goods, as well as certain packaging, labeling services, customer service support, warehouse and distribution services. If, for any reason, we are unable to obtain sufficient quantities of any of the finished goods or raw materials or components required for our products or services needed to conduct our business, it could have a material adverse effect on our business, financial condition, results of operations and cash flows.

In addition to the manufacturing and supply agreements described above, we have agreements with various companies for clinical development services. Although we have no reason to believe that the parties to these agreements will not meet their obligations, failure by any of these third parties to honor their contractual obligations may have a material adverse effect on our business, financial condition, results of operations and cash flows.

Jubilant HollisterStier Laboratories LLC (JHS)

During the second quarter of 2016, we entered into an agreement with JHS (the JHS Agreement). Pursuant to the JHS Agreement, JHS fills and lyophilizes the XIAFLEX^®bulk drug substance, which is manufactured by the Company, and produces sterile diluent. The initial term of the JHS Agreement is three years, with automatic renewal provisions thereafter for subsequent one-year terms, unless or until either party provides notification prior to expiration of the then current term of the contract. The Company is required to purchase a specified percentage of its total forecasted volume of XIAFLEX^®from JHS each year, unless JHS is unable to supply XIAFLEX^®within the timeframe established under such forecasts. Amounts purchased pursuant to the JHS Agreement were $8.6 million, $7.5 million and $5.6 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Milestones and Royalties

See Note 11. License and Collaboration Agreements for a description of future milestone and royalty commitments pursuant to our material license and collaboration agreements.

Legal Proceedings and Investigations

We and certain of our subsidiaries are involved in various claims, legal proceedings and internal and governmental investigations (collectively, proceedings) that arise from time to time, including, among others, those relating to product liability, intellectual property, regulatory compliance, consumer protection, tax and commercial matters. While we cannot predict the outcome of these proceedings and we intend to vigorously prosecute or defend our position as appropriate, there can be no assurance that we will be successful or obtain any requested relief. An adverse outcome in any of these proceedings could have a material adverse effect on our business, financial condition, results of operations and cash flows. Matters that are not being disclosed herein are, in the opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows. If and when such matters, in the opinion of our management, become material, either individually or in the aggregate, we will disclose them.

We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability or other matters are or may be covered in whole or in part under our insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the realization of the potential claim for recovery is considered probable. Amounts recovered under our insurance policies could be materially less than stated coverage limits and may not be adequate to cover damages, other relief and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

As of December 31, 2019, our accrual for loss contingencies totaled $513.0 million, the most significant components of which relate to product liability and related matters associated with vaginal mesh. Although we believe there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time. While the timing of the resolution of certain of the matters accrued for as loss contingencies remains uncertain and could extend beyond 12 months, as of December 31, 2019, the entire liability accrual amount is classified in the Current portion of legal settlement accrual in the Consolidated Balance Sheets.

Product Liability and Related Matters

We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various U.S. federal and state courts, and in Canada, Australia and other countries, alleging personal injury resulting from the use of certain products of our subsidiaries, including the product liability and other related matters described below in more detail.

Vaginal Mesh. Since 2008, we and certain of our subsidiaries, including AMS (subsequently converted to Astora Women’s Health Holding LLC and merged into Astora Women’s Health LLC and referred to herein as AMS and/or Astora), have been named as defendants in multiple lawsuits in various state and federal courts in the U.S. (including a federal multidistrict litigation (MDL) in the U.S. District Court for the Southern District of West Virginia), and in Canada, Australia and other countries, alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat POP and SUI. Plaintiffs claim a variety of personal injuries, including chronic pain, incontinence, inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.

We and certain plaintiffs’ counsel have entered into various Master Settlement Agreements (MSAs) and other agreements to resolve up to approximately 71,000 filed and unfiled mesh claims handled or controlled by the participating counsel in the U.S. These MSAs and other agreements were entered into at various times between June 2013 and the present, were solely by way of compromise and settlement and were not in any way an admission of liability or fault by us or any of our subsidiaries. All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of QSFs into which the settlement funds will be deposited, establish participation requirements and allow for a reduction of the total settlement payment in the event participation thresholds are not met. Funds deposited in QSFs are considered restricted cash and/or restricted cash equivalents. Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating product use, the dismissal of any lawsuit and the release of the claim as to us and all affiliates. Prior to receiving funds, an individual claimant must represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the settlement funds, amounts allocated to individual claimants and other terms of the agreement.

In October 2019, the Ontario Superior Court of Justice approved a class action settlement covering unresolved claims by Canadian women implanted with an AMS vaginal mesh device. Astora funded the settlement in February 2020.

The following table presents the changes in the QSFs and mesh liability accrual balances during the year ended December 31, 2019 (in thousands):



	Qualified Settlement Funds			Mesh Liability Accrual
Balance as of January 1, 2019	$	299,733		$	748,606
Additional charges	—			30,000
Cash contributions to Qualified Settlement Funds	253,520			—
Cash distributions to settle disputes from Qualified Settlement Funds	(314,266		)	(314,266		)
Cash distributions to settle disputes	—			(15,330		)
Other (1)	3,855			5,021
Balance as of December 31, 2019	$	242,842		$	454,031

__________

(1)

Amounts deposited in the QSFs may earn interest, which is generally used to pay administrative costs of the fund and is reflected in the table above as an increase to the QSF and Mesh Liability Accrual balances. Any interest remaining after all claims have been paid will generally be distributed to the claimants who participated in that settlement. Also included within this line are foreign currency adjustments for settlements not denominated in U.S. dollars.

Charges related to vaginal mesh liability and associated legal fees and other expenses for all periods presented are reported in Discontinued operations, net of tax in our Consolidated Statements of Operations.

To date, the Company has made total mesh liability payments of approximately $3.5 billion, $242.8 million of which remains in the QSFs as of December 31, 2019. We currently expect to fund into the QSFs during 2020 the remaining payments under all existing settlement agreements. As the funds are disbursed out of the QSFs from time to time, the liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes separate from the QSFs, which will also decrease the liability accrual and decrease cash and cash equivalents.

We were contacted in October 2012 regarding a civil investigation initiated by various state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and we have subsequently received additional subpoenas from California and other states. We are cooperating with the investigations.

We will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.

Although the Company believes it has appropriately estimated the probable total amount of loss associated with all mesh-related matters as of the date of this report, litigation is ongoing in certain cases that have not settled, trials may occur as early as April 2020, and it is reasonably possible that further claims may be filed or asserted and that adjustments to our overall liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Testosterone. A federal MDL in the U.S. District Court for the Northern District of Illinois includes multiple lawsuits against manufacturers of prescription medications containing testosterone, including our subsidiaries EPI and Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals, LLC and hereinafter referred to as Auxilium). Plaintiffs in these suits have generally alleged various personal injuries resulting from the use of such medications (including FORTESTA^® Gel, DELATESTRYL^®, TESTIM^®, TESTOPEL^®, AVEED^® and STRIANT^®), including pulmonary embolism, stroke or other vascular and/or cardiac injuries, and sought compensatory and/or punitive damages, where available.

In June 2018, counsel for plaintiffs, on the one hand, and Auxilium and EPI, on the other, executed an MSA allowing for the resolution of all known TRT product liability claims against our subsidiaries. The MSA was solely by way of compromise and settlement and was not in any way an admission of liability or fault by us or any of our subsidiaries.

The MSA established various guidelines and procedures for administering the settlement and the release of funds. Among other things, the MSA provides for the creation of a QSF into which the settlement funds will be deposited, establishes participation requirements and allows for a reduction of the total settlement payment in the event the participation threshold is not met. Auxilium and EPI funded the QSF in November 2019. Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating product use and injury as determined by a third-party special master, the dismissal of any lawsuit and the release of the claim as to us and all affiliates. Prior to receiving funds, an individual claimant must represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the settlement funds, amounts allocated to individual claimants and other terms of the agreement.

The MDL court has been dismissing cases pursuant to the settlement or for failure to comply with court orders. As of February 18, 2020, we were aware of approximately 5 cases (some of which may have been filed on behalf of multiple plaintiffs) that remained pending in the MDL against one or more of our subsidiaries.

The MDL also included a lawsuit filed in November 2014 in the U.S. District for the Northern District of Illinois against EPI, Auxilium and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payers. This lawsuit was not part of the settlement described above. After a series of motions to dismiss, plaintiff filed a third amended complaint in April 2016, asserting civil claims for alleged violations of the Racketeer Influenced and Corrupt Organizations Act and negligent misrepresentation based on defendants’ marketing of certain testosterone products. In February 2019, the court granted defendants’ motion for summary judgment. In November 2019, the Seventh Circuit affirmed.

Although the Company believes it has appropriately estimated the probable total amount of loss associated with testosterone-related matters as of the date of this report, it is reasonably possible that further claims may be filed or asserted and that adjustments to our overall liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Opioid-Related Matters

Since 2014, multiple U.S. states and other governmental persons or entities and private plaintiffs in the U.S. and Canada have filed suit against us and/or certain of our subsidiaries, including EHSI, EPI, PPI, PPCI, Endo Generics Holdings, Inc. (EGHI), Vintage Pharmaceuticals, LLC, Generics Bidco I, LLC and DAVA Pharmaceuticals, LLC, and in Canada, Paladin, as well as various other manufacturers, distributors, pharmacies and/or others, asserting claims relating to defendants’ alleged sales, marketing and/or distribution practices with respect to prescription opioid medications, including certain of our products. As of February 18, 2020, the cases in the U.S. of which we were aware include, but are not limited to, approximately 20 cases filed by or on behalf of states; approximately 2,700 cases filed by counties, cities, Native American tribes and/or other government-related persons or entities; approximately 280 cases filed by hospitals, health systems, unions, health and welfare funds or other third-party payers and approximately 160 cases filed by individuals. Certain of the cases have been filed as putative class actions. The Canadian cases include an action filed by British Columbia on behalf of a proposed class of all federal, provincial and territorial governments and agencies in Canada that paid healthcare, pharmaceutical and treatment costs related to opioids, as well as three additional putative class actions, filed in Ontario, Quebec and British Columbia, seeking relief on behalf of Canadian residents who were prescribed and/or consumed opioid medications.

Many of the U.S. cases have been coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Ohio. Other cases are pending in various federal or state courts. The cases are at various stages. The first MDL trial, relating to the claims of two Ohio counties (Track One plaintiffs), was set for October 2019 but did not go forward after most defendants settled. EPI, EHSI, PPI and PPCI executed a settlement agreement with the Track One plaintiffs in September 2019 which provided for payments totaling $10 million and up to $1 million of VASOSTRICT^® and/or ADRENALIN^®. Under the settlement agreement, the Track One plaintiffs may be entitled to additional payments in the event of a comprehensive resolution of government-related opioid claims. The settlement agreement was solely by way of compromise and settlement and was not in any way an admission of liability or fault by us or any of our subsidiaries. Certain state court cases are scheduled for trial in 2020, with the first of these trials currently scheduled to begin in March. Most other cases remain at the pleading and/or discovery stage.

The complaints in the cases assert a variety of claims, including but not limited to statutory claims asserting violations of public nuisance, consumer protection, unfair trade practices, racketeering, Medicaid fraud and/or drug dealer liability laws and/or common law claims for public nuisance, fraud/misrepresentation, strict liability, negligence and/or unjust enrichment. The claims are generally based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications and/or alleged failures to take adequate steps to identify and report suspicious orders and to prevent abuse and diversion. Plaintiffs generally seek declaratory and/or injunctive relief; compensatory, punitive and/or treble damages; restitution, disgorgement, civil penalties, abatement, attorneys’ fees, costs and/or other relief.

We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

In addition to the lawsuits described above, the Company and/or its subsidiaries have received certain subpoenas, civil investigative demands (CIDs) and informal requests for information concerning the sale, marketing and/or distribution of prescription opioid medications, including the following:

Various state attorneys general have served subpoenas and/or CIDs on EHSI and/or EPI. We are cooperating with the investigations.

In January 2018, our subsidiary EPI received a federal grand jury subpoena from the U.S. District Court for the Southern District of Florida seeking documents and information related to OPANA^® ER, other oxymorphone products and marketing of opioid medications. We are cooperating with the investigation.

In September 2019, EPI, EHSI, PPI and PPCI received subpoenas from the New York State Department of Financial Services seeking documents and information regarding the marketing, sale and distribution of opioid medications in New York. We are providing information responsive to these subpoenas.

Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

In January 2020, EPI and PPI executed a settlement agreement with the state of Oklahoma providing for a payment of approximately $8.75 million in resolution of potential opioid-related claims. The settlement agreement was solely by way of compromise and settlement and was not in any way an admission of liability or fault by us or any of our subsidiaries.

Generic Drug Pricing Matters

Since March 2016, various private plaintiffs and state attorneys general have filed cases against our subsidiary PPI and/or, in some instances, the Company, Generics Bidco I, LLC, DAVA Pharmaceuticals, LLC and/or PPCI, as well as other pharmaceutical manufacturers and, in some instances, other corporate and/or individual defendants, alleging price-fixing and other anticompetitive conduct with respect to generic pharmaceutical products. These cases, which include proposed class actions filed on behalf of direct purchasers, end-payers and indirect purchaser resellers, as well as non-class action suits, have generally been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Pennsylvania.

The various complaints and amended complaints generally assert claims under federal and/or state antitrust law, state consumer protection statutes and/or state common law regarding certain of our products, and seek damages, treble damages, civil penalties, disgorgement, declaratory and injunctive relief, costs and attorneys’ fees. Some claims are based on alleged product-specific conspiracies and other claims allege broader, multiple-product conspiracies. Under these overarching conspiracy theories, plaintiffs seek to hold all alleged participants in a particular conspiracy jointly and severally liable for all harms caused by the alleged conspiracy, not just harms related to the products manufactured and/or sold by a particular defendant.

The MDL court has issued various case management and substantive orders, including orders denying certain motions to dismiss, and discovery is ongoing.

In December 2014, our subsidiary PPI received from the Antitrust Division of the DOJ a federal grand jury subpoena issued by the U.S. District Court for the Eastern District of Pennsylvania addressed to “Par Pharmaceuticals.” The subpoena requested documents and information focused primarily on product and pricing information relating to the authorized generic version of Lanoxin (digoxin) oral tablets and generic doxycycline products, and on communications with competitors and others regarding those products. We are cooperating with the investigation.

In May 2018, we and our subsidiary PPCI each received a CID from the DOJ in relation to a False Claims Act investigation concerning whether generic pharmaceutical manufacturers engaged in price-fixing and market allocation agreements, paid illegal remuneration and caused the submission of false claims. We are cooperating with the investigation.

Other Antitrust Matters

Beginning in November 2013, multiple alleged purchasers of LIDODERM^® sued our subsidiary EPI and other pharmaceutical companies alleging violations of antitrust law arising out of their settlement of certain patent infringement litigation. The various complaints asserted claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law and sought damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. These cases were consolidated and/or coordinated in a federal MDL in the U.S. District Court for the Northern District of California. The last cases remaining in the MDL were dismissed with prejudice in September 2018, when the court approved EPI’s settlements with direct and indirect purchaser classes. Those settlement agreements provided for aggregate payments of approximately $100 million. Of this total, EPI paid approximately $60 million in 2018, $30 million in the first quarter of 2019 and $10 million in the first quarter of 2020. In September 2019, Blue Cross Blue Shield of Michigan and Blue Care Network of Michigan filed a complaint against EPI and other pharmaceutical companies in the Third Judicial Circuit Court, Wayne County, Michigan, asserting claims substantially similar to those asserted in the MDL. In October 2019, certain defendants removed the case to federal court. In November 2019, plaintiffs moved to remand the case to state court.

Beginning in June 2014, multiple alleged purchasers of OPANA^® ER sued our subsidiaries EHSI and EPI and other pharmaceutical companies (including Impax Laboratories, LLC (formerly Impax Laboratories, Inc. and referred to herein as Impax) and Penwest Pharmaceuticals Co., which our subsidiary EPI had acquired), alleging violations of antitrust law arising out of an agreement reached by EPI and Impax to settle certain patent infringement litigation and EPI’s introduction of reformulated OPANA^® ER. Some cases were filed on behalf of putative classes of direct and indirect purchasers, while others were filed on behalf of individual retailers or health care benefit plans. The cases have been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Illinois. The various complaints assert claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. In March 2019, direct and indirect purchaser plaintiffs filed motions for class certification, which remain pending.

Beginning in February 2009, the FTC and certain private plaintiffs sued our subsidiaries PPCI (since June 2016, EGHI) and/or PPI as well as other pharmaceutical companies alleging violations of antitrust law arising out of the settlement of certain patent litigation concerning the generic version of AndroGel^® and seeking damages, treble damages, equitable relief and attorneys’ fees and costs. The cases were consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Georgia. In May 2016, plaintiffs representing a putative class of indirect purchasers voluntarily dismissed their claims with prejudice. In February 2017, the FTC voluntarily dismissed its claims against EGHI with prejudice. In June 2018, the MDL court granted in part and denied in part various summary judgment and evidentiary motions filed by defendants. In particular, among other things, the court rejected two of the remaining plaintiffs’ causation theories and rejected damages claims related to AndroGel^® 1.62%. In July 2018, the court denied certain plaintiffs’ motion for certification of a direct purchaser class. In November 2019, PPI and PPCI entered into settlement agreements with all but one of the remaining plaintiffs in the MDL. The settlement agreements were solely by way of compromise and settlement and were not in any way an admission of liability or fault. Separately, in August 2019, several alleged direct purchasers filed suit in the U.S. District Court for the Eastern District of Pennsylvania asserting claims substantially similar to those asserted in the MDL, as well as additional claims against other defendants relating to other alleged conduct. In January 2020, the U.S. District Court for the Eastern District of Pennsylvania denied defendants’ motion to transfer venue to the Northern District of Georgia.

Beginning in February 2018, several alleged indirect purchasers filed proposed class actions against our subsidiary PPI and other pharmaceutical companies alleging violations of antitrust law arising out of the settlement of certain patent litigation concerning the generic version of Zetia^® (ezetimibe). The various complaints asserted claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law and sought injunctive relief, damages, treble damages, attorneys’ fees and costs. In June 2018, these and other related cases, including proposed direct purchaser class actions in which PPI was not named as a defendant, were consolidated and/or coordinated for pretrial proceedings in a federal MDL in the U.S. District Court for the Eastern District of Virginia. In September 2018, the indirect purchaser plaintiffs dismissed their claims against PPI without prejudice. In June and July 2019, the MDL court granted the direct purchaser plaintiffs and certain retailer plaintiffs leave to file amended complaints adding PPI as a defendant. In July 2019, PPI entered into settlement agreements with both the direct purchaser plaintiffs and the retailer plaintiffs. The direct purchaser settlement is subject to court approval. The settlement agreements were solely by way of compromise and settlement, were not in any way an admission of liability or fault and involved no monetary payment.

Beginning in May 2018, multiple complaints were filed in the U.S. District Court for the Southern District of New York against PPI, EPI and/or us, as well as other pharmaceutical companies, alleging violations of antitrust law arising out of the settlement of certain patent litigation concerning the generic version of Exforge^® (amlodipine/valsartan). Some cases were filed on behalf of putative classes of direct and indirect purchasers; others are non-class action suits. The various complaints assert claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, equitable relief and attorneys’ fees and costs. In September 2018, the putative class plaintiffs stipulated to the dismissal without prejudice of their claims against EPI and us, and the retailer plaintiffs later did the same. PPI filed a partial motion to dismiss certain claims in September 2018, which was granted in August 2019. The cases are currently in discovery.

Beginning in August 2019, multiple complaints were filed in the U.S. District Court for the Southern District of New York against PPI and other pharmaceutical companies alleging violations of antitrust law arising out the settlement of certain patent litigation concerning generic versions of Seroquel XR^®(extended release quetiapine fumarate). The claims against PPI are based on allegations that PPI entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals, LLC (Handa) in 2012 pursuant to which Handa assigned to PPI certain rights under a prior settlement agreement between Handa and AstraZeneca resolving certain patent litigation. Some cases were filed on behalf of putative classes of direct and indirect purchasers; others are non-class action suits. The various complaints assert claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, equitable relief and attorneys’ fees and costs. In October 2019, the defendants filed various motions to dismiss and, in the alternative, moved to transfer the litigation to the U.S. District Court for the District of Delaware.

To the extent unresolved, we will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

In February 2015, EGHI and affiliates received a CID from the Office of the Attorney General for the state of Alaska seeking documents and information regarding EGHI’s settlement of AndroGel^® patent litigation as well as documents produced in the aforementioned litigation filed by the FTC. Also in February 2015, EHSI received a CID from Alaska’s Office of the Attorney General seeking production of certain documents and information concerning agreements with Actavis and Impax settling OPANA^® ER patent litigation. We are cooperating with the investigations.

In July 2019, EPI received a CID from the FTC seeking documents and information regarding oxymorphone ER and EPI’s settlement of a contract dispute with Impax Laboratories (now Amneal) in August 2017. We are cooperating with the investigation.

Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Securities Litigation

In February 2017, a putative class action entitled Public Employees’ Retirement System of Mississippi v. Endo International plc was filed in the Court of Common Pleas of Chester County, Pennsylvania by an institutional purchaser of shares in our June 2, 2015 public offering. The complaint alleged violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 against us, certain of our current and former directors and officers, and the underwriters who participated in the offering, based on certain disclosures about Endo’s generics business. In June 2019, the parties entered into a settlement providing for, among other things, a $50 million payment to the investor class in exchange for a release of their claims. In December 2019, the court denied a petition to intervene filed by the lead plaintiff in the Pelletier litigation described below, and granted final approval of the settlement. In December 2019, the putative intervenor appealed the denial of its petition to intervene and the final approval order to Pennsylvania Superior Court. That appeal remains pending. As a result of the settlement, during the first quarter of 2019, the Company recorded an increase of approximately $50 million to its accrual for loss contingencies. As the Company’s insurers agreed to fund the settlement, the Company also recorded a corresponding insurance receivable of approximately $50 million during the first quarter of 2019, which was recorded as Prepaid expenses and other current assets in the Consolidated Balance Sheets. The Company’s insurers funded the settlement during the third quarter of 2019, resulting in corresponding decreases to the Company’s accrual for loss contingencies and insurance receivable.

In April 2017, a putative class action entitled Phaedra A. Makris v. Endo International plc, Rajiv Kanishka Liyanaarchchie de Silva and Suketu P. Upadhyay was filed in the Superior Court of Justice in Ontario, Canada by an individual shareholder on behalf of herself and similarly-situated Canadian-based investors who purchased Endo’s securities between January 11 and May 5, 2016. The statement of claim sought class certification, declaratory relief, damages, interest and costs based on alleged violations of the Ontario Securities Act arising out of alleged negligent misrepresentations concerning the Company’s revenues, profit margins and earnings per share; its receipt of a subpoena from the state of Connecticut regarding doxycycline hyclate, amitriptyline hydrochloride, doxazosin mesylate, methotrexate sodium and oxybutynin chloride; and the erosion of the Company’s U.S. generic pharmaceuticals business. In January 2019, plaintiff amended her statement of claim to add a claim on behalf of herself and similarly-situated Canadian investors who purchased Endo’s securities between January 11, 2016 and June 8, 2017, based on our decision to voluntarily remove reformulated OPANA^® ER from the market.

In August 2017, an alleged individual shareholder filed a putative class action entitled Bier v. Endo International plc in the U.S. District Court for the Eastern District of Pennsylvania, alleging violations of Sections 10(b) and 20(a) of the Exchange Act against us, EHSI and certain of our current and former directors and officers, based on our decision to voluntarily remove reformulated OPANA^® ER from the market. In December 2017, the court appointed SEB Investment Management AB lead plaintiff in the action. In August 2019, the parties entered into a settlement providing for, among other things, a payment of $82.5 million to the investor class in exchange for a release of their claims. The settlement received preliminary court approval in September 2019 and final approval in December 2019. As a result of the settlement, during the second quarter of 2019, the Company recorded an increase of approximately $82.5 million to its accrual for loss contingencies. As the Company’s insurers agreed to fund the settlement, the Company also recorded a corresponding insurance receivable of approximately $82.5 million during the second quarter of 2019, which was recorded as Prepaid expenses and other current assets in the Consolidated Balance Sheets. With respect to this settlement, the Company’s insurers funded $20.0 million during the third quarter of 2019 and the remainder in October 2019, resulting in corresponding decreases to the Company’s accrual for loss contingencies and insurance receivable.

In November 2017, a putative class action entitled Pelletier v. Endo International plc, Rajiv Kanishka Liyanaarchchie De Silva, Suketu P. Upadhyay and Paul V. Campanelli was filed in the U.S. District Court for the Eastern District of Pennsylvania by an individual shareholder on behalf of himself and all similarly situated shareholders. The lawsuit alleges violations of Section 10(b) and 20(a) of the Exchange Act relating to the pricing of various generic pharmaceutical products. In June 2018, the court appointed Park Employees’ and Retirement Board Employees’ Annuity Benefit Fund of Chicago lead plaintiff in the action. In September 2018, the defendants filed a motion to dismiss, which the court granted in part and denied in part in February 2020. In particular, the court granted the motion and dismissed the claims with prejudice insofar as they were based on an alleged price-fixing conspiracy; the court otherwise denied the motion to dismiss, allowing other aspects of lead plaintiff’s claims to proceed.

VASOSTRICT^®Related Matters

In July 2016, Fresenius sued our subsidiaries PPCI and PSP LLC in the U.S. District Court for the District of New Jersey alleging an anticompetitive scheme to exclude competition for PPCI’s VASOSTRICT^®, a vasopressin-based cardiopulmonary drug. In particular, Fresenius alleged violations of Sections 1 and 2 of the Sherman Antitrust Act, as well as state antitrust and common law, based on assertions that our subsidiaries entered into exclusive supply agreements with one or more API manufacturers and that, as a result, Fresenius could not obtain vasopressin API in order to file an ANDA to obtain U.S. FDA approval for its own vasopressin product. Fresenius sought actual, treble and punitive damages, attorneys’ fees and costs and injunctive relief. In February 2020, the court granted our subsidiaries’ motion for summary judgment on all claims and denied Fresenius’s cross-motion for partial summary judgment.

In August 2017, our subsidiaries PPI and PSP LLC filed a complaint for actual, exemplary and punitive damages, injunctive relief and other relief against QuVa, Stuart Hinchen, Peter Jenkins and Mike Rutkowski in the U.S. District Court for the District of New Jersey. The complaint alleges misappropriation in violation of the federal Defend Trade Secrets Act, New Jersey’s Trade Secrets Act and New Jersey common law, as well as unfair competition, breach of contract, breach of fiduciary duty, breach of the duty of loyalty, tortious interference with contractual relations and breach of the duty of confidence in connection with VASOSTRICT^®. In November 2017, we filed a motion for preliminary injunction seeking various forms of relief. In March 2018, the court granted in part our motion for preliminary injunction and enjoined QuVa from marketing and releasing its planned vasopressin product through the conclusion of trial. We subsequently deposited a bond to the court’s interest-bearing account to secure the preliminary injunction. In May 2018, defendants filed a notice of appeal to the Third Circuit Court of Appeals indicating intent to appeal the court’s preliminary injunction. In February 2019, the defendants filed counterclaims for defamation, tortious interference with contract, tortious interference with prospective business relations and witness interference. The counterclaims seek actual, exemplary and punitive damages and other relief. In March 2019, we filed a motion to dismiss all of the defendants’ counterclaims. In April 2019, the Third Circuit Court of Appeals affirmed the court’s preliminary injunction but remanded for additional fact-finding concerning the duration of the preliminary injunction and, if needed, consideration of the additional trade secrets raised in our motion for preliminary injunction but not addressed by the preliminary injunction order. In September 2019, following the decision in Athenex Inc. v. Azar, No. 19-cv-00603, 2019 WL 3501811 (D.D.C. Aug. 1, 2019), which upheld the FDA’s determination that there is no clinical need for outsourcing facilities to compound drugs using bulk vasopressin (described below), the parties submitted a proposed consent order to the district court agreeing to a lifting of the preliminary injunction against QuVa but reserving PPI and PSP LLC’s right to seek return or reduction of the bond. In January 2020, the court granted our motion to dismiss the defendants’ counterclaims and ordered the preliminary injunction lifted while the bond remains in place pending an adjudication on the merits.

Beginning in April 2018, PSP LLC and PPI received notice letters from Eagle, Sandoz, Inc., Amphastar Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, American Regent and Fresenius advising of the filing by such companies of ANDAs for generic versions of VASOSTRICT^® (vasopressin IV solution (infusion)) 20 units/ml and/or 200 units/10 ml. Beginning in May 2018, PSP LLC, PPI and EPIC filed lawsuits against the companies in the U.S. District Court for the District of Delaware and New Jersey within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. The earliest trial is scheduled for May 2020.

The Company’s accrual for loss contingencies includes, among other things, an estimated accrual for certain VASOSTRICT^®-related matters. We will continue to vigorously defend or prosecute the foregoing matters as appropriate, to protect our intellectual property rights, to pursue all available legal and regulatory avenues and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Other Proceedings and Investigations

Proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.

Other Comprehensive Loss	12 Months Ended
Other Comprehensive Loss	Dec. 31, 2019
Equity [Abstract]
OTHER COMPREHENSIVE LOSS	NOTE 16. OTHER COMPREHENSIVE LOSS There were no significant tax effects allocated to any component of Other comprehensive income (loss) for the years ended December 31, 2019, 2018 and 2017. The 2017 reclassification adjustment out of Other comprehensive income (loss) included in the Consolidated Statements of Comprehensive Loss, which relates to foreign currency translation, was recorded upon the liquidations of Litha and Somar in 2017. Substantially all of the Company’s Accumulated other comprehensive loss balances at December 31, 2019 and December 31, 2018 consist of Foreign currency translation loss.

Shareholders' Deficit	12 Months Ended
Shareholders' Deficit	Dec. 31, 2019
Equity [Abstract]
SHAREHOLDERS' DEFICIT	NOTE 17. SHAREHOLDERS' DEFICIT The Company has issued 4,000,000 euro deferred shares of $0.01 each at par. The euro deferred shares are held by nominees in order to satisfy an Irish legislative requirement to maintain a minimum level of issued share capital denominated in euro and to have at least seven registered shareholders. The euro deferred shares carry no voting rights and are not entitled to receive any dividend or distribution. Effects of Changes in Accounting Principles The Company early adopted ASU No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (ASU 2016-16) on January 1, 2017, resulting in, among other effects, the elimination of previously recorded deferred charges that were established in 2016. Specifically, effective January 1, 2017, the Company eliminated $372.8 million of deferred charges and recorded a corresponding increase to its Accumulated deficit. As further discussed in Note 2. Summary of Significant Accounting Policies, the Company adopted ASC 606 on January 1, 2018. This adoption resulted in a net decrease of $3.1 million to the Company’s Accumulated deficit at January 1, 2018. As further discussed in Note 2. Summary of Significant Accounting Policies, the Company adopted ASC 842 on January 1, 2019. This adoption resulted in a net increase of $4.6 million to the Company’s Accumulated deficit at January 1, 2019. Share Repurchase Program Pursuant to Article 11 of the Company’s Articles of Association, the Company has broad shareholder authority to conduct ordinary share repurchases by way of redemptions. The Company’s authority to repurchase ordinary shares is subject to legal limitations and the existence of sufficient distributable reserves. For example, the Companies Act requires Irish companies to have distributable reserves equal to or greater than the amount of any proposed ordinary share repurchase amount. Unless we are able to generate sufficient distributable reserves or create distributable reserves by reducing our share premium account, we will not be able to repurchase our ordinary shares. As permitted by Irish Law and the Company’s Articles of Association, any ordinary shares redeemed shall be cancelled upon redemption. The Board has approved the 2015 Share Buyback Program that authorizes the Company to redeem, in the aggregate, $2.5 billion of its outstanding ordinary shares. To date, the Company has redeemed and cancelled approximately 4.4 million of its ordinary shares under the 2015 Share Buyback Program for $250.0 million, not including related fees.

Shared-based Compensation

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Shared-based Compensation

NOTE 18. SHARE-BASED COMPENSATION

Stock Incentive Plans

In June 2015, the Company’s shareholders approved the 2015 Stock Incentive Plan (the 2015 Plan), which has subsequently been amended, as approved by the Company’s shareholders, on multiple occasions, including in 2017, 2018 and 2019. Under the 2015 Plan, stock options (including incentive stock options), stock appreciation rights, restricted stock awards, performance awards and other share- or cash-based awards may be issued at the discretion of the Compensation Committee of the Board from time to time. No ordinary shares are to be granted under previously approved plans, including the Company’s 2000, 2004, 2007, 2010 and Assumed Stock Incentive Plans. All awards previously granted and outstanding under these prior plans remain subject to the terms of those prior plans.

During the third quarter of 2017, the Company issued approximately 1.0 million stock options and 0.1 million restricted stock units that were initially subject to shareholder approval and were subsequently approved by shareholders on June 7, 2018 at the Company’s Annual General Meeting of Shareholders. The options have an exercise price equal to the closing share price on their issuance date in August 2017. For accounting and disclosure purposes, these stock options and restricted stock units were considered to have been granted in 2018 upon approval by shareholders.

As further described below, certain of the Company’s outstanding Performance Share Units (PSUs) are measured against targets covering three independent successive one-year performance periods, which are generally established for each performance period during the first quarter of that calendar year. The determination of the grant-date(s) underlying such PSUs depends in part on the date(s) on which each of the performance targets with respect to those PSUs are approved. Therefore, for certain PSUs, a single unit may give rise to multiple grant dates depending, in part, on the dates on which the respective performance targets are approved.

Beginning in 2017, long-term cash incentive (LTCI) awards were provided to certain employees. LTCI awards were designed to vest ratably, in equal amounts, over a three-year service period. Upon vesting, each vested LTCI unit would be settled in cash in an amount equal to the price of Endo’s ordinary shares on the vest date. As of September 30, 2018, approximately 3.0 million unvested LTCI awards were outstanding for approximately 570 employees. The outstanding awards had a weighted average remaining requisite service period of 2.3 years. A corresponding liability of $14.9 million was recorded as of September 30, 2018 in Accounts payable and accrued expenses and Other liabilities in the Company’s Consolidated Balance Sheets. On October 1, 2018, the Compensation Committee of the Board authorized the Company to settle each of the outstanding unvested LTCI awards in shares, rather than cash, upon vesting in accordance with the original vesting terms of the awards. With the authorization of the Compensation Committee, management’s intent to settle the awards in shares rather than cash is a modification that changes the awards’ classification from liability to equity, effective October 1, 2018. The accounting for the modification occurred in the fourth quarter of 2018. Prior to this modification, LTCI awards were excluded from amounts in this Note 18. Share-based Compensation. Subsequent to this modification, LTCI awards are generally treated the same as restricted stock units (RSUs), including for accounting, financial statement classification and disclosure purposes. However, adjustments to pre-modification amounts of LTCI expense that are recorded in the Consolidated Statements of Operations subsequent to this modification, including adjustments related to actual or estimated forfeitures, are excluded from the determination of share-based compensation expense.

At December 31, 2019, approximately 7.7 million ordinary shares were reserved for future grants under the 2015 Plan. As of December 31, 2019, stock options, restricted stock awards, PSUs, RSUs and LTCI awards have been granted under the stock incentive plans.

Generally, the grant-date fair value of each award is recognized as expense over the requisite service period. However, expense recognition differs in the case of certain performance share units where the ultimate payout is performance-based. For these awards, at each reporting period, the Company estimates the ultimate payout and adjusts the cumulative expense based on its estimate and the percent of the requisite service period that has elapsed.

Presented below are the components of total share-based compensation as recorded in our Consolidated Statements of Operations for the years ended December 31, 2019, 2018 and 2017 (in thousands).



	2019		2018		2017
Selling, general and administrative expenses	$	44,159	$	44,454	$	38,292
Research and development expenses	4,501		2,251		4,197
Cost of revenues	10,482		7,366		7,660
Total share-based compensation expense	$	59,142	$	54,071	$	50,149

As of December 31, 2019, the total remaining unrecognized compensation cost related to all non-vested share-based compensation awards for which a grant date has been established as of December 31, 2019 amounted to $48.3 million.

Stock Options

From time to time, the Company grants stock options to its employees as part of their annual share compensation awards and, in certain circumstances, on an ad hoc basis or upon their commencement of service with the Company.

Employee stock options generally vest ratably, in equal amounts, over a three or four-year service period and generally expire ten years from the grant date. The fair value of option grants is estimated at the date of grant using the Black-Scholes option-pricing model. This model utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero as the Company has not paid cash dividends to date and does not currently expect to pay cash dividends) and the expected term of the option. Expected volatilities utilized in the model are based mainly on the historical volatility of the Company’s share price over a period commensurate with the expected life of the share option as well as other factors. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. We estimate the expected term of options granted based on our historical experience with our employees’ exercise of stock options and other factors.

A summary of the activity for each of the years ended December 31, 2019, 2018 and 2017 is presented below:



	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (1)
Outstanding as of January 1, 2017	4,325,209		$	41.70
Granted	5,288,675		$	10.42
Forfeited	(623,987	)	$	28.32
Expired	(741,767	)	$	40.29
Outstanding as of December 31, 2017	8,248,130		$	22.79
Granted	971,590		$	7.55
Exercised	(94,392	)	$	9.89
Forfeited	(605,737	)	$	19.01
Expired	(446,873	)	$	36.80
Outstanding as of December 31, 2018	8,072,718		$	20.62
Exercised	(557	)	$	7.55
Forfeited	(125,739	)	$	14.38
Expired	(665,883	)	$	40.37
Outstanding as of December 31, 2019	7,280,539		$	18.93	6.30	$	—
Vested and expected to vest as of December 31, 2019	7,212,334		$	19.00	6.29	$	—
Exercisable as of December 31, 2019	5,003,163		$	21.60	6.07	$	—

__________


(1)	The intrinsic value of a stock option is the excess, if any, of the closing price of the Company’s ordinary shares on the last trading day of the fiscal year over the exercise price. The aggregate intrinsic values presented in the table above represent sum of the intrinsic values of all corresponding stock options that are “in-the-money,” if any.

The range of exercise prices for the above stock options outstanding at December 31, 2019 is from $7.55 to $86.54.

The total intrinsic values of options exercised during the years ended December 31, 2019 and 2018 were less than $0.1 million and $0.6 million, respectively. No tax benefits from stock option exercises were realized during the years ended December 31, 2019, 2018 and 2017. The weighted average grant-date fair values of the stock options granted during the years ended December 31, 2018 and 2017 were $3.97 and $4.73 per option, respectively, determined using the following weighted average assumptions:



	2018		2017
Expected term (years)	4.0		4.0
Risk-free interest rate	2.7	%	1.7	%
Dividend yield	—		—
Expected volatility	63	%	58	%

As of December 31, 2019, the weighted average remaining requisite service period of non-vested stock options was 0.9 years and the total remaining unrecognized compensation cost related to non-vested stock options amounted to $3.1 million.

Restricted Stock Units and Performance Share Units

From time to time, the Company grants RSUs and PSUs to its employees as part of their annual share compensation awards and, in certain circumstances, on an ad hoc basis or upon their commencement of service with the Company.

RSUs vest ratably, in equal amounts, over a three or four-year service period. PSUs vest in full after a three-year service period and are conditional upon the achievement of performance and/or market conditions established by the Compensation Committee of the Board.

PSUs awarded in 2019, 2018 and 2017 were based upon two discrete measures: relative total shareholder return (TSR) and an adjusted free cash flow performance metric (FCF), each accounting for 50% of the PSU awards upon issuance. TSR performance is measured against the three-year TSR of a custom index of companies. For PSUs awarded in 2019, FCF performance is measured against a target covering a single three-year performance period, which is generally established at the grant date. For PSUs awarded in 2018 and 2017, FCF performance is measured against targets covering three independent successive one-year performance periods, which are generally established for each performance period during the first quarter of that calendar year. Upon the completion of the three-year performance period, the PSUs vest and the actual number of shares awarded is adjusted to between zero and 200% of the target award amount based upon the performance criteria described above. In addition to meeting the performance conditions, grant recipients are also generally subject to being employed by the Company until the conclusion of the three-year vesting period in order to receive the awards. TSR is considered a market condition under applicable authoritative guidance, while FCF is considered performance condition.

RSUs are valued based on the closing price of Endo’s ordinary shares on the date of grant. PSUs with TSR conditions are valued using a Monte-Carlo variant valuation model, while those with adjusted free cash flow conditions are valued taking into consideration the probability of achieving the specified performance goal. The Monte-Carlo variant valuation model considered a variety of potential future share prices for Endo as well as our peer companies in a selected market index.

A summary of our non-vested RSUs and PSUs for the years ended December 31, 2019, 2018 and 2017 is presented below:



	Number of Shares		Aggregate Intrinsic Value (1)
Non-vested as of January 1, 2017	1,685,060
Granted	4,168,477
Forfeited	(552,981	)
Vested	(575,883	)
Non-vested as of December 31, 2017	4,724,673
Granted	5,609,561
LTCI modification (2)	2,989,965
Forfeited	(753,653	)
Vested	(1,551,074	)
Non-vested as of December 31, 2018	11,019,472
Granted	6,687,695
Forfeited	(918,425	)
Vested	(3,872,453	)
Non-vested as of December 31, 2019	12,916,289		$	60,577,395
Vested and expected to vest as of December 31, 2019	12,098,438		$	56,741,674

__________


(1)	The aggregate intrinsic values of RSUs and PSUs presented in the table above are calculated by multiplying the closing price of the Company’s ordinary shares on the last trading day of the fiscal year by the corresponding number of RSUs and PSUs.


(2)	As a result of the October 1, 2018 modification to the Company’s LTCI awards described above, modified LTCI awards are treated as RSUs for disclosure purposes; thus, the table above reflects an increase to the non-vested number of shares on the modification date.

As of December 31, 2019, the weighted average remaining requisite service period of the units presented in the table above was 1.6 years and the corresponding total remaining unrecognized compensation cost amounted to $39.4 million in the case of RSUs and LTCI awards and $5.8 million in the case of PSUs. The weighted average grant-date fair value of the units granted during the years ended December 31, 2019, 2018 and 2017 was $7.72, $6.88 and $11.42 per unit, respectively.

Other Expense (Income), Net

12 Months Ended

Dec. 31, 2019

Component of Operating Income [Abstract]

OTHER EXPENSE (INCOME), NET

NOTE 19. OTHER EXPENSE (INCOME), NET

The components of Other expense (income), net for the years ended December 31, 2019, 2018 and 2017 are as follows (in thousands):



	2019			2018			2017
Net gain on sale of business and other assets (1)	$	(6,367	)	$	(45,155	)	$	(13,809	)
Foreign currency loss (gain), net (2)	5,247			(3,762		)	(2,801		)
Net loss from our investments in the equity of other companies (3)	2,346			3,444			898
Other miscellaneous, net (4)	15,451			(6,480		)	(1,311		)
Other expense (income), net	$	16,677		$	(51,953	)	$	(17,023	)

__________


(1)	Amounts in 2018 include a $12.5 million gain on the sale of the Company’s Huntsville, Alabama facilities, as further discussed in Note 4. Restructuring. Amounts in 2017 include a $10.1 million gain resulting from the sale of Litha, as further described in Note 3. Discontinued Operations and Divestitures. The remaining amounts primarily relate to the sales of various ANDAs.


(2)	Amounts relate to the remeasurement of the Company’s foreign currency denominated assets and liabilities.


(3)	Amounts relate to the income statement impacts of our investments in the equity of other companies, including investments accounted for under the equity method.

(4)

Amounts in 2019 primarily relate to $17.5 million of contract termination costs incurred as a result of certain product discontinuation activities in our International Pharmaceuticals segment.

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 20. INCOME TAXES

Tax Reform

The TCJA, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system, including the reduction of the U.S. statutory federal corporate income tax rate from 35% to 21% effective January 1, 2018. The TCJA also contains a broad range of domestic and international provisions, many of which differ significantly from those contained in previous U.S. tax law. Although the rate of U.S. federal income tax was reduced prospectively, changes in tax rates and laws are accounted for in the period of enactment. Therefore, during the year ended December 31, 2017, we recorded a benefit of $36.2 million as our provisional estimate of the impact of the TCJA in accordance with Staff Accounting Bulletin 118. This benefit, which is primarily related to remeasurement of deferred tax liabilities related to tax deductible goodwill, has been recorded in our Consolidated Statements of Operations in the Income tax expense (benefit) line. The Company has completed its accounting for the tax effects of the TCJA in accordance with Staff Accounting Bulletin 118. There were no significant subsequent adjustments to the provisional amounts recorded.

Loss from continuing operations before income tax

Our operations are conducted through our various subsidiaries in numerous jurisdictions throughout the world. We have provided for income taxes based upon the tax laws and rates in the jurisdictions in which our operations are conducted.

The components of our Loss from continuing operations before income tax by geography for the years ended December 31, 2019, 2018 and 2017 are as follows (in thousands):



	2019			2018			2017
U.S.	$	(688,224	)	$	(1,342,860	)	$	(1,866,222	)
International	343,320			404,028			383,218
Total (loss) income from continuing operations before income tax	$	(344,904	)	$	(938,832	)	$	(1,483,004	)

Income tax from continuing operations consists of the following for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019			2018			2017
Current:
U.S. Federal	$	15,317		$	6,236		$	(86,478	)
U.S. State	(3,002		)	2,864			(6,462		)
International	8,926			8,278			(1,224		)
Total current income tax	$	21,241		$	17,378		$	(94,164	)
Deferred:
U.S. Federal	$	(515	)	$	10,084		$	(124,682	)
U.S. State	(482		)	(778		)	(3,225		)
International	(4,564		)	(3,749		)	(28,222		)
Total deferred income tax	$	(5,561	)	$	5,557		$	(156,129	)
Total income tax	$	15,680		$	22,935		$	(250,293	)

Tax Rate

A reconciliation of income tax from continuing operations at the U.S. federal statutory income tax rate to the total income tax provision from continuing operations for the years ended December 31, 2019, 2018 and 2017 is as follows (in thousands):



	2019			2018			2017
Notional U.S. federal income tax provision at the statutory rate	$	(72,430	)	$	(197,155	)	$	(519,051	)
State income tax, net of federal benefit	(4,455		)	494			(11,473		)
U.S. tax reform impact	—			5,664			(36,216		)
Uncertain tax positions	43,273			46,317			58,120
Residual tax on non-U.S. net earnings	(67,987		)	(638,724		)	(1,350,811		)
Non-deductible goodwill impairment	27,493			109,189			60,808
Change in valuation allowance	30,123			748,562			1,644,879
Intra-entity transfers of assets	—			(63,335		)	(53,509		)
International Pharmaceuticals segment divestitures	—			—			(56,092		)
Base erosion minimum tax	13,662			—			—
Non-deductible expenses	21,299			3,446			3,957
Executive compensation limitation	4,547			5,955			2,178
Other	20,155			2,522			6,917
Income tax	$	15,680		$	22,935		$	(250,293	)

The income tax expense in 2019 primarily related to accrued interest on uncertain tax positions. The income tax expense in 2018 primarily related to the establishment of a valuation allowance against certain U.S. deferred tax assets. The income tax benefit in 2017 primarily related to pre-tax losses incurred by certain U.S. subsidiaries.

Deferred Tax Assets and Liabilities

Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The significant components of the net deferred income tax liability shown on the balance sheets as of December 31, 2019 and 2018 are as follows (in thousands):



	December 31, 2019			December 31, 2018
Deferred tax assets:
Accrued expenses and customer allowances	$	112,489		$	185,910
Deferred interest expense	317,997			240,736
Fixed assets and intangible assets	598,730			604,385
Loss on capital assets	61,971			62,033
Net operating loss carryforward	9,743,763			8,751,544
Other	89,501			65,266
Research and development and other tax credit carryforwards	16,620			9,551
Total gross deferred income tax assets	$	10,941,071		$	9,919,425
Deferred tax liabilities:
Other	$	(10,086	)	$	(1,965	)
Outside basis difference	—			(73,652		)
Intercompany notes	(1,131,537		)	—
Total gross deferred income tax liabilities	$	(1,141,623	)	$	(75,617	)
Valuation allowance	(9,828,959		)	(9,877,617		)
Net deferred income tax liability	$	(29,511	)	$	(33,809	)

At December 31, 2019, the Company had the following significant deferred tax assets for tax credits, net operating and capital loss carryforwards, net of unrecognized tax benefits (in thousands):



Jurisdiction	Amount		Begin to Expire
Ireland	$	16,862	Indefinite
Luxembourg	$	9,336,611	2034
U.S.:
Federal-ordinary losses	$	200,671	2021
Federal-capital losses	$	34,740	2020
Federal-tax credits	$	7,305	2026
State-ordinary losses	$	186,211	2020
State-capital losses	$	26,459	2026
State-tax credits	$	6,643	2020

A valuation allowance is required when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The Company assesses the available positive and negative evidence to estimate whether the existing deferred tax assets will be realized.

The Company has recorded a valuation allowance against certain jurisdictional net operating loss carryforwards and other tax attributes. As of December 31, 2019 and 2018, the total valuation allowance was $9,829.0 million and $9,877.6 million, respectively. During the year ended December 31, 2019, the Company decreased its valuation allowance by $48.7 million, which was primarily driven by statutory rate changes in Luxembourg. During the year ended December 31, 2018, the Company increased its valuation allowance by $1,814.6 million, which was primarily driven by losses within jurisdictions unable to support recognition of a deferred tax asset, of which the largest jurisdiction was Luxembourg, where the Company had significant interest expense and losses on its investments in the equity of consolidated subsidiaries.

At December 31, 2019, the Company had the following significant valuation allowances (in thousands):



Jurisdiction	December 31, 2019
Ireland	$	189,581
Luxembourg	$	8,205,074
U.S.	$	1,430,762

We have provided income taxes for earnings that are currently distributed as well as the taxes associated with certain earnings that are expected to be distributed in the future. No additional provision has been made for Irish and non-Irish income taxes on the undistributed earnings of subsidiaries or for unrecognized deferred tax liabilities for temporary differences related to basis differences in investments in subsidiaries as such earnings are expected to be indefinitely reinvested. As of December 31, 2019, certain subsidiaries had approximately $1,092.0 million of cumulative undistributed earnings that have been permanently reinvested because our plans do not demonstrate a need to repatriate such earnings. A liability could arise if our intention to indefinitely reinvest such earnings were to change and amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed. It is not practicable to estimate the additional income taxes related to indefinitely reinvested earnings or the basis differences related to investments in subsidiaries.

Uncertain Tax Positions

The Company and its subsidiaries are subject to income taxes in the U.S., various states and numerous foreign jurisdictions with varying statutes as to which tax years are subject to examination by the tax authorities. The Company has taken positions on its tax returns that may be challenged by various tax authorities. The Company believes it has appropriately established reserves for tax-related uncertainties. The Company endeavors to resolve matters with a tax authority at the examination level and could reach agreement with a tax authority at any time. The accruals for tax-related uncertainties are based on the Company’s best estimate of the potential tax exposures. When particular matters arise, a number of years may elapse before such matters are audited and finally resolved, and the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in our financial statements. Favorable resolution of such matters could be recognized as a reduction of the Company’s effective tax rate in the year of resolution, while a resolution that is not favorable could increase the effective tax rate and may require the use of cash, including in the year of resolution. Uncertain tax positions are reviewed quarterly and adjusted as necessary when events occur that affect potential tax liabilities, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, identification of new issues and issuance of new legislation, regulations or case law.

As of December 31, 2019, the Company had total unrecognized income tax benefits (UTBs) of $530.2 million. If recognized in future years, $320.3 million of such amounts would impact the income tax provision and effective tax rate. As of December 31, 2018, the Company had total UTBs of $479.4 million. If recognized in future years, $304.3 million of such amounts would have impacted the income tax provision and effective tax rate. The following table summarizes the activity related to UTBs during the years ended December 31, 2019, 2018 and 2017 (in thousands):



	Unrecognized Tax Benefit Federal, State, and Foreign Tax
UTB Balance at January 1, 2017	$	424,601
Gross additions for current year positions	44,293
Gross reductions for prior period positions	(64,887		)
Gross additions for prior period positions	22,765
Decrease due to lapse of statute of limitations	(13,151		)
Currency translation adjustment	2,330
UTB Balance at December 31, 2017	$	415,951
Gross additions for current year positions	36,088
Gross reductions for prior period positions	(3,570		)
Gross additions for prior period positions	7,950
Decrease due to lapse of statute of limitations	(2,129		)
Currency translation adjustment	(2,600		)
UTB Balance at December 31, 2018	$	451,690
Gross additions for current year positions	35,766
Gross reductions for prior period positions	(2,377		)
Gross additions for prior period positions	880
Decrease due to lapse of statute of limitations	(1,006		)
Currency translation adjustment	1,528
UTB Balance at December 31, 2019	$	486,481
Accrued interest and penalties	43,710
Total UTB balance including accrued interest and penalties	$	530,191

The Company records accrued interest as well as penalties related to uncertain tax positions as part of the provision for income taxes. As of December 31, 2019 and 2018, $43.7 million and $27.7 million, respectively, of corresponding accrued interest and penalties is included in the Consolidated Balance Sheets, all of which is recorded in income taxes.

During the years ended December 31, 2019, 2018, and 2017, we recognized expense of $13.8 million, $8.6 million and $1.4 million, respectively. The expense is primarily related to interest. The current portion of our UTB liability of $6.8 million is included in our Consolidated Balance Sheet as Accounts payable and accrued expenses. The noncurrent portion of our UTB liability is included in our Consolidated Balance Sheet as Other liabilities or, if and to the extent appropriate, as a reduction to Deferred tax assets.

Our subsidiaries file income tax returns in the countries in which they have operations. Generally, these countries have statutes of limitations ranging from 3 to 5 years. Certain subsidiary tax returns are currently under examination by taxing authorities, including U.S. tax returns for the 2011 through 2015 tax years by the IRS.

It is expected that the amount of UTBs will change during the next twelve months; however, the Company does not currently anticipate any adjustments that would lead to a material impact on our results of operations or our financial position.

As of December 31, 2019, we may be subject to examination in the following major tax jurisdictions:



Jurisdiction		Open Years
Canada		2013 through 2019
India		2012 through 2019
Ireland		2014 through 2019
Luxembourg		2014 through 2019
U.S. - federal, state and local		2006 through 2019

Net Loss Per Share

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

NET LOSS PER SHARE

NOTE 21. NET LOSS PER SHARE

The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019			2018			2017
Numerator:
Loss from continuing operations	$	(360,584	)	$	(961,767	)	$	(1,232,711	)
Loss from discontinued operations, net of tax	(62,052		)	(69,702		)	(802,722		)
Net loss	$	(422,636	)	$	(1,031,469	)	$	(2,035,433	)
Denominator:
For basic per share data—weighted average shares	226,050			223,960			223,198
Dilutive effect of ordinary share equivalents	—			—			—
For diluted per share data—weighted average shares	226,050			223,960			223,198

Basic net loss per share amounts are computed based on the weighted average number of ordinary shares outstanding during the period. Diluted net loss per share amounts are computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations during the period, the dilutive effect of ordinary share equivalents outstanding during the period.

The dilutive effect of ordinary share equivalents is measured using the treasury stock method. Stock options and awards that have been issued but for which a grant date has not yet been established are not considered in the calculation of basic or diluted weighted average shares.

All potentially dilutive items were excluded from the diluted share calculation for the years ended December 31, 2019, 2018 and 2017 because their effect would have been anti-dilutive, as the Company was in a loss position.

Savings and Investment Plan and Deferred Compensation Plans	12 Months Ended
	Dec. 31, 2019
Savings And Investment Plan And Deferred Compensation Plans [Abstract]
SAVINGS AND INVESTMENT PLAN AND DEFERRED COMPENSATION PLANS	NOTE 22. SAVINGS AND INVESTMENT PLAN AND DEFERRED COMPENSATION PLANS Savings and Investment Plan The Company maintains a defined contribution Savings and Investment Plan (the Endo 401(k) Plan) covering all U.S.-based eligible employees. The Company matches 100% of the first 3% of eligible cash compensation that a participant contributes to the Endo 401(k) Plan plus 50% of the next 2% for a total of up to 4%, subject to statutory limitations. Participants are immediately vested with respect to their own contributions and the Company’s matching contributions, except that, for employees hired after 2017, the Company’s matching contributions will vest ratably over a two-year period. Costs incurred for contributions made by the Company to the Endo 401(k) Plan amounted to $7.4 million, $6.4 million and $9.4 million for the years ended December 31, 2019, 2018 and 2017, respectively. Directors Stock Election Plan The Company maintains a directors stock election plan. The purpose of this plan is to provide non-employee directors the opportunity to have their cash retainer fees, or a portion thereof, delivered in the form of Endo ordinary shares. The amount of shares will be determined by dividing the portion of cash fees elected to be received as shares by the closing price of the shares on the day the payment would have otherwise been paid in cash.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Data [Abstract]

QUARTERLY FINANCIAL DATA (UNAUDITED)

NOTE 23. QUARTERLY FINANCIAL DATA (UNAUDITED)

The following table presents select unaudited financial data for each of the three-month periods ending March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019, as well as the comparable 2018 periods (in thousands, except per share data):



	Quarter Ended
	March 31,			June 30,			September 30,			December 31,
2019 (1)
Total revenues	$	720,411		$	699,727		$	729,426		$	764,800
Gross profit	$	328,502		$	311,519		$	340,261		$	364,744
Loss from continuing operations	$	(12,612	)	$	(98,052	)	$	(41,431	)	$	(208,489	)
Discontinued operations, net of tax	$	(5,961	)	$	(7,953	)	$	(37,984	)	$	(10,154	)
Net loss	$	(18,573	)	$	(106,005	)	$	(79,415	)	$	(218,643	)
Net loss per share—Basic:
Continuing operations	$	(0.06	)	$	(0.43	)	$	(0.18	)	$	(0.92	)
Discontinued operations	(0.02		)	(0.04		)	(0.17		)	(0.04		)
Basic	$	(0.08	)	$	(0.47	)	$	(0.35	)	$	(0.96	)
Net loss per share—Diluted:
Continuing operations	$	(0.06	)	$	(0.43	)	$	(0.18	)	$	(0.92	)
Discontinued operations	(0.02		)	(0.04		)	(0.17		)	(0.04		)
Diluted	$	(0.08	)	$	(0.47	)	$	(0.35	)	$	(0.96	)
Weighted average shares—Basic	224,594			226,221			226,598			226,787
Weighted average shares—Diluted	224,594			226,221			226,598			226,787
2018 (2)
Total revenues	$	700,527		$	714,696		$	745,466		$	786,389
Gross profit	$	296,929		$	332,791		$	332,501		$	353,175
Loss from continuing operations	$	(497,738	)	$	(52,479	)	$	(146,071	)	$	(265,479	)
Discontinued operations, net of tax	$	(7,751	)	$	(8,388	)	$	(27,134	)	$	(26,429	)
Net loss	$	(505,489	)	$	(60,867	)	$	(173,205	)	$	(291,908	)
Net loss per share—Basic:
Continuing operations	$	(2.23	)	$	(0.23	)	$	(0.65	)	$	(1.18	)
Discontinued operations	(0.03		)	(0.04		)	(0.12		)	(0.12		)
Basic	$	(2.26	)	$	(0.27	)	$	(0.77	)	$	(1.30	)
Net loss per share—Diluted:
Continuing operations	$	(2.23	)	$	(0.23	)	$	(0.65	)	$	(1.18	)
Discontinued operations	(0.03		)	(0.04		)	(0.12		)	(0.12		)
Diluted	$	(2.26	)	$	(0.27	)	$	(0.77	)	$	(1.30	)
Weighted average shares—Basic	223,521			223,834			224,132			224,353
Weighted average shares—Diluted	223,521			223,834			224,132			224,353

__________

(1)

Loss from continuing operations for the year ended December 31, 2019 was impacted by (i) acquisition-related and integration items, net of $(37.5) million, $(5.5) million, $16.0 million and $(19.1) million during the first, second, third and fourth quarters, respectively, which related primarily to changes in the fair value of contingent consideration, (ii) asset impairment charges of $165.4 million, $88.4 million, $4.8 million and $267.4 million during the first, second, third and fourth quarters, respectively, (iii) certain retention and separation benefits and other cost reduction initiatives incurred in connection with continued efforts to enhance the Company’s operations of $2.0 million, $2.1 million, $11.0 million and $19.4 million during the first, second, third and fourth quarters, respectively, (iv) amounts related to litigation-related and other contingent matters totaling $10.3 million, $(14.4) million and $15.3 million during the second, third and fourth quarters, respectively, and (v) amounts related to sales of businesses and other assets of $1.3 million, $(2.5) million, $(1.9) million and $(3.3) million during the first, second, third and fourth quarters, respectively.

(2)

Loss from continuing operations for the year ended December 31, 2018 was impacted by (i) acquisition-related and integration items, net of $6.8 million, $5.2 million, $1.3 million and $8.6 million during the first, second, third and fourth quarters, respectively, which related primarily to changes in the fair value of contingent consideration, (ii) asset impairment charges of $448.4 million, $22.8 million, $142.2 million and $303.5 million during the first, second, third and fourth quarters, respectively, (iii) certain retention and separation benefits and other cost reduction initiatives incurred in connection with continued efforts to enhance the Company’s operations of $49.0 million, $29.2 million, $4.0 million and $4.2 million during the first, second, third and fourth quarters, respectively, (iv) amounts related to litigation-related and other contingent matters totaling $(2.5) million, $19.6 million, $(1.8) million and $(1.6) million during the first, second, third and fourth quarters, respectively, and (v) amounts related to sales of businesses and other assets of $(2.4) million, $(24.6) million, $(2.9) million and $(15.3) million during the first, second, third and fourth quarters, respectively.

The operating results of the Astora business are reported as Discontinued operations, net of tax in the Consolidated Statements of Operations for all periods presented. For additional information, see Note 3. Discontinued Operations and Divestitures. Quarterly and year-to-date computations of per share amounts are made independently; therefore, the sum of the per share amounts for the quarters may not equal the per share amounts for the year.

SCHEDULE II--Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2019

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

SCHEDULE II--Valuation and Qualifying Accounts

SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS

(in thousands)



	Balance at Beginning of Period		Additions, Costs and Expenses		Deductions, Write-offs			Other (1)			Balance at End of Period
Valuation Allowance For Deferred Tax Assets:
Year Ended December 31, 2017	$	4,841,209	$	3,811,982	$	—		$	(590,216	)	$	8,062,975
Year Ended December 31, 2018	$	8,062,975	$	2,569,175	$	(2,259	)	$	(752,274	)	$	9,877,617
Year Ended December 31, 2019	$	9,877,617	$	299,372	$	(9,078	)	$	(338,952	)	$	9,828,959

__________


(1)	Represents the remeasurement of net deferred tax assets due to changes in statutory tax rates.

All other financial statement schedules have been omitted because they are not applicable or the required information is included in the Consolidated Financial Statements or notes thereto.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Consolidation and Basis of Presentation

The Consolidated Financial Statements include the accounts of wholly-owned subsidiaries after the elimination of intercompany accounts and transactions.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation.

Use of Estimates

The preparation of our Consolidated Financial Statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts and disclosures in our Consolidated Financial Statements, including the notes thereto, and elsewhere in this report. For example, we are required to make significant estimates and assumptions related to revenue recognition, including sales deductions, long-lived assets, goodwill, other intangible assets, income taxes, contingencies, financial instruments and share-based compensation, among others. Some of these estimates can be subjective and complex. Although we believe that our estimates and assumptions are reasonable, there may be other reasonable estimates or assumptions that differ significantly from ours. Further, our estimates and assumptions are based upon information available at the time they were made. Actual results may differ significantly from our estimates.

Customer, Product and Supplier Concentration

We primarily sell our branded and generic products to wholesalers, retail drug store chains, supermarket chains, mass merchandisers, distributors, mail order accounts, hospitals and government agencies. Our wholesalers and distributors purchase products from us and, in turn, supply products to retail drug store chains, independent pharmacies and MCOs. Customers in the managed care market include health maintenance organizations, nursing homes, hospitals, clinics, pharmacy benefit management companies and mail order customers.

Revenue from Contract with Customer

Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred when that right is conditioned on something other than the passage of time. The Company records revenue and a corresponding contract asset when it fulfills a contractual performance obligation, but must also fulfill one or more additional performance obligations before being entitled to payment. Once the Company’s right to consideration becomes unconditional, the contract asset amount is reclassified as Accounts receivable.

Our provision for rebates, sales incentives and other allowances can generally be categorized into the following four types:


•	direct rebates;


•	indirect rebates;


•	governmental rebates, including those for Medicaid, Medicare and TRICARE, among others; and


•	managed-care rebates.

Cost of revenues includes all costs directly related to bringing both purchased and manufactured products to their final selling destination. Amounts include purchasing and receiving costs, direct and indirect costs to manufacture products including direct materials, direct labor and direct overhead expenses necessary to acquire and convert purchased materials and supplies into finished goods, royalties paid or owed by Endo on certain in-licensed products, inspection costs, depreciation of certain property, plant and equipment, amortization of intangible assets, lease costs, warehousing costs, freight charges, costs to operate our equipment and other shipping and handling costs, among others.Consistent with industry practice, we maintain a return policy that allows our customers to return products within a specified period of time both subsequent to and, in certain cases, prior to the products’ expiration dates. Our return policy generally allows customers to receive credit for expired products within We market and sell products to both: (i) direct customers including wholesalers, distributors, warehousing pharmacy chains and other direct purchasing groups and (ii) indirect customers including independent pharmacies, non-warehousing chains, MCOs, GPOs and government entities. We enter into agreements with certain of our indirect customers to establish contract pricing for certain products. These indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, we may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, we provide credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler’s invoice price. Such credit is called a chargeback.

Prior to the adoption of ASC 606, the Company accounted for revenue recognition and sales deductions under Accounting Standards Codification Topic 605, Revenue Recognition (ASC 605).

The Company adopted ASC 606 on January 1, 2018 using the modified retrospective method for all revenue-generating contracts, including modifications thereto, that were not completed contracts at the date of adoption. ASC 606 applies to contracts with commercial substance that establish the payment terms and each party’s rights regarding the goods or services to be transferred, to the extent collection of substantially all of the related consideration is probable. Under ASC 606, we recognize revenue for contracts meeting these criteria when (or as) we satisfy our performance obligations for such contracts by transferring control of the underlying promised goods or services to our customers. The amount of revenue we recognize reflects our estimate of the consideration we expect to be entitled to receive, subject to certain constraints, in exchange for such goods or services. This amount is referred to as the transaction price.

R & D

Expenditures for R&D are expensed as incurred. Total R&D expenses include, among other things, the costs of discovery research, preclinical development, early- and late-clinical development and drug formulation, clinical trials, materials, medical support of marketed products and certain upfront and milestone payments. R&D spending also includes enterprise-wide costs which support our overall R&D infrastructure. Property, plant and equipment that are acquired or constructed for R&D activities and that have alternate future uses are capitalized and depreciated over their estimated useful lives on a straight-line basis. Contractual upfront and milestone payments made to third parties are generally: (i) expensed as incurred up to the point of regulatory approval and (ii) capitalized and amortized over the related product’s remaining useful life subsequent to regulatory approval. Amounts capitalized for such payments are included in Other intangibles, net in the Consolidated Balance Sheets.

Cash and Cash Equivalents

The Company considers all highly liquid money market instruments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2019 and 2018, cash equivalents were deposited in financial institutions and consisted almost entirely of immediately available fund balances. The Company maintains its cash deposits and cash equivalents with financial institutions it believes to be well-k

Restricted Cash and Cash Equivalents

Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are excluded from Cash and cash equivalents in the Consolidated Balance Sheets. For additional information see Note 6. Fair Value Measurements.

Accounts Receivable

Accounts receivable are stated at their net realizable value and the Company maintains an allowance for doubtful accounts against gross accounts receivable. The allowance is not material to the Company’s Consolidated Financial Statements at December 31, 2019 or 2018. In addition, our accounts receivable balance is reduced by certain sales deduction reserves where we have the right of offset with

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents, restricted cash equivalents and accounts receivable. From time to time, we invest our excess cash in high-quality, liquid money market instruments maintained by major banks and financial institutions. We have not experienced any losses on our cash equivalents.

Inventories

Inventories consist of raw materials, work-in-process and finished goods. Inventory that is in excess of the amount expected to be sold within one year is classified as long-term inventory and is recorded in Other assets in the Consolidated Balance Sheets. The Company capitalizes inventory costs associated with certain products prior to regulatory approval and product launch when it is reasonably certain, based on management’s judgment of future commercial use and net realizable value, that the pre-launch inventories will be saleable. The determination to capitalize is made on a product-by-product basis. The Company could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, a denial or delay of approval by regulatory bodies, a delay in commercialization or other potential factors. Our inventories are stated at the lower of cost or net realizable value.

Property, Plant and Equipment

Property, plant and equipment is generally stated at cost less accumulated depreciation. Major improvements are capitalized, while routine maintenance and repairs are expensed as incurred. Costs incurred during the construction or development of property, plant and equipment are capitalized as assets under construction. Once an asset has been placed into service, depreciation expense is taken on a straight-line basis over the estimated useful life of the related assets or, in the case of leasehold improvements and finance lease assets, over the shorter of the estimated useful life and the lease term.

Computer Software

4 years to 20 years, with a weighted average useful life of approximately 11 years. We determine amortization periods and methods of amortization for developed technology assets based on our assessment of various factors impacting estimated useful lives and the timing and extent of estimated cash flows of the acquired assets, including the strength of the intellectual property protection of the product (if applicable), contractual terms and various other competitive and regulatory issues.The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including external direct costs of material and services, and payroll costs for employees directly involved with the software development. Capitalized software costs are included in Property, plant and equipment, net in the Consolidated Balance Sheets and depreciated beginning when the software project is substantially complete and the asset is ready for its intended use. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.

Lease Accounting

The Company adopted ASC 842 on January 1, 2019. For further discussion of the adoption, refer to the “Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2019” section below. ASC 842 applies to a number of arrangements to which the Company is party.

For each lease, the Company must then determine the lease term, the present value of lease payments and the classification of the lease as either an operating or finance lease.

The present value of lease payments is calculated based on:

•

Prior to the adoption of ASC 842, the Company accounted for leases under Accounting Standards Codification Topic 840, Leases (ASC 840).

Cloud Computing Arrangements

The Company may from time to time incur costs in connection with hosting arrangements that are service contracts. Subsequent to the Company’s January 1, 2019 adoption of Accounting Standards Update (ASU) No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (ASU 2018-15), which is further described below, the Company capitalizes any such implementation costs, expenses them over the terms of the respective hosting arrangements and subjects them to impairment testing consistent with other long-lived assets.

Finite-Lived Intangible Assets

Our finite-lived intangible assets consist of license rights and developed technology. Upon acquisition, intangible assets are generally initially recorded at fair value if acquired in a business combination, or at cost if otherwise. There are several methods that can be used to determine fair value. For intangible assets, we typically use an income approach. This approach starts with our forecast of all of the expected future net cash flows. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and, if applicable, the life of any estimated period of marketing exclusivity, such as that granted by a patent. The pricing, margins and expense levels of similar products are considered if available. For certain licensed assets, our estimates of future cash flows consider periods covered by renewal options to the extent we have the intent and ability, at the date of the estimate, to renew the underlying license agreements. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.

As further described below under the heading “Long-Lived Asset Impairment Testing,” our finite-lived intangible assets are also subject to impairment reviews.

License Rights

Our license rights subject to amortization have useful lives ranging from 12 years to 15 years, with a weighted average useful life of approximately 14 years. We determine amortization periods for licenses based on our assessment of various factors including the expected launch date of the product, the strength of the intellectual property protection of the product (if applicable), contractual terms and various other competitive, developmental and regulatory issues.

Long-Lived Asset Impairment Testing

Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are assessed for impairment whenever events or changes in circumstances indicate the carrying amounts of the assets may not be recoverable. Recoverability of an asset that will continue to be used in our operations is measured by comparing the carrying amount of the asset to the forecasted undiscounted future cash flows related to the asset. In the event the carrying amount of the asset exceeds its undiscounted future cash flows and the carrying amount is not considered recoverable, impairment may exist. An impairment loss, if any, is measured as the excess of the asset’s carrying amount over its fair value, generally based on a discounted future cash flow method, independent appraisals or offers from prospective buyers. An impairment loss would be recognized in the Consolidated Statements of Operations in the period that the impairment occurs.

In-Process Research and Development Assets

In-process research and development acquired in an asset acquisition is expensed in the period it is acquired, assuming the assets have no alternative future use to the Company. Otherwise, acquired in-process research and development is generally recognized as an indefinite-lived intangible asset. Such assets are generally initially recorded at fair value if acquired in a business combination, or at cost if otherwise. Indefinite-lived intangible assets are not subject to amortization. Instead, they are tested for impairment annually and when events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1. If the fair value of the intangible assets is less than its carrying amount, an impairment loss is recognized for the difference. For those assets that reach commercialization, the assets are reclassified and accounted for as finite-lived intangible assets.

Goodwill

Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. While amortization expense is not recorded on goodwill, goodwill is subject to impairment reviews. An impairment assessment is conducted as of October 1, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired.We perform the goodwill impairment test by comparing the fair value and carrying amount of each reporting unit. Any goodwill impairment charge we recognize for a reporting unit is equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value.

Contingencies

The Company is subject to various patent challenges, product liability claims, government investigations and other legal proceedings in the ordinary course of business. Contingent accruals and legal settlements are recorded in the Consolidated Statements of Operations as Litigation-related and other contingencies, net (or as Discontinued operations, net of tax in the case of vaginal mesh matters) when the Company determines that a loss is both probable and reasonably estimable. Legal fees and other expenses related to litigation are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations (or as Discontinued operations, net of tax in the case of vaginal mesh matters).

Contingent Consideration

Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the occurrence of a future event, such as (i) the achievement of specified regulatory, operational and/or commercial milestones or (ii) royalty payments, such as those relating to future product sales. Contingent consideration liabilities related to an asset acquisition are initially recorded when considered probable and reasonably estimable, which may occur subsequent to the acquisition date. Subsequent changes in the recorded amounts are recorded as adjustments to the cost of the acquired assets. Contingent consideration liabilities related to a business combination are initially recorded at fair value on the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the Company remeasures its contingent consideration liabilities to their current estimated fair values, with changes recorded in earnings. Changes to any of the inputs used in determining fair value may result in fair value adjustments that differ significantly from the actual remeasurement adjustments recognized.

Share Repurchases

The Company accounts for the repurchase of ordinary shares, if any, at par value. Under applicable Irish law, ordinary shares repurchased are retired and not displayed separately as treasury stock. Upon retirement of the ordinary shares, the Company records the difference between the weighted average cost of such ordinary shares and the par value of the ordinary shares as an adjustment to Accumulated deficit in the Consolidated Balance Sheets.

Advertising Costs

Advertising costs are expensed as incurred and included in Selling, general and administrative expenses in the Consolidated Statements of Operations.

Share-Based Compensation

The Company grants share-based compensation awards to certain employees and non-employee directors. Generally, the grant-date fair value of each award is recognized as expense over the requisite service period. However, expense recognition differs in the case of certain performance share units where the ultimate payout is performance-based. For these awards, at each reporting period, the Company estimates the ultimate payout and adjusts the cumulative expense based on its estimate and the percent of the requisite service period that has elapsed. Share-based compensation expense is reduced for estimated future forfeitures. These estimates are revised in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation expense in the period in which the change in estimate occurs. New ordinary shares are generally issued upon the exercise of stock options or vesting of stock awards by employees and non-employee directors.

Foreign Currency

The Company operates in various jurisdictions both inside and outside of the U.S. While the Company’s reporting currency is the U.S. dollar, the Company has concluded that certain of its distinct and separable operations have functional currencies other than the U.S. dollar. Further, certain of the Company’s operations hold assets and liabilities and recognize income and expenses denominated in various local currencies, which may differ from their functional currencies.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. In making such a determination, the Company considers all available positive and negative evidence, including projected future taxable income, tax-planning strategies and results of recent operations. In the event that the Company were to determine that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income tax.

Comprehensive Income

Comprehensive income or loss includes all changes in equity during a period except those that resulted from investments by or distributions to a company’s shareholders. Other comprehensive income or loss refers to revenues, expenses, gains and losses that are included in comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to shareholders’ equity.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted at December 31, 2019

Recent Accounting Pronouncements Adopted or Otherwise Effective as of December 31, 2019

The Company adopted ASC 842 using the modified retrospective approach with an effective date of January 1, 2019 for leases that existed on that date.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedules of concentration of risk, by risk factor

Total revenues from direct customers that accounted for 10% or more of our total consolidated revenues during the years ended December 31, 2019, 2018 and 2017 are as follows:



	2019		2018		2017
AmerisourceBergen Corporation	34	%	32	%	25	%
McKesson Corporation	26	%	27	%	25	%
Cardinal Health, Inc.	25	%	26	%	25	%

Schedule of property, plant and equipment

Property, Plant and Equipment. Property, plant and equipment is generally

Changes in the amount of Property, plant and equipment for the year ended December 31, 2019 are set forth in the table below (in thousands).



Cost:	Land and Buildings			Machinery and Equipment			Leasehold Improvements			Computer Equipment and Software			Furniture and Fixtures			Assets under Construction			Total
At January 1, 2019	$	230,035		$	211,491		$	69,256		$	117,134		$	12,495		$	121,024		$	761,435
Additions (1)	49,716			56,888			9,934			8,359			954			(46,715		)	79,136
Disposals, transfers, impairments and other (2)	6,115			(6,394		)	(8,926		)	(8,951		)	(515		)	(1,096		)	(19,767		)
Effect of currency translation	—			71			60			495			509			—			1,135
At December 31, 2019	$	285,866		$	262,056		$	70,324		$	117,037		$	13,443		$	73,213		$	821,939
Accumulated Depreciation:
At January 1, 2019	$	(69,656	)	$	(83,906	)	$	(30,600	)	$	(71,437	)	$	(6,944	)	$	—		$	(262,543	)
Additions	(17,670		)	(22,012		)	(7,337		)	(20,696		)	(1,285		)	—			(69,000		)
Disposals, transfers and other (2)	2,850			1,605			1,110			8,617			515			—			14,697
Effect of currency translation	—			(44		)	(31		)	(142		)	(11		)	—			(228		)
At December 31, 2019	$	(84,476	)	$	(104,357	)	$	(36,858	)	$	(83,658	)	$	(7,725	)	$	—		$	(317,074	)
Net Book Amount:
At December 31, 2019	$	201,390		$	157,699		$	33,466		$	33,379		$	5,718		$	73,213		$	504,865
At December 31, 2018	$	160,379		$	127,585		$	38,656		$	45,697		$	5,551		$	121,024		$	498,892

__________


(1)	Costs incurred during the construction or development of property, plant and equipment are initially recorded as additions to Assets under Construction. Once an asset has been placed into service, the cost of that asset is transferred from Assets under Construction to one of the other classes of assets.

(2)

Amounts include the effect of the Company’s January 1, 2019 adoption of ASC 842, which is further described in Note 2. Summary of Significant Accounting Policies

Discontinued Operations and Divestitures (Tables)

12 Months Ended

Dec. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

Schedule of disposal groups, including discontinued operations, income statement, balance sheet and additional disclosures

The following table provides the operating results of Astora Discontinued operations, net of tax, for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019			2018			2017
Litigation-related and other contingencies, net	$	30,400		$	34,000		$	775,474
Loss from discontinued operations before income taxes	$	(62,052	)	$	(69,702	)	$	(816,426	)
Income tax benefit	$	—		$	—		$	(13,704	)
Discontinued operations, net of tax	$	(62,052	)	$	(69,702	)	$	(802,722	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Restructuring (Tables)

12 Months Ended

Dec. 31, 2019

Restructuring and Related Activities [Abstract]

Schedule of restructuring reserve by type of cost

Changes to this liability during the years ended December 31, 2019 and 2018 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2018	$	22,975		$	1,610		$	24,585
Expenses	9,090			11,294			20,384
Cash distributions	(27,826		)	(12,856		)	(40,682		)
Liability balance as of December 31, 2018	$	4,239		$	48		$	4,287
Cash distributions	(4,239		)	(48		)	(4,287		)
Liability balance as of December 31, 2019	$	—		$	—		$	—

Changes to this liability during the years ended December 31, 2019 and 2018 were as follows (in thousands):



	Employee Separation and Other Benefit-Related Costs			Other Restructuring Costs			Total
Liability balance as of January 1, 2018	$	—		$	650		$	650
Expenses	21,754			1,764			23,518
Cash distributions	(20,925		)	(2,094		)	(23,019		)
Liability balance as of December 31, 2018	$	829		$	320		$	1,149
Cash distributions	(829		)	(320		)	(1,149		)
Liability balance as of December 31, 2019	$	—		$	—		$	—

Segment Results (Tables)

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Schedule of reportable segments information



	2019			2018			2017
Total consolidated loss from continuing operations before income tax	$	(344,904	)	$	(938,832	)	$	(1,483,004	)
Interest expense, net	538,734			521,656			488,228
Corporate unallocated costs (1)	168,136			200,592			165,298
Amortization of intangible assets	543,862			622,339			773,766
Inventory step-up	—			261			390
Upfront and milestone payments to partners	6,623			45,108			9,483
Retention and separation benefits and other cost reduction initiatives (2)	34,598			86,295			212,448
Certain litigation-related and other contingencies, net (3)	11,211			13,809			185,990
Asset impairment charges (4)	526,082			916,939			1,154,376
Acquisition-related and integration items, net (5)	(46,098		)	21,914			58,086
(Gain) loss on extinguishment of debt	(119,828		)	—			51,734
Foreign currency impact related to the remeasurement of intercompany debt instruments	4,362			(5,486		)	(1,403		)
Other, net (6)	23,890			(43,456		)	(7,217		)
Total segment adjusted income from continuing operations before income tax	$	1,346,668		$	1,441,139		$	1,608,175

__________


(1)	Amounts include certain corporate overhead costs, such as headcount, facility and corporate litigation expenses and certain other income and expenses.

(2)


(3)	Amounts include adjustments to our accruals for litigation-related settlement charges and certain settlement proceeds related to suits filed by our subsidiaries. Our material legal proceedings and other contingent matters are described in more detail in Note 15. Commitments and Contingencies.


(4)	Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 10. Goodwill and Other Intangibles as well as charges to write down certain property, plant and equipment as further described in Note 4. Restructuring, Note 6. Fair Value Measurements and Note 9. Property, Plant and Equipment.


(5)	Amounts primarily relate to changes in the fair value of contingent consideration.

(6)

The following represents depreciation expense for our reportable segments for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019		2018		2017
Branded Pharmaceuticals	$	12,573	$	14,542	$	16,957
Sterile Injectables	14,287		10,500		8,411
Generic Pharmaceuticals	32,689		66,016		174,652
International Pharmaceuticals	4,234		4,925		3,332
Corporate unallocated	5,217		5,385		6,647
Total depreciation expense	$	69,000	$	101,368	$	209,999

The following represents selected information for the Company’s reportable segments for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019		2018		2017
Net revenues from external customers:
Branded Pharmaceuticals	$	855,402	$	862,832	$	957,525
Sterile Injectables	1,063,131		929,566		750,471
Generic Pharmaceuticals	879,882		1,012,215		1,530,530
International Pharmaceuticals (1)	115,949		142,465		230,332
Total net revenues from external customers	$	2,914,364	$	2,947,078	$	3,468,858
Segment adjusted income from continuing operations before income tax:
Branded Pharmaceuticals	$	362,711	$	368,790	$	485,515
Sterile Injectables	780,799		695,363		563,103
Generic Pharmaceuticals	158,400		317,892		501,249
International Pharmaceuticals	44,758		59,094		58,308
Total segment adjusted income from continuing operations before income tax	$	1,346,668	$	1,441,139	$	1,608,175

__________

(1)

Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada and, prior to the sale of Litha in July 2017 and Somar in October 2017, South Africa and Latin America.

Disaggregation of revenue

The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.



	2019		2018		2017
Branded Pharmaceuticals:
Specialty Products:
XIAFLEX®	$	327,638	$	264,638	$	213,378
SUPPRELIN® LA	86,797		81,707		86,211
Other Specialty (1)	105,241		98,230		84,161
Total Specialty Products	$	519,676	$	444,575	$	383,750
Established Products:
PERCOCET®	$	116,012	$	122,901	$	125,231
TESTOPEL®	55,244		58,377		69,223
Other Established (2)	164,470		236,979		379,321
Total Established Products	$	335,726	$	418,257	$	573,775
Total Branded Pharmaceuticals (3)	$	855,402	$	862,832	$	957,525
Sterile Injectables:
VASOSTRICT®	$	531,737	$	453,767	$	399,909
ADRENALIN®	179,295		143,489		76,523
Ertapenem for injection	104,679		57,668		—
APLISOL®	61,826		64,913		66,286
Other Sterile Injectables (4)	185,594		209,729		207,753
Total Sterile Injectables (3)	$	1,063,131	$	929,566	$	750,471
Total Generic Pharmaceuticals (5)	$	879,882	$	1,012,215	$	1,530,530
Total International Pharmaceuticals (6)	$	115,949	$	142,465	$	230,332
Total revenues, net	$	2,914,364	$	2,947,078	$	3,468,858

__________


(1)	Products included within Other Specialty are NASCOBAL^®Nasal Spray and AVEED^®. Beginning with our first-quarter 2019 reporting, TESTOPEL^®, which was previously included in Other Specialty, has been reclassified and is now included in the Established Products portfolio for all periods presented.


(2)	Products included within Other Established include, but are not limited to, LIDODERM^®, EDEX^® and VOLTAREN^® Gel.


(3)	Individual products presented above represent the top two performing products in each product category for the year ended December 31, 2019 and/or any product having revenues in excess of $100 million during any of the years ended December 31, 2019, 2018 or 2017 or $25 million during any quarterly period in 2019 or 2018.


(4)	Products included within Other Sterile Injectables include ephedrine sulfate injection, treprostinil for injection and others.

(5)

(6)

The International Pharmaceuticals segment, which accounted for 4%, 5% and 7% of consolidated total revenues in 2019, 2018 and 2017, respectively, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin. This segment also included Litha, which was sold in July 2017, and Somar, which was sold in October 2017.

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Schedule of cash and cash equivalents

The following table presents current and noncurrent restricted cash and cash equivalent balances at December 31, 2019 and December 31, 2018 (in thousands):



	December 31, 2019		December 31, 2018
Restricted cash and cash equivalents—current portion (1)	$	247,457	$	305,368
Restricted cash and cash equivalents—noncurrent portion (2)	18,400		22,356
Restricted cash and cash equivalents—total (3)	$	265,857	$	327,724

__________


(1)	These amounts are reported in our Consolidated Balance Sheets as Restricted cash and cash equivalents.


(2)	These amounts are reported in our Consolidated Balance Sheets as Other assets.

(3)

Approximately $242.8 million and $299.7 million of our restricted cash and cash equivalents are held in QSFs for mesh-related matters at December 31, 2019 and December 31, 2018, respectively. The remaining restricted cash and cash equivalents primarily relates to other litigation-related matters. See Note 15. Commitments and Contingencies for further information.

Restrictions on cash and cash equivalents

The following table presents current and noncurrent restricted cash and cash equivalent balances at December 31, 2019 and December 31, 2018 (in thousands):



	December 31, 2019		December 31, 2018
Restricted cash and cash equivalents—current portion (1)	$	247,457	$	305,368
Restricted cash and cash equivalents—noncurrent portion (2)	18,400		22,356
Restricted cash and cash equivalents—total (3)	$	265,857	$	327,724

__________


(1)	These amounts are reported in our Consolidated Balance Sheets as Restricted cash and cash equivalents.


(2)	These amounts are reported in our Consolidated Balance Sheets as Other assets.

(3)

Financial assets and liabilities measured at fair value on recurring basis

The Company’s financial assets and liabilities measured at fair value on a recurring basis at December 31, 2019 and 2018 were as follows (in thousands):



	Fair Value Measurements at December 31, 2019 using:
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total
Assets:
Money market funds	$	427,033	$	—	$	—	$	427,033
Liabilities:
Acquisition-related contingent consideration—current	$	—	$	—	$	6,534	$	6,534
Acquisition-related contingent consideration—noncurrent	$	—	$	—	$	23,123	$	23,123



	Fair Value Measurements at December 31, 2018 using:
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total
Assets:
Money market funds	$	137,215	$	—	$	—	$	137,215
Liabilities:
Acquisition-related contingent consideration—current	$	—	$	—	$	36,514	$	36,514
Acquisition-related contingent consideration—noncurrent	$	—	$	—	$	80,189	$	80,189

Changes to liability for acquisition-related contingent consideration

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2019 by acquisition (in thousands):



	Balance as of December 31, 2018		Changes in Fair Value Recorded in Earnings			Amounts Settled and Other			Balance as of December 31, 2019
Auxilium acquisition	$	14,157	$	777		$	(1,727	)	$	13,207
Lehigh Valley Technologies, Inc. acquisitions	34,700		(8,614		)	(19,286		)	6,800
VOLTAREN® Gel acquisition (1)	56,240		(37,184		)	(18,870		)	186
Other	11,606		(1,077		)	(1,065		)	9,464
Total	$	116,703	$	(46,098	)	$	(40,948	)	$	29,657

__________


(1)	The change in fair value recorded in earnings includes the impact of certain competitive events occurring during 2019.

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the year ended December 31, 2018 by acquisition (in thousands):



	Balance as of December 31, 2017		Changes in Fair Value Recorded in Earnings			Amounts Settled and Other			Balance as of December 31, 2018
Auxilium acquisition	$	13,061	$	2,941		$	(1,845	)	$	14,157
Lehigh Valley Technologies, Inc. acquisitions	63,001		19,146			(47,447		)	34,700
VOLTAREN® Gel acquisition	98,124		9			(41,893		)	56,240
Other	16,256		(2,186		)	(2,464		)	11,606
Total	$	190,442	$	19,910		$	(93,649	)	$	116,703



	2019			2018
Beginning of period	$	116,703		$	190,442
Amounts settled	(41,448		)	(92,627		)
Changes in fair value recorded in earnings	(46,098		)	19,910
Effect of currency translation	500			(1,022		)
End of period	$	29,657		$	116,703

Summary of nonrecurring fair value measurements

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the years ended December 31, 2019 and 2018 were as follows (in thousands):



	Fair Value Measurements during the Year Ended December 31, 2019 (1) using:						Total Expense for the Year Ended December 31, 2019
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total Expense for the Year Ended December 31, 2019
Intangible assets, excluding goodwill (Note 10)	$	—	$	—	$	229,680	$	(347,706	)
Certain property, plant and equipment (Note 9)	—		—		—		(6,468		)
Total	$	—	$	—	$	229,680	$	(354,174	)



	Fair Value Measurements during the Year Ended December 31, 2018 (1) using:						Total Expense for the Year Ended December 31, 2018
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total Expense for the Year Ended December 31, 2018
Intangible assets, excluding goodwill (Note 10)	$	—	$	—	$	239,857	$	(230,418	)
Certain property, plant and equipment (Note 9)	—		—		—		(6,521		)
Total	$	—	$	—	$	239,857	$	(236,939	)

__________

(1)

The fair value amounts are presented as of the date of the fair value measurement as these assets are not measured at fair value on a recurring basis. Such measurements generally occur in connection with our quarter-end financial reporting close procedures.

Inventories (Tables)

12 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Schedule of inventory

Inventories consist of the following at December 31, 2019 and December 31, 2018 (in thousands):



	December 31, 2019		December 31, 2018
Raw materials (1)	$	124,171	$	122,825
Work-in-process (1)	65,392		70,458
Finished goods (1)	138,302		128,896
Total	$	327,865	$	322,179

__________

(1) The components of inventory shown in the table above are net of allowance for obsolescence.

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Assets and liabilities, lessee

The following table presents information about the Company's ROU assets and lease liabilities at December 31, 2019 (in thousands):



	Consolidated Balance Sheets Line Items	December 31, 2019
ROU assets:
Operating lease ROU assets	Operating lease assets	$	51,700
Finance lease ROU assets	Property, plant and equipment, net	56,793
Total ROU assets		$	108,493
Operating lease liabilities:
Current operating lease liabilities	Current portion of operating lease liabilities	$	10,763
Noncurrent operating lease liabilities	Operating lease liabilities, less current portion	48,299
Total operating lease liabilities		$	59,062
Finance lease liabilities:
Current finance lease liabilities	Accounts payable and accrued expenses	$	5,672
Noncurrent finance lease liabilities	Other liabilities	31,312
Total finance lease liabilities		$	36,984

Lease, cost

The following table provides certain cash flow and supplemental noncash information related to our lease liabilities for the year ended December 31, 2019 (in thousands):



	2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$	14,940
Operating cash payments for finance leases	$	2,000
Financing cash payments for finance leases	$	9,196
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	623
Finance leases	$	5,953

The following table provides the weighted average remaining lease term and weighted average discount rates for our leases as of December 31, 2019:



	December 31, 2019
Weighted average remaining lease term (years), weighted based on lease liability balances:
Operating leases	5.9 years
Finance leases	9.5 years
Weighted average discount rate (percentages), weighted based on the remaining balance of lease payments:
Operating leases	5.8	%
Finance leases	5.5	%

The following table presents information about lease costs and expenses and sublease income for the year ended December 31, 2019 (in thousands):



	Consolidated Statements of Operations Line Items	2019
Operating lease cost	Various (1)	$	13,648
Finance lease cost:
Amortization of ROU assets	Various (1)	$	9,407
Interest on lease liabilities	Interest expense, net	$	1,986
Other lease costs and income:
Variable lease costs (2)	Various (1)	$	9,653
Sublease income	Various (1)	$	(3,689	)

__________


(1)	Amounts are included in the Consolidated Statements of Operations based on the function that the underlying leased asset supports. The following table presents the components of such aggregate amounts for the year ended December 31, 2019 (in thousands):



	2019
Cost of revenues	$	11,168
Selling, general and administrative	$	17,648
Research and development	$	203

(2)

Amounts represent variable lease costs incurred that were not included in the initial measurement of the lease liability such as common area maintenance and utilities costs associated with leased real estate and certain costs associated with our automobile leases.

Lessee, operating lease, liability, maturity



	Operating Leases		Finance Leases
2020	$	14,103	$	7,446
2021	13,262		7,593
2022	12,688		7,743
2023	10,017		7,897
2024	5,176		8,054
Thereafter	15,332		13,483
Total future lease payments	$	70,578	$	52,216
Less: amount representing interest	11,516		15,232
Present value of future lease payments (lease liability)	$	59,062	$	36,984

Finance lease, liability, maturity



	Operating Leases		Finance Leases
2020	$	14,103	$	7,446
2021	13,262		7,593
2022	12,688		7,743
2023	10,017		7,897
2024	5,176		8,054
Thereafter	15,332		13,483
Total future lease payments	$	70,578	$	52,216
Less: amount representing interest	11,516		15,232
Present value of future lease payments (lease liability)	$	59,062	$	36,984

Schedule of future minimum rental payments for operating leases



	Capital Leases (1)		Operating Leases
2019	$	6,884	$	15,800
2020	6,819		14,519
2021	6,921		12,883
2022	7,072		12,454
2023	7,225		9,945
Thereafter	9,127		20,573
Total minimum lease payments	$	44,048	$	86,174
Less: Amount representing interest	4,084
Total present value of minimum payments	$	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$	34,119

__________

(1)

The Malvern, Pennsylvania location’s lease arrangement is included under Capital Leases.

Schedule of future minimum lease payments for capital leases



	Capital Leases (1)		Operating Leases
2019	$	6,884	$	15,800
2020	6,819		14,519
2021	6,921		12,883
2022	7,072		12,454
2023	7,225		9,945
Thereafter	9,127		20,573
Total minimum lease payments	$	44,048	$	86,174
Less: Amount representing interest	4,084
Total present value of minimum payments	$	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	$	34,119

__________

(1)

The Malvern, Pennsylvania location’s lease arrangement is included under Capital Leases.

Property, Plant And Equipment (Tables)

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Schedule of property, plant and equipment

Property, Plant and Equipment. Property, plant and equipment is generally

Changes in the amount of Property, plant and equipment for the year ended December 31, 2019 are set forth in the table below (in thousands).



Cost:	Land and Buildings			Machinery and Equipment			Leasehold Improvements			Computer Equipment and Software			Furniture and Fixtures			Assets under Construction			Total
At January 1, 2019	$	230,035		$	211,491		$	69,256		$	117,134		$	12,495		$	121,024		$	761,435
Additions (1)	49,716			56,888			9,934			8,359			954			(46,715		)	79,136
Disposals, transfers, impairments and other (2)	6,115			(6,394		)	(8,926		)	(8,951		)	(515		)	(1,096		)	(19,767		)
Effect of currency translation	—			71			60			495			509			—			1,135
At December 31, 2019	$	285,866		$	262,056		$	70,324		$	117,037		$	13,443		$	73,213		$	821,939
Accumulated Depreciation:
At January 1, 2019	$	(69,656	)	$	(83,906	)	$	(30,600	)	$	(71,437	)	$	(6,944	)	$	—		$	(262,543	)
Additions	(17,670		)	(22,012		)	(7,337		)	(20,696		)	(1,285		)	—			(69,000		)
Disposals, transfers and other (2)	2,850			1,605			1,110			8,617			515			—			14,697
Effect of currency translation	—			(44		)	(31		)	(142		)	(11		)	—			(228		)
At December 31, 2019	$	(84,476	)	$	(104,357	)	$	(36,858	)	$	(83,658	)	$	(7,725	)	$	—		$	(317,074	)
Net Book Amount:
At December 31, 2019	$	201,390		$	157,699		$	33,466		$	33,379		$	5,718		$	73,213		$	504,865
At December 31, 2018	$	160,379		$	127,585		$	38,656		$	45,697		$	5,551		$	121,024		$	498,892

__________


(1)	Costs incurred during the construction or development of property, plant and equipment are initially recorded as additions to Assets under Construction. Once an asset has been placed into service, the cost of that asset is transferred from Assets under Construction to one of the other classes of assets.

(2)

Amounts include the effect of the Company’s January 1, 2019 adoption of ASC 842, which is further described in Note 2. Summary of Significant Accounting Policies

Goodwill and Other Intangibles (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of changes in the carrying amount of goodwill

Changes in the carrying amount of our goodwill for the years ended December 31, 2019 and 2018 were as follows (in thousands):



	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals			International Pharmaceuticals			Total
Goodwill as of December 31, 2017	$	828,818	$	—	$	3,531,301		$	89,963		$	4,450,082
Allocation to current segments (1)	—		2,731,193		(2,731,193		)	—			—
Effect of currency translation	—		—		—			(5,446		)	(5,446		)
Goodwill impairment charges	—		—		(649,000		)	(31,000		)	(680,000		)
Goodwill as of December 31, 2018	$	828,818	$	2,731,193	$	151,108		$	53,517		$	3,764,636
Effect of currency translation	—		—		—			2,456			2,456
Goodwill impairment charges	—		—		(151,108		)	(20,800		)	(171,908		)
Goodwill as of December 31, 2019	$	828,818	$	2,731,193	$	—		$	35,173		$	3,595,184

__________

(1)

This allocation relates to the change in segments described below under the heading “Impairments.” The amount of goodwill allocated was determined using a relative fair value methodology in accordance with U.S. GAAP.

The carrying amounts of goodwill at December 31, 2019 and December 31, 2018 are net of the following accumulated impairments (in thousands):



	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2018	$	855,810	$	—	$	2,991,549	$	456,408	$	4,303,767
Accumulated impairment losses as of December 31, 2019	$	855,810	$	—	$	3,142,657	$	500,417	$	4,498,884

Schedule of other intangible assets

Changes in the amount of other intangible assets from December 31, 2018 to December 31, 2019 are set forth in the table below (in thousands).



Cost basis:	Balance as of December 31, 2018			Acquisitions			Impairments			Other (1)			Effect of Currency Translation			Balance as of December 31, 2019
Indefinite-lived intangibles:
In-process research and development	$	93,900		$	—		$	—		$	—		$	—		$	93,900
Total indefinite-lived intangibles	$	93,900		$	—		$	—		$	—		$	—		$	93,900
Finite-lived intangibles:
Licenses (weighted average life of 14 years)	$	457,402		$	—		$	—		$	—		$	—		$	457,402
Tradenames	6,409			—			—			—			—			6,409
Developed technology (weighted average life of 11 years)	6,182,015			—			(347,706		)	(2,197		)	12,327			5,844,439
Total finite-lived intangibles (weighted average life of 11 years)	$	6,645,826		$	—		$	(347,706	)	$	(2,197	)	$	12,327		$	6,308,250
Total other intangibles	$	6,739,726		$	—		$	(347,706	)	$	(2,197	)	$	12,327		$	6,402,150

Accumulated amortization:	Balance as of December 31, 2018			Amortization			Impairments			Other (1)			Effect of Currency Translation			Balance as of December 31, 2019
Finite-lived intangibles:
Licenses	$	(398,182	)	$	(12,154	)	$	—		$	—		$	—		$	(410,336	)
Tradenames	(6,409		)	—			—			—			—			(6,409		)
Developed technology	(2,877,829		)	(531,708		)	—			2,197			(6,798		)	(3,414,138		)
Total other intangibles	$	(3,282,420	)	$	(543,862	)	$	—		$	2,197		$	(6,798	)	$	(3,830,883	)
Net other intangibles	$	3,457,306														$	2,571,267

__________

(1)

Other adjustments relate to the removal of certain fully amortized intangible assets.

Schedule of future amortization expense

Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2019 is as follows (in thousands):



2020	$	437,420
2021	$	396,864
2022	$	381,312
2023	$	351,805
2024	$	308,986

Schedule of intangible asset impairment charges including goodwill

During the years ended December 31, 2019, 2018 and 2017, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):



	2019		2018		2017
Goodwill impairment charges	$	171,908	$	680,000	$	288,745
Other intangible asset impairment charges	$	347,706	$	230,418	$	799,955

Contract Assets and Liabilities (Tables)

12 Months Ended

Dec. 31, 2019

Contract with Customer, Asset and Liability [Abstract]

Contract assets and liabilities

The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):



	December 31, 2019		December 31, 2018		$ Change			% Change
Contract assets, net (1)	$	—	$	12,065	$	(12,065	)	(100	)%
Contract liabilities, net (2)	$	6,592	$	19,217	$	(12,625	)	(66	)%

__________

(1)

(2)

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2019

Accounts Payable and Accrued Liabilities, Current [Abstract]

Schedule of accounts payable and accrued liabilities

Accounts payable and accrued expenses include the following at December 31, 2019 and December 31, 2018 (in thousands):



	December 31, 2019		December 31, 2018
Trade accounts payable	$	101,532	$	96,024
Returns and allowances	206,248		236,946
Rebates	129,056		144,860
Chargebacks	1,594		2,971
Accrued interest	112,860		130,182
Accrued payroll and related benefits	79,869		89,895
Accrued royalties and other distribution partner payables	115,816		122,028
Acquisition-related contingent consideration—current	6,534		36,514
Other	146,440		149,780
Total	$	899,949	$	1,009,200

Debt (Tables)

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Schedule of long-term debt instruments

The following table presents information about the Company’s total indebtedness at December 31, 2019 and December 31, 2018 (dollars in thousands):



	December 31, 2019						December 31, 2018
	Effective Interest Rate		Principal Amount		Carrying Amount		Effective Interest Rate		Principal Amount		Carrying Amount
7.25% Senior Notes due 2022	7.25	%	$	8,294	$	8,294	7.91	%	$	400,000	$	392,947
5.75% Senior Notes due 2022	5.75	%	182,479		182,479		6.04	%	700,000		694,464
5.375% Senior Notes due 2023	5.62	%	210,440		209,018		5.62	%	750,000		743,438
6.00% Senior Notes due 2023	6.28	%	1,439,840		1,426,998		6.28	%	1,635,000		1,616,817
5.875% Senior Secured Notes due 2024	6.14	%	300,000		296,647		6.14	%	300,000		296,062
6.00% Senior Notes due 2025	6.27	%	1,200,000		1,185,726		6.27	%	1,200,000		1,183,415
7.50% Senior Secured Notes due 2027	7.71	%	1,500,000		1,482,212				—		—
Term Loan Facility	6.21	%	3,329,625		3,302,675		7.02	%	3,363,775		3,331,276
Revolving Credit Facility	4.25	%	300,000		300,000				—		—
Total long-term debt, net			$	8,470,678	$	8,394,049			$	8,348,775	$	8,258,419
Less current portion, net			34,150		34,150				34,150		34,150
Total long-term debt, less current portion, net			$	8,436,528	$	8,359,899			$	8,314,625	$	8,224,269

Schedule of maturities of long-term debt

The following table presents the maturities on our long-term debt for each of the five fiscal years subsequent to December 31, 2019 (in thousands):



	Maturities (1)
2020	$	34,150
2021	$	34,150
2022 (2)	$	247,723
2023	$	1,684,430
2024 (2)	$	3,770,225

__________

(1)

(2)

Based on the Company’s borrowings under the Revolving Credit Facility that were outstanding at December 31, 2019, $22.8 million will mature in 2022, with the remainder maturing in 2024.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Changes in qualified settlement funds accounts and product liability balance

The following table presents the changes in the QSFs and mesh liability accrual balances during the year ended December 31, 2019 (in thousands):



	Qualified Settlement Funds			Mesh Liability Accrual
Balance as of January 1, 2019	$	299,733		$	748,606
Additional charges	—			30,000
Cash contributions to Qualified Settlement Funds	253,520			—
Cash distributions to settle disputes from Qualified Settlement Funds	(314,266		)	(314,266		)
Cash distributions to settle disputes	—			(15,330		)
Other (1)	3,855			5,021
Balance as of December 31, 2019	$	242,842		$	454,031

__________

(1)

- Definition

Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248

+ Details

Shared-based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Schedule of allocation of stock-based compensation

Presented below are the components of total share-based compensation as recorded in our Consolidated Statements of Operations for the years ended December 31, 2019, 2018 and 2017 (in thousands).



	2019		2018		2017
Selling, general and administrative expenses	$	44,159	$	44,454	$	38,292
Research and development expenses	4,501		2,251		4,197
Cost of revenues	10,482		7,366		7,660
Total share-based compensation expense	$	59,142	$	54,071	$	50,149

Summary of activity under stock incentive plans

A summary of the activity for each of the years ended December 31, 2019, 2018 and 2017 is presented below:



	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (1)
Outstanding as of January 1, 2017	4,325,209		$	41.70
Granted	5,288,675		$	10.42
Forfeited	(623,987	)	$	28.32
Expired	(741,767	)	$	40.29
Outstanding as of December 31, 2017	8,248,130		$	22.79
Granted	971,590		$	7.55
Exercised	(94,392	)	$	9.89
Forfeited	(605,737	)	$	19.01
Expired	(446,873	)	$	36.80
Outstanding as of December 31, 2018	8,072,718		$	20.62
Exercised	(557	)	$	7.55
Forfeited	(125,739	)	$	14.38
Expired	(665,883	)	$	40.37
Outstanding as of December 31, 2019	7,280,539		$	18.93	6.30	$	—
Vested and expected to vest as of December 31, 2019	7,212,334		$	19.00	6.29	$	—
Exercisable as of December 31, 2019	5,003,163		$	21.60	6.07	$	—

__________

(1)

The intrinsic value of a stock option is the excess, if any, of the closing price of the Company’s ordinary shares on the last trading day of the fiscal year over the exercise price. The aggregate intrinsic values presented in the table above represent sum of the intrinsic values of all corresponding stock options that are “in-the-money,” if any.

Stock option assumption

The weighted average grant-date fair values of the stock options granted during the years ended December 31, 2018 and 2017 were $3.97 and $4.73 per option, respectively, determined using the following weighted average assumptions:



	2018		2017
Expected term (years)	4.0		4.0
Risk-free interest rate	2.7	%	1.7	%
Dividend yield	—		—
Expected volatility	63	%	58	%

Summary of restricted and performance stock units activity

A summary of our non-vested RSUs and PSUs for the years ended December 31, 2019, 2018 and 2017 is presented below:



	Number of Shares		Aggregate Intrinsic Value (1)
Non-vested as of January 1, 2017	1,685,060
Granted	4,168,477
Forfeited	(552,981	)
Vested	(575,883	)
Non-vested as of December 31, 2017	4,724,673
Granted	5,609,561
LTCI modification (2)	2,989,965
Forfeited	(753,653	)
Vested	(1,551,074	)
Non-vested as of December 31, 2018	11,019,472
Granted	6,687,695
Forfeited	(918,425	)
Vested	(3,872,453	)
Non-vested as of December 31, 2019	12,916,289		$	60,577,395
Vested and expected to vest as of December 31, 2019	12,098,438		$	56,741,674

__________


(1)	The aggregate intrinsic values of RSUs and PSUs presented in the table above are calculated by multiplying the closing price of the Company’s ordinary shares on the last trading day of the fiscal year by the corresponding number of RSUs and PSUs.

(2)

As a result of the October 1, 2018 modification to the Company’s LTCI awards described above, modified LTCI awards are treated as RSUs for disclosure purposes; thus, the table above reflects an increase to the non-vested number of shares on the modification date.

Other Expense (Income), Net (Tables)

12 Months Ended

Dec. 31, 2019

Component of Operating Income [Abstract]

Schedule of components of other income, net

The components of Other expense (income), net for the years ended December 31, 2019, 2018 and 2017 are as follows (in thousands):



	2019			2018			2017
Net gain on sale of business and other assets (1)	$	(6,367	)	$	(45,155	)	$	(13,809	)
Foreign currency loss (gain), net (2)	5,247			(3,762		)	(2,801		)
Net loss from our investments in the equity of other companies (3)	2,346			3,444			898
Other miscellaneous, net (4)	15,451			(6,480		)	(1,311		)
Other expense (income), net	$	16,677		$	(51,953	)	$	(17,023	)

__________


(1)	Amounts in 2018 include a $12.5 million gain on the sale of the Company’s Huntsville, Alabama facilities, as further discussed in Note 4. Restructuring. Amounts in 2017 include a $10.1 million gain resulting from the sale of Litha, as further described in Note 3. Discontinued Operations and Divestitures. The remaining amounts primarily relate to the sales of various ANDAs.


(2)	Amounts relate to the remeasurement of the Company’s foreign currency denominated assets and liabilities.


(3)	Amounts relate to the income statement impacts of our investments in the equity of other companies, including investments accounted for under the equity method.

(4)

Amounts in 2019 primarily relate to $17.5 million of contract termination costs incurred as a result of certain product discontinuation activities in our International Pharmaceuticals segment.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Schedule of income before income tax, domestic and foreign

The components of our Loss from continuing operations before income tax by geography for the years ended December 31, 2019, 2018 and 2017 are as follows (in thousands):



	2019			2018			2017
U.S.	$	(688,224	)	$	(1,342,860	)	$	(1,866,222	)
International	343,320			404,028			383,218
Total (loss) income from continuing operations before income tax	$	(344,904	)	$	(938,832	)	$	(1,483,004	)

Schedule of of components of income tax expense (benefit)

Income tax from continuing operations consists of the following for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019			2018			2017
Current:
U.S. Federal	$	15,317		$	6,236		$	(86,478	)
U.S. State	(3,002		)	2,864			(6,462		)
International	8,926			8,278			(1,224		)
Total current income tax	$	21,241		$	17,378		$	(94,164	)
Deferred:
U.S. Federal	$	(515	)	$	10,084		$	(124,682	)
U.S. State	(482		)	(778		)	(3,225		)
International	(4,564		)	(3,749		)	(28,222		)
Total deferred income tax	$	(5,561	)	$	5,557		$	(156,129	)
Total income tax	$	15,680		$	22,935		$	(250,293	)

Schedule of effective income tax rate reconciliation



	2019			2018			2017
Notional U.S. federal income tax provision at the statutory rate	$	(72,430	)	$	(197,155	)	$	(519,051	)
State income tax, net of federal benefit	(4,455		)	494			(11,473		)
U.S. tax reform impact	—			5,664			(36,216		)
Uncertain tax positions	43,273			46,317			58,120
Residual tax on non-U.S. net earnings	(67,987		)	(638,724		)	(1,350,811		)
Non-deductible goodwill impairment	27,493			109,189			60,808
Change in valuation allowance	30,123			748,562			1,644,879
Intra-entity transfers of assets	—			(63,335		)	(53,509		)
International Pharmaceuticals segment divestitures	—			—			(56,092		)
Base erosion minimum tax	13,662			—			—
Non-deductible expenses	21,299			3,446			3,957
Executive compensation limitation	4,547			5,955			2,178
Other	20,155			2,522			6,917
Income tax	$	15,680		$	22,935		$	(250,293	)

Schedule of deferred tax assets and liabilities

The significant components of the net deferred income tax liability shown on the balance sheets as of December 31, 2019 and 2018 are as follows (in thousands):



	December 31, 2019			December 31, 2018
Deferred tax assets:
Accrued expenses and customer allowances	$	112,489		$	185,910
Deferred interest expense	317,997			240,736
Fixed assets and intangible assets	598,730			604,385
Loss on capital assets	61,971			62,033
Net operating loss carryforward	9,743,763			8,751,544
Other	89,501			65,266
Research and development and other tax credit carryforwards	16,620			9,551
Total gross deferred income tax assets	$	10,941,071		$	9,919,425
Deferred tax liabilities:
Other	$	(10,086	)	$	(1,965	)
Outside basis difference	—			(73,652		)
Intercompany notes	(1,131,537		)	—
Total gross deferred income tax liabilities	$	(1,141,623	)	$	(75,617	)
Valuation allowance	(9,828,959		)	(9,877,617		)
Net deferred income tax liability	$	(29,511	)	$	(33,809	)

Summary of tax credit carryforwards

At December 31, 2019, the Company had the following significant deferred tax assets for tax credits, net operating and capital loss carryforwards, net of unrecognized tax benefits (in thousands):



Jurisdiction	Amount		Begin to Expire
Ireland	$	16,862	Indefinite
Luxembourg	$	9,336,611	2034
U.S.:
Federal-ordinary losses	$	200,671	2021
Federal-capital losses	$	34,740	2020
Federal-tax credits	$	7,305	2026
State-ordinary losses	$	186,211	2020
State-capital losses	$	26,459	2026
State-tax credits	$	6,643	2020

Summary of valuations allowance

At December 31, 2019, the Company had the following significant valuation allowances (in thousands):



Jurisdiction	December 31, 2019
Ireland	$	189,581
Luxembourg	$	8,205,074
U.S.	$	1,430,762

Schedule of reconciliation of change in uncertain tax benefits

The following table summarizes the activity related to UTBs during the years ended December 31, 2019, 2018 and 2017 (in thousands):



	Unrecognized Tax Benefit Federal, State, and Foreign Tax
UTB Balance at January 1, 2017	$	424,601
Gross additions for current year positions	44,293
Gross reductions for prior period positions	(64,887		)
Gross additions for prior period positions	22,765
Decrease due to lapse of statute of limitations	(13,151		)
Currency translation adjustment	2,330
UTB Balance at December 31, 2017	$	415,951
Gross additions for current year positions	36,088
Gross reductions for prior period positions	(3,570		)
Gross additions for prior period positions	7,950
Decrease due to lapse of statute of limitations	(2,129		)
Currency translation adjustment	(2,600		)
UTB Balance at December 31, 2018	$	451,690
Gross additions for current year positions	35,766
Gross reductions for prior period positions	(2,377		)
Gross additions for prior period positions	880
Decrease due to lapse of statute of limitations	(1,006		)
Currency translation adjustment	1,528
UTB Balance at December 31, 2019	$	486,481
Accrued interest and penalties	43,710
Total UTB balance including accrued interest and penalties	$	530,191

Summary of income tax examinations

As of December 31, 2019, we may be subject to examination in the following major tax jurisdictions:



Jurisdiction		Open Years
Canada		2013 through 2019
India		2012 through 2019
Ireland		2014 through 2019
Luxembourg		2014 through 2019
U.S. - federal, state and local		2006 through 2019

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Reconciliation of the numerator and denominator of basic and diluted net loss per share

The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the years ended December 31, 2019, 2018 and 2017 (in thousands):



	2019			2018			2017
Numerator:
Loss from continuing operations	$	(360,584	)	$	(961,767	)	$	(1,232,711	)
Loss from discontinued operations, net of tax	(62,052		)	(69,702		)	(802,722		)
Net loss	$	(422,636	)	$	(1,031,469	)	$	(2,035,433	)
Denominator:
For basic per share data—weighted average shares	226,050			223,960			223,198
Dilutive effect of ordinary share equivalents	—			—			—
For diluted per share data—weighted average shares	226,050			223,960			223,198

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Data [Abstract]

Schedule of Quarterly Financial Information



	Quarter Ended
	March 31,			June 30,			September 30,			December 31,
2019 (1)
Total revenues	$	720,411		$	699,727		$	729,426		$	764,800
Gross profit	$	328,502		$	311,519		$	340,261		$	364,744
Loss from continuing operations	$	(12,612	)	$	(98,052	)	$	(41,431	)	$	(208,489	)
Discontinued operations, net of tax	$	(5,961	)	$	(7,953	)	$	(37,984	)	$	(10,154	)
Net loss	$	(18,573	)	$	(106,005	)	$	(79,415	)	$	(218,643	)
Net loss per share—Basic:
Continuing operations	$	(0.06	)	$	(0.43	)	$	(0.18	)	$	(0.92	)
Discontinued operations	(0.02		)	(0.04		)	(0.17		)	(0.04		)
Basic	$	(0.08	)	$	(0.47	)	$	(0.35	)	$	(0.96	)
Net loss per share—Diluted:
Continuing operations	$	(0.06	)	$	(0.43	)	$	(0.18	)	$	(0.92	)
Discontinued operations	(0.02		)	(0.04		)	(0.17		)	(0.04		)
Diluted	$	(0.08	)	$	(0.47	)	$	(0.35	)	$	(0.96	)
Weighted average shares—Basic	224,594			226,221			226,598			226,787
Weighted average shares—Diluted	224,594			226,221			226,598			226,787
2018 (2)
Total revenues	$	700,527		$	714,696		$	745,466		$	786,389
Gross profit	$	296,929		$	332,791		$	332,501		$	353,175
Loss from continuing operations	$	(497,738	)	$	(52,479	)	$	(146,071	)	$	(265,479	)
Discontinued operations, net of tax	$	(7,751	)	$	(8,388	)	$	(27,134	)	$	(26,429	)
Net loss	$	(505,489	)	$	(60,867	)	$	(173,205	)	$	(291,908	)
Net loss per share—Basic:
Continuing operations	$	(2.23	)	$	(0.23	)	$	(0.65	)	$	(1.18	)
Discontinued operations	(0.03		)	(0.04		)	(0.12		)	(0.12		)
Basic	$	(2.26	)	$	(0.27	)	$	(0.77	)	$	(1.30	)
Net loss per share—Diluted:
Continuing operations	$	(2.23	)	$	(0.23	)	$	(0.65	)	$	(1.18	)
Discontinued operations	(0.03		)	(0.04		)	(0.12		)	(0.12		)
Diluted	$	(2.26	)	$	(0.27	)	$	(0.77	)	$	(1.30	)
Weighted average shares—Basic	223,521			223,834			224,132			224,353
Weighted average shares—Diluted	223,521			223,834			224,132			224,353

__________

(1)

(2)

Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($) segment customer	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Jan. 01, 2019 USD ($)
Product Information [Line Items]
Number of segments with significant sales deductions \| segment	3
Allowances for sales returns and allowances	$ 660,300	$ 772,300
Advertising expense	63,100	49,600	$ 42,000
Operating lease ROU assets	51,700	0
Current operating lease liabilities	10,763	0
Noncurrent operating lease liabilities	$ 48,299	$ 0
Effect of adopting accounting principle in period of adoption				$ 4,646
ASC 842
Product Information [Line Items]
Operating lease ROU assets				59,400
Current operating lease liabilities				11,000
Noncurrent operating lease liabilities				57,300
Credit Concentration Risk \| Trade Accounts Receivable
Product Information [Line Items]
Concentration risk, percentage	88.00%	87.00%
Number of customers \| customer	3
Vasostrict® \| Product Concentration Risk \| Revenue Benchmark
Product Information [Line Items]
Concentration risk, percentage	18.00%	15.00%	12.00%
XIAFLEX® \| Product Concentration Risk \| Revenue Benchmark
Product Information [Line Items]
Concentration risk, percentage	11.00%
Minimum
Product Information [Line Items]
Revenue from contract with customer, return period	6 months
Maximum
Product Information [Line Items]
Revenue from contract with customer, return period	1 year
Weighted average
Product Information [Line Items]
Intangible life (years)	11 years
Developed technology \| Minimum
Product Information [Line Items]
Intangible life (years)	4 years
Developed technology \| Maximum
Product Information [Line Items]
Intangible life (years)	20 years
Developed technology \| Weighted average
Product Information [Line Items]
Intangible life (years)	11 years
Licensing \| Minimum
Product Information [Line Items]
Intangible life (years)	12 years
Licensing \| Maximum
Product Information [Line Items]
Intangible life (years)	15 years
Licensing \| Weighted average
Product Information [Line Items]
Intangible life (years)	14 years
Accumulated Deficit \| ASC 842
Product Information [Line Items]
Effect of adopting accounting principle in period of adoption				$ 4,646

Summary of Significant Accounting Policies - Customer Concentration Risk (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
AmerisourceBergen Corporation
Product Information [Line Items]
Concentration risk, percentage	34.00%	32.00%	25.00%
McKesson Corporation
Product Information [Line Items]
Concentration risk, percentage	26.00%	27.00%	25.00%
Cardinal Health, Inc.
Product Information [Line Items]
Concentration risk, percentage	25.00%	26.00%	25.00%

Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2019
Buildings \| Minimum
Property, Plant and Equipment [Line Items]
PP&E Useful life	10 years
Buildings \| Maximum
Property, Plant and Equipment [Line Items]
PP&E Useful life	30 years
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
PP&E Useful life	1 year
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
PP&E Useful life	15 years
Computer equipment and software \| Minimum
Property, Plant and Equipment [Line Items]
PP&E Useful life	1 year
Computer equipment and software \| Maximum
Property, Plant and Equipment [Line Items]
PP&E Useful life	10 years
Furniture and fixtures \| Minimum
Property, Plant and Equipment [Line Items]
PP&E Useful life	1 year
Furniture and fixtures \| Maximum
Property, Plant and Equipment [Line Items]
PP&E Useful life	10 years

Discontinued Operations and Divestitures - Astora - Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operations, net of tax	$ (10,154)	$ (37,984)	$ (7,953)	$ (5,961)	$ (26,429)	$ (27,134)	$ (8,388)	$ (7,751)	$ (62,052)	$ (69,702)	$ (802,722)
Discontinued operations, disposed of by means other than sale, abandonment \| Astora
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Litigation-related and other contingencies, net									30,400	34,000	775,474
Loss from discontinued operations before income taxes									(62,052)	(69,702)	(816,426)
Income tax benefit									0	0	(13,704)
Discontinued operations, net of tax									$ (62,052)	$ (69,702)	$ (802,722)

- Definition

Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Discontinued Operations and Divestitures - Astora (Narrative) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Loss from discontinued operations, net of tax	$ (10,154,000)	$ (37,984,000)	$ (7,953,000)	$ (5,961,000)	$ (26,429,000)	$ (27,134,000)	$ (8,388,000)	$ (7,751,000)	$ (62,052,000)	$ (69,702,000)	$ (802,722,000)
Discontinued operations, disposed of by means other than sale, abandonment \| Astora
Restructuring Cost and Reserve [Line Items]
Loss from discontinued operations, net of tax									(62,052,000)	(69,702,000)	(802,722,000)
Cash used in investing activities									0	0	0
Depreciation and amortization									$ 0	$ 0	$ 0

- Definition

+ References + Details

Discontinued Operations and Divestitures - Lithia (Narrative) (Details) - USD ($)		1 Months Ended		12 Months Ended
	Jul. 03, 2017	Dec. 31, 2017	Oct. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business, net				$ 6,577,000	$ 70,369,000	$ 223,237,000
Litha Healthcare Group Limited \| Disposal group, disposed of by sale, not discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of business, net	$ 94,200,000
Consideration receivable			$ 4,400,000
Gain on sale of business	$ 0	$ 10,100,000				$ 10,100,000

Discontinued Operations and Divestitures - Somar (Narrative) (Details) - USD ($) $ in Thousands		3 Months Ended								12 Months Ended
	Oct. 25, 2017	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of business		$ (3,300)	$ (1,900)	$ (2,500)	$ 1,300	$ (15,300)	$ (2,900)	$ (24,600)	$ (2,400)	$ 6,367	$ 45,155	$ 13,809
Somar \| Disposal group, disposed of by sale, not discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate purchase price	$ 124,000
Gain on sale of business	$ 1,300

Restructuring - 2016 Restructuring Initiative (Narrative) (Details)		3 Months Ended									12 Months Ended
	Oct. 31, 2016 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2016 position	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Restructuring Cost and Reserve [Line Items]
Expenses		$ 19,400,000	$ 11,000,000.0	$ 2,100,000	$ 2,000,000.0	$ 4,200,000	$ 4,000,000.0	$ 29,200,000	$ 49,000,000.0
US Generic Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost											$ 0	$ 0	$ 0
US Branded Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost											0	$ 0	0
Number of positions reduced \| position										375
Employee separation, retention, and other benefit related costs \| US Generic Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Expenses													10,700,000
Employee separation, retention, and other benefit related costs \| US Branded Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Expenses													16,500,000
Contract termination
Restructuring Cost and Reserve [Line Items]
Expenses											$ 17,500,000
Contract termination \| US Branded Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Expenses													$ 5,200,000
Charlotte, North Carolina Facility \| US Generic Pharmaceuticals Restructuring 2016
Restructuring Cost and Reserve [Line Items]
Proceeds from sale of property, plant and equipment	$ 14,000,000

Restructuring - 2017 Restructuring Initiatives (Narrative) (Details) $ in Thousands		3 Months Ended								12 Months Ended
	Jan. 26, 2017 position	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Restructuring Cost and Reserve [Line Items]
Expenses		$ 19,400	$ 11,000	$ 2,100	$ 2,000	$ 4,200	$ 4,000	$ 29,200	$ 49,000
January 2017 Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected number of positions eliminated \| position	90
Expenses										$ 2,700	$ 12,400
2017 US generic pharmaceuticals restructuring
Restructuring Cost and Reserve [Line Items]
Expenses										20,384
2017 US generic pharmaceuticals restructuring \| Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Expenses										61,600	286,700
2017 US generic pharmaceuticals restructuring \| Employee separation, retention, and other benefit related costs
Restructuring Cost and Reserve [Line Items]
Expenses											29,600
2017 US generic pharmaceuticals restructuring \| Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Expenses										35,200	123,300
2017 US generic pharmaceuticals restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Cost and Reserve [Line Items]
Expenses										9,090
2017 US generic pharmaceuticals restructuring \| Asset impairment charges
Restructuring Cost and Reserve [Line Items]
Expenses										2,600
2017 US generic pharmaceuticals restructuring \| Certain other charges
Restructuring Cost and Reserve [Line Items]
Expenses										14,700	17,000
2017 US generic pharmaceuticals restructuring \| Property, plant and equipment impairment charges
Restructuring Cost and Reserve [Line Items]
Expenses										104,700
2017 US generic pharmaceuticals restructuring \| Increase excess inventory reserves
Restructuring Cost and Reserve [Line Items]
Expenses										12,100
Huntsville, Alabama manufacturing and distributing facility \| Disposal group, disposed of by sale, not discontinued operations \| 2017 US generic pharmaceuticals restructuring \| Facility closing
Restructuring Cost and Reserve [Line Items]
Proceeds from sale of property, plant and equipment						23,100
Net gain on disposal						$ 12,500				$ 12,500
Operating segments \| January 2017 Restructuring \| U.S. Branded - Specialty & Established Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Expenses											6,900
Operating segments \| January 2017 Restructuring \| Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Expenses											3,300
Operating segments \| January 2017 Restructuring \| Employee separation, retention, and other benefit related costs
Restructuring Cost and Reserve [Line Items]
Expenses											15,100
Corporate unallocated costs \| January 2017 Restructuring
Restructuring Cost and Reserve [Line Items]
Expenses											$ 4,900

Restructuring - Schedule of Restructuring Roll Forward (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restructuring Reserve [Roll Forward]
Expenses	$ 19,400	$ 11,000	$ 2,100	$ 2,000	$ 4,200	$ 4,000	$ 29,200	$ 49,000
Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Expenses									$ 11,000	$ 16,500	$ 22,000
2017 US generic pharmaceuticals restructuring
Restructuring Reserve [Roll Forward]
Beginning liability balance				4,287				24,585	4,287	24,585
Expenses										20,384
Cash distributions									(4,287)	(40,682)
Ending liability balance	0				4,287				0	4,287	24,585
2017 US generic pharmaceuticals restructuring \| Employee separation, retention and other benefit-related costs
Restructuring Reserve [Roll Forward]
Beginning liability balance				4,239				22,975	4,239	22,975
Expenses										9,090
Cash distributions									(4,239)	(27,826)
Ending liability balance	0				4,239				0	4,239	22,975
2017 US generic pharmaceuticals restructuring \| Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance				48				1,610	48	1,610
Expenses										11,294
Cash distributions									(48)	(12,856)
Ending liability balance	0				48				0	48	1,610
January 2018 restructuring initiative
Restructuring Reserve [Roll Forward]
Beginning liability balance				1,149				650	1,149	650
Expenses										23,518
Cash distributions									(1,149)	(23,019)
Ending liability balance	0				1,149				0	1,149	650
January 2018 restructuring initiative \| Employee separation, retention and other benefit-related costs
Restructuring Reserve [Roll Forward]
Beginning liability balance				829				0	829	0
Expenses										21,754
Cash distributions									(829)	(20,925)
Ending liability balance	0				829				0	829	0
January 2018 restructuring initiative \| Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance				$ 320				$ 650	320	650
Expenses										1,764
Cash distributions									(320)	(2,094)
Ending liability balance	$ 0				$ 320				$ 0	$ 320	$ 650

Restructuring - January 2018 Restructuring Initiative (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Expenses	$ 19,400	$ 11,000	$ 2,100	$ 2,000	$ 4,200	$ 4,000	$ 29,200	$ 49,000
January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Expenses									$ 23,518
Employee separation, retention, and other benefit related costs \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Expenses									21,700
Certain other charges \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Expenses									1,800
Restructuring costs and asset impairment charges										$ 600
Asset impairment charges \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Expenses										2,000
Generic Pharmaceuticals \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Expenses									23,500	$ 2,600
Operating segments \| Generic Pharmaceuticals \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Expenses									10,600
Operating segments \| Sterile Injectables \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Expenses									3,900
Operating segments \| International Pharmaceuticals \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Expenses									3,100
Operating segments \| Branded Pharmaceuticals \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Expenses									700
Corporate unallocated costs \| January 2018 restructuring initiative
Restructuring Cost and Reserve [Line Items]
Expenses									$ 5,200

Segment Results - Schedule of Reportable Segments Information (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2019 USD ($) Reportable_Business_Segments	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments \| Reportable_Business_Segments									4
Total net revenues from external customers	$ 764,800	$ 729,426	$ 699,727	$ 720,411	$ 786,389	$ 745,466	$ 714,696	$ 700,527	$ 2,914,364	$ 2,947,078	$ 3,468,858
Total segment adjusted income from continuing operations before income tax									1,346,668	1,441,139	1,608,175
Branded Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues from external customers									855,402	862,832	957,525
Total segment adjusted income from continuing operations before income tax									362,711	368,790	485,515
Sterile Injectables
Segment Reporting Information [Line Items]
Total net revenues from external customers									1,063,131	929,566	750,471
Total segment adjusted income from continuing operations before income tax									780,799	695,363	563,103
Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues from external customers									879,882	1,012,215	1,530,530
Total segment adjusted income from continuing operations before income tax									158,400	317,892	501,249
International Pharmaceuticals
Segment Reporting Information [Line Items]
Total net revenues from external customers									115,949	142,465	230,332
Total segment adjusted income from continuing operations before income tax									$ 44,758	$ 59,094	$ 58,308

Segment Results - Schedule of Reconciliations of Consolidated Adjusted Income (Loss) Before Income Tax (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax									$ (344,904)	$ (938,832)	$ (1,483,004)
Interest expense, net									538,734	521,656	488,228
Amortization of intangible assets									543,862	622,300	773,800
Inventory step-up									0	261	390
Asset impairment charges	$ 267,400	$ 4,800	$ 88,400	$ 165,400	$ 303,500	$ 142,200	$ 22,800	$ 448,400	526,082	916,939	1,154,376
Acquisition-related costs	(19,100)	16,000	(5,500)	(37,500)	8,600	1,300	5,200	6,800	(46,098)	21,914	58,086
(Gain) loss on extinguishment of debt									(119,828)	0	51,734
Expenses	$ 19,400	$ 11,000	$ 2,100	$ 2,000	$ 4,200	$ 4,000	$ 29,200	$ 49,000
Accelerated depreciation										35,200
Retention bonus
Segment Reporting Information [Line Items]
Expenses									14,700
Other restructuring charges
Segment Reporting Information [Line Items]
Expenses									11,000	16,500	22,000
Accelerated depreciation											123,700
Employee severance
Segment Reporting Information [Line Items]
Expenses									8,900	31,700	53,000
Inventory write-offs
Segment Reporting Information [Line Items]
Expenses										2,900	13,700
Contract termination
Segment Reporting Information [Line Items]
Expenses									17,500
Premium associated with extending reporting period on expiring insurance program
Segment Reporting Information [Line Items]
Expenses									14,100
Segment reconciling items
Segment Reporting Information [Line Items]
Interest expense, net									538,734	521,656	488,228
Corporate unallocated costs									168,136	200,592	165,298
Amortization of intangible assets									543,862	622,339	773,766
Inventory step-up									0	261	390
Upfront and milestone payments to partners									6,623	45,108	9,483
Separation benefits and other cost reduction initiatives									34,598	86,295	212,448
Certain litigation-related and other contingencies, net									11,211	13,809	185,990
Asset impairment charges									526,082	916,939	1,154,376
Acquisition-related costs									(46,098)	21,914	58,086
(Gain) loss on extinguishment of debt									(119,828)	0	51,734
Foreign currency impact related to the remeasurement of intercompany debt instruments									4,362	(5,486)	(1,403)
Other, net									23,890	(43,456)	(7,217)
Operating segments
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax									$ 1,346,668	$ 1,441,139	$ 1,608,175

Segment Results - Schedule of Disaggregation of Revenues (Details) - USD ($)	3 Months Ended									12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	$ 764,800,000	$ 729,426,000	$ 699,727,000	$ 720,411,000	$ 786,389,000	$ 745,466,000	$ 714,696,000	$ 700,527,000		$ 2,914,364,000	$ 2,947,078,000	$ 3,468,858,000
Product line revenue reporting threshold	$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000		100,000,000	100,000,000	100,000,000
Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										855,402,000	862,832,000	957,525,000
Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										1,063,131,000	929,566,000	750,471,000
Generic Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										879,882,000	1,012,215,000	1,530,530,000
International Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										$ 115,949,000	$ 142,465,000	$ 230,332,000
International Pharmaceuticals \| Revenue Benchmark \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage										4.00%	5.00%	7.00%
Specialty Products \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										$ 519,676,000	$ 444,575,000	$ 383,750,000
XIAFLEX® \| Revenue Benchmark \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage										11.00%
XIAFLEX® \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										$ 327,638,000	264,638,000	213,378,000
SUPPRELIN® LA \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										86,797,000	81,707,000	86,211,000
Other Specialty \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										105,241,000	98,230,000	84,161,000
Established Products \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										335,726,000	418,257,000	573,775,000
PERCOCET® \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										116,012,000	122,901,000	125,231,000
TESTOPEL® \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										55,244,000	58,377,000	69,223,000
Other Established \| Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										$ 164,470,000	$ 236,979,000	$ 379,321,000
Vasostrict® \| Revenue Benchmark \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage										18.00%	15.00%	12.00%
Vasostrict® \| Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										$ 531,737,000	$ 453,767,000	$ 399,909,000
ADRENALIN® \| Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										179,295,000	143,489,000	76,523,000
Ertapenem for injection \| Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										104,679,000	57,668,000	0
APLISOL® \| Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										61,826,000	64,913,000	66,286,000
Other Sterile Injectables \| Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET										$ 185,594,000	$ 209,729,000	$ 207,753,000
Colchicine Tablets \| Generic Pharmaceuticals \| Revenue Benchmark \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage										6.00%
Ezetimibe and Quetiapine ER Tablets \| Generic Pharmaceuticals \| Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage									7.00%

Segment Results - Schedule of Depreciation Expense for Reportable Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Depreciation expense	$ 69,000	$ 101,368	$ 209,999
Operating segments \| U.S. Branded - Specialty & Established Pharmaceuticals
Segment Reporting Information [Line Items]
Depreciation expense	12,573	14,542	16,957
Operating segments \| U.S. Branded - Sterile Injectables
Segment Reporting Information [Line Items]
Depreciation expense	14,287	10,500	8,411
Operating segments \| U.S. Generic Pharmaceuticals
Segment Reporting Information [Line Items]
Depreciation expense	32,689	66,016	174,652
Operating segments \| International Pharmaceuticals
Segment Reporting Information [Line Items]
Depreciation expense	4,234	4,925	3,332
Corporate unallocated
Segment Reporting Information [Line Items]
Depreciation expense	$ 5,217	$ 5,385	$ 6,647

Fair Value Measurements - Restricted Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents, current	$ 247,457	$ 305,368
Restricted cash and cash equivalents, noncurrent	18,400	22,356
Restricted cash and cash equivalents	265,857	327,724
Vaginal mesh cases
Restricted Cash and Cash Equivalents Items [Line Items]
Settlement funds	$ 242,842	$ 299,733

Fair Value Measurements - (Narrative) (Details) $ in Millions	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Discount rate \| Minimum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.095
Discount rate \| Maximum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.150
Discount rate \| Weighted average
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.109
Money market funds \| Restricted cash and cash equivalents
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Settlement funds	$ 70.2	$ 86.9

Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Details) - Fair value, measurements, recurring - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Acquisition-related contingent consideration—current
Liabilities:
Fair value of financial liabilities measured on recurring basis	$ 6,534	$ 36,514
Acquisition-related contingent consideration—noncurrent
Liabilities:
Fair value of financial liabilities measured on recurring basis	23,123	80,189
Money market funds
Assets:
Fair value of financial assets measured on recurring basis	427,033	137,215
Level 1 Inputs \| Acquisition-related contingent consideration—current
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Level 1 Inputs \| Acquisition-related contingent consideration—noncurrent
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Level 1 Inputs \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	427,033	137,215
Level 2 Inputs \| Acquisition-related contingent consideration—current
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Level 2 Inputs \| Acquisition-related contingent consideration—noncurrent
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Level 2 Inputs \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	0	0
Level 3 Inputs \| Acquisition-related contingent consideration—current
Liabilities:
Fair value of financial liabilities measured on recurring basis	6,534	36,514
Level 3 Inputs \| Acquisition-related contingent consideration—noncurrent
Liabilities:
Fair value of financial liabilities measured on recurring basis	23,123	80,189
Level 3 Inputs \| Money market funds
Assets:
Fair value of financial assets measured on recurring basis	$ 0	$ 0

Fair Value Measurements - Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (Details) - Acquisition-related contingent consideration - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	$ 116,703	$ 190,442
Amounts settled	(41,448)	(92,627)
Changes in fair value recorded in earnings	(46,098)	19,910
Effect of currency translation	500	(1,022)
Changes in Fair Value Recorded in Earnings	(46,098)	19,910
Amounts Settled and Other	(40,948)	(93,649)
End of period	29,657	116,703
Auxilium acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	14,157	13,061
Changes in Fair Value Recorded in Earnings	777	2,941
Amounts Settled and Other	(1,727)	(1,845)
End of period	13,207	14,157
Lehigh Valley Technologies, Inc. acquisitions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	34,700	63,001
Changes in Fair Value Recorded in Earnings	(8,614)	19,146
Amounts Settled and Other	(19,286)	(47,447)
End of period	6,800	34,700
VOLTAREN® Gel acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	56,240	98,124
Changes in Fair Value Recorded in Earnings	(37,184)	9
Amounts Settled and Other	(18,870)	(41,893)
End of period	186	56,240
Other
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	11,606	16,256
Changes in Fair Value Recorded in Earnings	(1,077)	(2,186)
Amounts Settled and Other	(1,065)	(2,464)
End of period	$ 9,464	$ 11,606

Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Assets:
Total expense for the year	$ (267,400)	$ (4,800)	$ (88,400)	$ (165,400)	$ (303,500)	$ (142,200)	$ (22,800)	$ (448,400)	$ (526,082)	$ (916,939)	$ (1,154,376)
Fair value, measurements, nonrecurring
Assets:
Total expense for the year									(354,174)	(236,939)
Fair value, measurements, nonrecurring \| Intangible assets
Assets:
Total expense for the year									(347,706)	(230,418)
Fair value, measurements, nonrecurring \| Certain property, plant and equipment
Assets:
Total expense for the year									(6,468)	(6,521)
Level 1 Inputs \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	0				0				0	0
Certain property, plant and equipment	0				0				0	0
Total	0				0				0	0
Level 2 Inputs \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	0				0				0	0
Certain property, plant and equipment	0				0				0	0
Total	0				0				0	0
Level 3 Inputs \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	229,680				239,857				229,680	239,857
Certain property, plant and equipment	0				0				0	0
Total	$ 229,680				$ 239,857				$ 229,680	$ 239,857

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 124,171	$ 122,825
Work-in-process	65,392	70,458
Finished goods	138,302	128,896
Total	327,865	322,179
Long-term inventory	29,000	8,100
Inventories not yet available for sale	$ 17,600	$ 12,500

Leases - Narrative (Details) $ in Thousands	12 Months Ended
Leases - Narrative (Details) $ in Thousands	Dec. 31, 2019 renewal_options	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Lessee, Lease, Description [Line Items]
Lessee, operating lease, number of renewal options \| renewal_options	3
Lessee. operating lease, renewal term	60 months
Capital lease obligations, current		$ 5,845
Capital lease obligations, noncurrent		34,119
Operating lease, rent expense		18,700	$ 18,700
Build-to-Suit Lease Arrangements
Lessee, Lease, Description [Line Items]
Capital leased assets, net		49,000
Capital lease obligations		36,100
Capital leased assets, gross		98,300
Capital leases assets, accumulated depreciation		49,300
Capital lease obligations, current		5,300
Capital lease obligations, noncurrent		$ 30,800

Leases - Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
ROU assets:
Operating lease ROU assets	$ 51,700	$ 0
Finance lease ROU assets	56,793
Total ROU assets	108,493
Operating lease liabilities:
Current operating lease liabilities	10,763	0
Noncurrent operating lease liabilities	48,299	$ 0
Total operating lease liabilities	59,062
Finance lease liabilities:
Current finance lease liabilities	5,672
Noncurrent finance lease liabilities	31,312
Total finance lease liabilities	$ 36,984

Leases - Components of Lease Expense (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Operating lease cost	$ 13,648
Finance lease cost:
Amortization of ROU assets	9,407
Interest on lease liabilities	1,986
Other lease costs and income:
Variable lease costs	9,653
Sublease income	(3,689)
Cost of revenues
Lessee, Lease, Description [Line Items]
Lease, cost	11,168
Selling, general and administrative expenses
Lessee, Lease, Description [Line Items]
Lease, cost	17,648
Research and development expenses
Lessee, Lease, Description [Line Items]
Lease, cost	$ 203

Leases - Maturities of Operating and Finance Lease Liabilities (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Operating Leases
2020	$ 14,103
2021	13,262
2022	12,688
2023	10,017
2024	5,176
Thereafter	15,332
Total future lease payments	70,578
Less: amount representing interest	11,516
Total operating lease liabilities	59,062
Finance Leases
2020	7,446
2021	7,593
2022	7,743
2023	7,897
2024	8,054
Thereafter	13,483
Total future lease payments	52,216
Less: amount representing interest	15,232
Total finance lease liabilities	$ 36,984

Leases - Future Minimum Lease Payment Obligations Under Operating and Capital Leases (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Capital Leases
2019	$ 6,884
2020	6,819
2021	6,921
2022	7,072
2023	7,225
Thereafter	9,127
Total minimum lease payments	44,048
Less: Amount representing interest	4,084
Total present value of minimum payments	39,964
Less: Current portion of such obligations	5,845
Long-term capital lease obligations	34,119
Operating Leases
2019	15,800
2020	14,519
2021	12,883
2022	12,454
2023	9,945
Thereafter	20,573
Total minimum lease payments	$ 86,174

Leases - Weighted Average Term Lease and Discount Rates (Details)	Dec. 31, 2019
Weighted average remaining lease term (years), weighted based on lease liability balances:
Operating leases	5 years 10 months 24 days
Finance leases	9 years 6 months
Weighted average discount rate (percentages), weighted based on the remaining balance of lease payments:
Operating leases	5.80%
Finance leases	5.50%

Leases - Cash Flow and Supplemental Noncash Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$ 14,940
Operating cash payments for finance leases	2,000
Financing cash payments for finance leases	9,196
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	623
Finance leases	$ 5,953

Property, Plant And Equipment - Schedule Of Property, Plant And Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cost:
Beginning Balance	$ 761,435
Additions	79,136
Disposals, transfers, impairments and other	(19,767)
Effect of currency translation	1,135
Ending Balance	821,939
Accumulated Depreciation:
Beginning Balance	(262,543)
Additions	(69,000)
Disposals, transfers and other	14,697
Effect of currency translation	(228)
Ending Balance	(317,074)
Net Book Amount:	504,865	$ 498,892
Land and Buildings
Cost:
Beginning Balance	230,035
Additions	49,716
Disposals, transfers, impairments and other	6,115
Effect of currency translation	0
Ending Balance	285,866
Accumulated Depreciation:
Beginning Balance	(69,656)
Additions	(17,670)
Disposals, transfers and other	2,850
Effect of currency translation	0
Ending Balance	(84,476)
Net Book Amount:	201,390	160,379
Machinery and Equipment
Cost:
Beginning Balance	211,491
Additions	56,888
Disposals, transfers, impairments and other	(6,394)
Effect of currency translation	71
Ending Balance	262,056
Accumulated Depreciation:
Beginning Balance	(83,906)
Additions	(22,012)
Disposals, transfers and other	1,605
Effect of currency translation	(44)
Ending Balance	(104,357)
Net Book Amount:	157,699	127,585
Leasehold Improvements
Cost:
Beginning Balance	69,256
Additions	9,934
Disposals, transfers, impairments and other	(8,926)
Effect of currency translation	60
Ending Balance	70,324
Accumulated Depreciation:
Beginning Balance	(30,600)
Additions	(7,337)
Disposals, transfers and other	1,110
Effect of currency translation	(31)
Ending Balance	(36,858)
Net Book Amount:	33,466	38,656
Computer Equipment and Software
Cost:
Beginning Balance	117,134
Additions	8,359
Disposals, transfers, impairments and other	(8,951)
Effect of currency translation	495
Ending Balance	117,037
Accumulated Depreciation:
Beginning Balance	(71,437)
Additions	(20,696)
Disposals, transfers and other	8,617
Effect of currency translation	(142)
Ending Balance	(83,658)
Net Book Amount:	33,379	45,697
Furniture and Fixtures
Cost:
Beginning Balance	12,495
Additions	954
Disposals, transfers, impairments and other	(515)
Effect of currency translation	509
Ending Balance	13,443
Accumulated Depreciation:
Beginning Balance	(6,944)
Additions	(1,285)
Disposals, transfers and other	515
Effect of currency translation	(11)
Ending Balance	(7,725)
Net Book Amount:	5,718	5,551
Assets under Construction
Cost:
Beginning Balance	121,024
Additions	(46,715)
Disposals, transfers, impairments and other	(1,096)
Effect of currency translation	0
Ending Balance	73,213
Accumulated Depreciation:
Beginning Balance	0
Additions	0
Disposals, transfers and other	0
Effect of currency translation	0
Ending Balance	0
Net Book Amount:	$ 73,213	$ 121,024

Property, Plant And Equipment (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total depreciation expense									$ 69,000	$ 101,368	$ 209,999
Asset impairment charges of long-lived assets									6,500	6,500	65,700
Asset impairment charges	$ 267,400	$ 4,800	$ 88,400	$ 165,400	$ 303,500	$ 142,200	$ 22,800	$ 448,400	$ 526,082	$ 916,939	1,154,376
Somar \| Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges											11,900
2017 US generic pharmaceuticals restructuring
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset impairment charges											$ 47,200

Goodwill and Other Intangibles - Schedule of Changes in the Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 3,764,636		$ 4,450,082
Allocation to current segments		$ 0
Effect of currency translation	2,456	(5,446)
Goodwill impairment charges	(171,908)	(680,000)	(288,745)
Goodwill, ending balance	3,595,184	3,764,636
Branded Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance	828,818		828,818
Allocation to current segments		0
Effect of currency translation	0	0
Goodwill impairment charges	0	0
Goodwill, ending balance	828,818	828,818
Sterile Injectables
Goodwill [Roll Forward]
Goodwill, beginning balance	2,731,193		0
Allocation to current segments		2,731,193
Effect of currency translation	0	0
Goodwill impairment charges	0	0
Goodwill, ending balance	2,731,193	2,731,193
Generic Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance	151,108		3,531,301
Allocation to current segments		(2,731,193)
Effect of currency translation	0	0
Goodwill impairment charges	(151,108)	(649,000)
Goodwill, ending balance	0	151,108
International Pharmaceuticals
Goodwill [Roll Forward]
Goodwill, beginning balance	53,517		$ 89,963
Allocation to current segments		0
Effect of currency translation	2,456	(5,446)
Goodwill impairment charges	(20,800)	(31,000)
Goodwill, ending balance	$ 35,173	$ 53,517

Goodwill and Other Intangibles - Accumulated Impairment (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Goodwill [Line Items]
Accumulated impairment losses	$ 4,498,884	$ 4,303,767
Branded Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	855,810	855,810
Sterile Injectables
Goodwill [Line Items]
Accumulated impairment losses	0	0
Generic Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	3,142,657	2,991,549
International Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	$ 500,417	$ 456,408

Goodwill and Other Intangibles - Schedule of Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Indefinite-lived intangibles:
Beginning Balance		$ 93,900
Acquisitions		0
Impairments		0
Other		0
Effect of Currency Translation		0
Ending Balance		93,900	$ 93,900
Finite-lived intangibles:
Beginning Balance		6,645,826
Acquisitions		0
Impairments		(347,706)
Other		(2,197)
Effect of Currency Translation		12,327
Ending Balance		6,308,250	6,645,826
Total other intangibles
Beginning balance		6,739,726
Acquisitions		0
Impairments		(347,706)	(230,418)	$ (799,955)
Other		(2,197)
Effect of Currency Translation		12,327
Ending balance		6,402,150	6,739,726
Accumulated amortization:
Beginning Balance		(3,282,420)
Amortization		(543,862)	(622,300)	$ (773,800)
Impairments		0
Other		2,197
Effect of Currency Translation		(6,798)
Ending Balance		(3,830,883)	(3,282,420)
Net other intangibles		2,571,267	3,457,306
Licensing
Finite-lived intangibles:
Beginning Balance		457,402
Acquisitions		0
Impairments		0
Other		0
Effect of Currency Translation		0
Ending Balance		457,402	457,402
Accumulated amortization:
Beginning Balance		(398,182)
Amortization		(12,154)
Impairments		0
Other		0
Effect of Currency Translation		0
Ending Balance		(410,336)	(398,182)
Tradenames
Finite-lived intangibles:
Beginning Balance		6,409
Acquisitions		0
Impairments		0
Other		0
Effect of Currency Translation		0
Ending Balance		6,409	6,409
Accumulated amortization:
Beginning Balance		(6,409)
Amortization		0
Impairments		0
Other		0
Effect of Currency Translation		0
Ending Balance		(6,409)	(6,409)
Developed technology
Finite-lived intangibles:
Beginning Balance		6,182,015
Acquisitions		0
Impairments		(347,706)
Other		(2,197)
Effect of Currency Translation		12,327
Ending Balance		5,844,439	6,182,015
Total other intangibles
Impairments	$ (20,600)
Accumulated amortization:
Beginning Balance		(2,877,829)
Amortization		(531,708)
Impairments		0
Other		2,197
Effect of Currency Translation		(6,798)
Ending Balance		(3,414,138)	(2,877,829)
In-process research and development
Indefinite-lived intangibles:
Beginning Balance		93,900
Acquisitions		0
Impairments		0
Other		0
Effect of Currency Translation		0
Ending Balance		$ 93,900	$ 93,900
Weighted average
Accumulated amortization:
Intangible life (years)		11 years
Weighted average \| Licensing
Accumulated amortization:
Intangible life (years)		14 years
Weighted average \| Developed technology
Accumulated amortization:
Intangible life (years)		11 years

Goodwill and Other Intangibles - Other Intangibles (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 543,862	$ 622,300	$ 773,800

Goodwill and Other Intangibles - Schedule of Estimated Amortization of Intangibles (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 437,420
2021	396,864
2022	381,312
2023	351,805
2024	$ 308,986

Goodwill and Other Intangibles - Schedule of Intangible Asset Impairment Charges Including Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment charges	$ 171,908	$ 680,000	$ 288,745
Other intangible asset impairment charges	$ 347,706	$ 230,418	$ 799,955

Goodwill and Other Intangibles - Impairments Narrative (Details)	3 Months Ended							12 Months Ended
	Dec. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Mar. 31, 2018 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Oct. 01, 2019	Oct. 01, 2018	Oct. 01, 2017
Goodwill [Line Items]
Goodwill impairment charges								$ 171,908,000	$ 680,000,000	$ 288,745,000
Asset impairment charges								347,706,000	230,418,000	$ 799,955,000
Generic Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges								$ 151,108,000	$ 649,000,000
Paladin labs inc.
Goodwill [Line Items]
Goodwill impairment charges	$ 20,800,000			$ 31,000,000.0
Generic Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges		$ 65,100,000	$ 86,000,000.0	$ 258,000,000.0	$ 391,000,000.0
Generic Pharmaceuticals \| Discount rate
Goodwill [Line Items]
Intangible assets and goodwill, measurement input		0.105	0.105
Former U.S generic pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges					0
Sterile injectables
Goodwill [Line Items]
Goodwill impairment charges					$ 0
Minimum \| Level 3 Inputs \| Discount rate
Goodwill [Line Items]
Intangible assets and goodwill, measurement input											0.095	0.095	0.095
Maximum \| Level 3 Inputs \| Discount rate
Goodwill [Line Items]
Intangible assets and goodwill, measurement input											0.135	0.115	0.125
Developed technology
Goodwill [Line Items]
Asset impairment charges						$ 20,600,000
Developed technology \| Generic Pharmaceuticals
Goodwill [Line Items]
Asset impairment charges						57,500,000
Developed technology \| U.S. Branded - Specialty & Established Pharmaceuticals
Goodwill [Line Items]
Asset impairment charges						180,400,000
Serelaxin In Process Research and Development Intangible Assets
Goodwill [Line Items]
Asset impairment charges							$ 45,500,000
Paladin labs inc.
Goodwill [Line Items]
Goodwill impairment charges							$ 82,600,000
Somar \| Disposal Group, Held-for-sale, Not Discontinued Operations
Goodwill [Line Items]
Goodwill impairment charges						25,700,000
Asset impairment charges						$ 89,500,000

License and Collaboration Agreements (Details) - product_candidates	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2019
License And Collaboration Agreements [Line Items]
License agreement, exclusivity period		12 years
Termination of agreement notice period		90 days
Number of sterile injectable product candidates	5
Minimum
License And Collaboration Agreements [Line Items]
Royalty rate on net sales		5.00%
Maximum
License And Collaboration Agreements [Line Items]
Royalty rate on net sales		15.00%

Contract Assets and Liabilities - Contract Assets and Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Contract with Customer, Asset and Liability [Abstract]
Contract assets, net	$ 0	$ 12,065
Contract assets, net - $ change	$ (12,065)
Contract assets, net - % change	(100.00%)
Contract liabilities, net	$ 6,592	19,217
Contract liabilities, net - $ change	$ (12,625)
Contract liabilities, net - % change	(66.00%)
Contract asset amounts classified as current		9,300
Contract liability amounts classified as current	$ 1,400	$ 1,700
Increase in contract liability	4,000
Reductions	14,900
Revenue recognized	$ 1,200

Contract Assets and Liabilities - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Contract with Customer, Asset and Liability [Abstract]
Performance obligation satisfaction period	7 days
Performance obligation satisfied in previous period	$ 10.8

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounts Payable and Accrued Liabilities, Current [Abstract]
Trade accounts payable	$ 101,532	$ 96,024
Returns and allowances	206,248	236,946
Rebates	129,056	144,860
Chargebacks	1,594	2,971
Accrued interest	112,860	130,182
Accrued payroll and related benefits	79,869	89,895
Accrued royalties and other distribution partner payables	115,816	122,028
Acquisition-related contingent consideration—current	6,534	36,514
Other	146,440	149,780
Total	$ 899,949	$ 1,009,200

Debt (Components of Total Indebtedness) (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Principal Amount	$ 8,470,678,000			$ 8,348,775,000
Carrying Amount	8,394,049,000			8,258,419,000
Less current portion, net	34,150,000			34,150,000
Principal amount of total long-term debt, less current portion, net	8,436,528,000			8,314,625,000
Carrying amount of total long-term debt, less current portion, net	8,359,899,000			8,224,269,000
Fair value of long term debt	$ 7,400,000,000			$ 7,200,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Effective interest rate (as percent)	4.25%
Principal Amount	$ 300,000,000	$ 300,000,000.0		$ 0
Carrying Amount	$ 300,000,000			$ 0
7.25% Senior Notes due 2022
Debt Instrument [Line Items]
Effective interest rate (as percent)	7.25%			7.91%
Principal Amount	$ 8,294,000			$ 400,000,000
Carrying Amount	$ 8,294,000			$ 392,947,000
Interest rate (as percent)	7.25%		7.25%
5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Effective interest rate (as percent)	5.75%			6.04%
Principal Amount	$ 182,479,000			$ 700,000,000
Carrying Amount	$ 182,479,000			$ 694,464,000
Interest rate (as percent)	5.75%		5.75%
5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Effective interest rate (as percent)	5.62%			5.62%
Principal Amount	$ 210,440,000			$ 750,000,000
Carrying Amount	$ 209,018,000			$ 743,438,000
Interest rate (as percent)	5.375%
6.00% Senior Notes due 2023
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.28%			6.28%
Principal Amount	$ 1,439,840,000			$ 1,635,000,000
Carrying Amount	$ 1,426,998,000			$ 1,616,817,000
Interest rate (as percent)	6.00%
5.875% Senior Secured Notes due 2024
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.14%			6.14%
Principal Amount	$ 300,000,000.0			$ 300,000,000
Carrying Amount	$ 296,647,000			$ 296,062,000
Interest rate (as percent)	5.875%
6.00% Senior Notes due 2025
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.27%			6.27%
Principal Amount	$ 1,200,000,000			$ 1,200,000,000
Carrying Amount	$ 1,185,726,000			$ 1,183,415,000
Interest rate (as percent)	6.00%
7.50% Senior Secured Notes due 2027
Debt Instrument [Line Items]
Effective interest rate (as percent)	7.71%
Principal Amount	$ 1,500,000,000		$ 1,500,000,000.0	$ 0
Carrying Amount	$ 1,482,212,000			$ 0
Interest rate (as percent)	7.50%		7.50%
Term Loan Facility
Debt Instrument [Line Items]
Effective interest rate (as percent)	6.21%			7.02%
Principal Amount	$ 3,329,625,000			$ 3,363,775,000
Carrying Amount	$ 3,302,675,000			$ 3,331,276,000

Debt (Credit Facility) (Narrative) (Details) - USD ($)	12 Months Ended
Debt (Credit Facility) (Narrative) (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Line of Credit Facility [Line Items]
Principal amount	$ 8,470,678,000			$ 8,348,775,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Principal amount	300,000,000	$ 300,000,000.0		$ 0
Credit facility, remaining borrowing capacity	$ 696,800,000
Term Loan Facility
Line of Credit Facility [Line Items]
Quarter periodic payment, percent	0.25%
2017 credit agreement \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Principal amount	$ 1,000,000,000.0
Commitments not extended	76,000,000.0		$ 76,000,000.0
Term Loan Facility \| 2017 credit agreement
Line of Credit Facility [Line Items]
Principal amount	$ 3,415,000,000.0
London Interbank Offered Rate (LIBOR) \| Term Loan Facility \| 2017 credit agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	4.25%
Basis spread on variable rate, floor	0.75%
London Interbank Offered Rate (LIBOR) \| Minimum \| Revolving Credit Facility \| 2017 credit agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.50%
London Interbank Offered Rate (LIBOR) \| Maximum \| Revolving Credit Facility \| 2017 credit agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	3.00%
Base Rate \| Term Loan Facility \| 2017 credit agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	3.25%
Basis spread on variable rate, floor	1.75%
Base Rate \| Minimum \| Revolving Credit Facility \| 2017 credit agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Base Rate \| Maximum \| Revolving Credit Facility \| 2017 credit agreement
Line of Credit Facility [Line Items]
Basis spread on variable rate	2.00%

Debt (Senior Notes and Senior Secured Notes) (Details)	1 Months Ended	12 Months Ended
Debt (Senior Notes and Senior Secured Notes) (Details)	Mar. 31, 2019	Dec. 31, 2019
Non-Call Period
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	100.00%	100.00%
After Non-Call Period
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	105.625%	100.00%
After Non-Call Period \| Minimum
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)		100.00%
After Non-Call Period \| Maximum
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)		105.625%
As of December 31, 2019
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)	100.00%
Percentage of principal that may be redeemed		35.00%
5.875% Senior Secured Notes due 2024
Debt Instrument, Redemption [Line Items]
Interest rate (as percent)		5.875%
5.875% Senior Secured Notes due 2024 \| As of December 31, 2019
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)		105.875%
6.00% Senior Notes due 2025
Debt Instrument, Redemption [Line Items]
Interest rate (as percent)		6.00%
7.50% Senior Secured Notes due 2027
Debt Instrument, Redemption [Line Items]
Interest rate (as percent)	7.50%	7.50%
7.50% Senior Secured Notes due 2027 \| As of December 31, 2019
Debt Instrument, Redemption [Line Items]
Redemption price (as percent)		107.50%

Debt (April 2017 Refinancing) (Details) - USD ($)		1 Months Ended	3 Months Ended
Debt (April 2017 Refinancing) (Details) - USD ($)	Apr. 27, 2017	Mar. 31, 2019	Jun. 30, 2017	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Principal amount				$ 8,470,678,000	$ 8,348,775,000
Debt issuance costs	$ 56,700,000
Deferred debt issuance costs	10,100,000	$ 26,200,000	$ 51,700,000
2017 credit agreement \| Term Loan Facility
Debt Instrument [Line Items]
Principal amount				3,415,000,000.0
Debt issuance costs	41,300,000
2017 credit agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt issuance costs	10,500,000
2017 credit agreement \| Senior Secured Notes
Debt Instrument [Line Items]
Debt issuance costs	$ 4,900,000
5.875% Senior Secured Notes due 2024
Debt Instrument [Line Items]
Principal amount				$ 300,000,000.0	$ 300,000,000
Interest rate (as percent)				5.875%

Debt (March 2019 Refinancing) (Details) - USD ($)		1 Months Ended	3 Months Ended	12 Months Ended
Debt (March 2019 Refinancing) (Details) - USD ($)	Apr. 27, 2017	Mar. 31, 2019	Jun. 30, 2017	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Principal amount				$ 8,470,678,000		$ 8,348,775,000
Repurchase principal amount of debt		$ 1,642,200,000
Repayments of debt		1,500,000,000.0
Gain on extinguishment of debt		124,000,000.0
Unamortized discount (premium) and debt issuance costs, net	$ 10,100,000	$ 26,200,000	$ 51,700,000
Before April 1, 2022
Debt Instrument [Line Items]
Redemption price (as percent)		100.00%		100.00%
On or after April 1, 2022 beginning principal redemption
Debt Instrument [Line Items]
Redemption price (as percent)		105.625%		100.00%
On or after April 1, 2022 beginning principal redemption \| Minimum
Debt Instrument [Line Items]
Redemption price (as percent)				100.00%
On or after April 1, 2022 beginning principal redemption \| Maximum
Debt Instrument [Line Items]
Redemption price (as percent)				105.625%
Until April 1, 2025 decrease in amount redeemed
Debt Instrument [Line Items]
Redemption price (as percent)		100.00%
Before April 1, 2022 principal redeemed, in part
Debt Instrument [Line Items]
Redemption percent of principal amount outstanding		35.00%
7.50% Senior Secured Notes due 2027
Debt Instrument [Line Items]
Principal amount		$ 1,500,000,000.0		$ 1,500,000,000		0
Interest rate (as percent)		7.50%		7.50%
Extinguishment of debt		$ 1,624,000,000.0
Unamortized discount (premium) and debt issuance costs, net		$ 19,100,000
7.50% Senior Secured Notes due 2027 \| Until April 1, 2025 decrease in amount redeemed
Debt Instrument [Line Items]
Redemption price (as percent)				107.50%
7.50% Senior Secured Notes due 2027 \| Before April 1, 2022 principal amount redeemed
Debt Instrument [Line Items]
Redemption price (as percent)		107.50%
7.25% Senior Notes due 2022
Debt Instrument [Line Items]
Principal amount				$ 8,294,000		400,000,000
Interest rate (as percent)		7.25%		7.25%
Repurchase principal amount of debt		$ 389,900,000
5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Principal amount				$ 182,479,000		700,000,000
Interest rate (as percent)		5.75%		5.75%
5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Principal amount				$ 210,440,000		750,000,000
Interest rate (as percent)				5.375%
6.00% Senior Notes due 2023
Debt Instrument [Line Items]
Principal amount				$ 1,439,840,000		1,635,000,000
Interest rate (as percent)				6.00%
Senior notes \| 5.75% Senior Notes due 2022
Debt Instrument [Line Items]
Repurchase principal amount of debt		$ 517,500,000
Senior notes \| 5.375% Senior Notes due 2023
Debt Instrument [Line Items]
Repurchase principal amount of debt		539,600,000
Senior notes \| 6.00% Senior Notes due 2023
Debt Instrument [Line Items]
Repurchase principal amount of debt		195,200,000
Senior notes \| Note repurchases
Debt Instrument [Line Items]
Unamortized discount (premium) and debt issuance costs, net		4,200,000
Revolving Credit Facility
Debt Instrument [Line Items]
Principal amount				$ 300,000,000	$ 300,000,000.0	$ 0
Unamortized discount (premium) and debt issuance costs, net		2,900,000
Revolving Credit Facility \| 2017 credit agreement
Debt Instrument [Line Items]
Principal amount				1,000,000,000.0
Commitments not extended		$ 76,000,000.0		$ 76,000,000.0
Revolving Credit Facility \| 2017 credit agreement \| Minimum
Debt Instrument [Line Items]
Secured leverage ratio		3.50
Revolving Credit Facility \| 2017 credit agreement \| Maximum
Debt Instrument [Line Items]
Secured leverage ratio		4.50

Debt (Maturities of Long-Term Debt) (Details) - USD ($)	12 Months Ended
Debt (Maturities of Long-Term Debt) (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Principal amount	$ 8,470,678,000		$ 8,348,775,000
Maturities
2020			34,150,000
2021			34,150,000
2022			247,723,000
2023			1,684,430,000
2024			3,770,225,000
Senior notes \| Senior notes maturing due 2022
Maturities
Long-term debt, maturity repayment deadline	91 days
Revolving Credit Facility
Debt Instrument [Line Items]
Principal amount	$ 300,000,000	$ 300,000,000.0	$ 0
Maturities
2022	$ 22,800,000

Commitments and Contingencies (Narrative) (Details) $ in Thousands	1 Months Ended								3 Months Ended				12 Months Ended			21 Months Ended
	Jan. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	Aug. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)	May 31, 2019 class_action	Sep. 30, 2018 USD ($)	May 31, 2018	Apr. 30, 2018 case	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Jun. 30, 2016	Dec. 31, 2019 USD ($) case	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2019 USD ($)	Feb. 18, 2020 USD ($) case claim
Loss Contingencies [Line Items]
Reserve for loss contingencies													$ 513,000
Vaginal mesh cases
Loss Contingencies [Line Items]
Payments to plaintiffs and qualified settlement funds																$ 3,500,000
Settlement funds													$ 242,842	$ 299,733
Testosterone cases \| Subsequent event
Loss Contingencies [Line Items]
Pending claims, number \| claim																	5
Opioid-related matters
Loss Contingencies [Line Items]
Number of putative class actions \| class_action					3
Number of cases set for trial \| case								2
Settlement, amount awarded to other party		$ 10,000
Opioid-related matters \| Subsequent event
Loss Contingencies [Line Items]
Pending claims, number \| case																	2,700
Number of cases filed by states \| case																	20
Number of cases filed by hospitals, health systems, unions, welfare funds or other third-party \| case																	280
Number of cases alleging personal injury and/or wrongful death \| case																	160
Settlement, amount awarded to other party	$ 8,750
Lidoderm cases
Loss Contingencies [Line Items]
Payments to plaintiffs and qualified settlement funds											$ 30,000			60,000
Settlement, amount awarded to other party						$ 100,000
Lidoderm cases \| Subsequent event
Loss Contingencies [Line Items]
Reserve for loss contingencies																	$ 10,000
Public Employees' Retirement System of Mississippi vs. Endo International PLC
Loss Contingencies [Line Items]
Settlement, amount awarded to other party				$ 50,000
Loss contingency accrual, period increase (decrease)											50,000
Loss contingency, receivable											$ 50,000
Bier v. endo international plc, et al.
Loss Contingencies [Line Items]
Settlement, amount awarded to other party			$ 82,500
Loss contingency accrual, period increase (decrease)										$ 82,500
Loss contingency, receivable				$ 82,500						$ 82,500
Loss contingency, receivable, period increase (decrease)									$ 20,000
AMS \| Vaginal mesh cases
Loss Contingencies [Line Items]
Loss contingency, claims settled, number \| case													71,000
Par Pharmaceutical, Inc. [Member] \| VASOSTRICT Related Matters [Member]
Loss Contingencies [Line Items]
Lawsuit filing period							45 days
Stay of approval period, Hatch-Waxman Act							30 months
VASOSTRICT and/or ADRENALIN \| Opioid-related matters
Loss Contingencies [Line Items]
Settlement, amount awarded to other party		$ 1,000
Jubilant Hollister Stier Laboratories LLC
Loss Contingencies [Line Items]
Long-term purchase commitment, term												3 years
Long-term purchase commitment, subsequent term												1 year
Long-term purchase commitment, purchased amount													$ 8,600	$ 7,500	$ 5,600

Commitments and Contingencies - Schedule of Loss Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Qualified Settlement Funds
Cash contributions to Qualified Settlement Funds	$ 253,520	$ 336,648	$ 668,306
Mesh Liability Accrual
Ending balance	513,000
Vaginal mesh cases
Qualified Settlement Funds
Beginning balance	299,733
Cash contributions to Qualified Settlement Funds	253,520
Cash distributions to settle disputes from Qualified Settlement Funds	(314,266)
Other	3,855
Ending balance	242,842	299,733
Mesh Liability Accrual
Other	3,855
Vaginal mesh cases \| Mesh product liability accrual
Qualified Settlement Funds
Additional charges	30,000
Other	5,021
Mesh Liability Accrual
Beginning balance	748,606
Cash distributions to settle disputes from Qualified Settlement Funds	(314,266)
Cash distributions to settle disputes	(15,330)
Other	5,021
Ending balance	$ 454,031	$ 748,606

Other Comprehensive Loss - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Other comprehensive income (loss), tax, portion attributable to parent	$ 0	$ 0	$ 0

Shareholders' Deficit (Details)	12 Months Ended	36 Months Ended
Shareholders' Deficit (Details)	Dec. 31, 2019 USD ($) registered_shareholders $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Jan. 01, 2019 USD ($)	Jan. 01, 2018 USD ($)	Jan. 01, 2017 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Euro deferred shares, shares issued (in shares) \| shares	4,000,000	4,000,000
Euro deferred shares, par value (in dollars per share) \| $ / shares	$ 0.01	$ 0.01
Number of registered shareholders \| registered_shareholders	7
Effect of adopting accounting principle in period of adoption			$ 4,646,000
ASU 2016-06
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effect of adopting accounting principle in period of adoption					$ 372,825,000
ASU 2016-06 \| Accumulated Deficit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effect of adopting accounting principle in period of adoption					$ 372,825,000
ASC 606
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effect of adopting accounting principle in period of adoption				$ (3,076,000)
ASC 606 \| Accumulated Deficit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effect of adopting accounting principle in period of adoption				$ (3,076,000)
ASC 842 \| Accumulated Deficit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effect of adopting accounting principle in period of adoption			$ 4,646,000
2015 Share Buyback Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount	$ 2,500,000,000
Treasury stock, shares, acquire (in shares) \| shares		4,400,000
Treasury stock, value, acquired, cost method		$ 250,000,000.0

Shared-based Compensation (Narrative) (Details)	3 Months Ended	12 Months Ended
Shared-based Compensation (Narrative) (Details)	Sep. 30, 2018 USD ($) employee shares	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 $ / shares shares	Dec. 31, 2016 $ / shares
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Target amount of share-based compensation awards, stock options (in shares) \| shares	1,000,000.0		971,590	5,288,675
Exercise price range, lower range limit (in dollars per share) \| $ / shares		$ 7.55
Exercise price range, upper range limit (in dollars per share) \| $ / shares		$ 86.54
Options exercised intrinsic value		$ 100,000	$ 600,000
Tax benefit from exercise of stock options		0
Options granted, weighted average grant date fair value (in dollars per share) \| $ / shares			$ 3.97	$ 4.73
Unrecognized compensation cost		$ 48,300,000
Nonvested Restricted Stock
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Target amount of share-based compensation awards (in shares) \| shares	100,000
Long-term Cash Incentive
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Service period		3 years	2 years 3 months 18 days
Unvested awards outstanding (in shares) \| shares	3,000,000.0
Number of employees \| employee	570
Corresponding liability	$ 14,900,000
Stock Options
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Expiration period		10 years
Dividend yield		0.00%	0.00%	0.00%
Stock Options \| Minimum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period		3 years
Stock Options \| Maximum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period		4 years
Nonvested Stock Options
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Weighted average remaining requisite service period, non-vested stock options		10 months 24 days
Unrecognized compensation cost		$ 3,100,000
Performance Stock Units
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period		3 years
Service period		3 years
Unrecognized compensation cost		$ 5,800,000
PSU award percentage using free cash flow performance metric		50.00%
Performance Stock Units \| Minimum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Award adjustment rate		0.00%
Performance Stock Units \| Maximum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Award adjustment rate		200.00%
Restricted Stock Units (RSUs)
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost		$ 39,400,000
Weighted average remaining requisite service period, non-vested restricted stock units		1 year 7 months 6 days
Restricted and performance stock units, weighted average grant date fair value (in dollars per share) \| $ / shares		$ 7.72	$ 6.88		$ 11.42
Restricted Stock Units (RSUs) \| Minimum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period		3 years
Restricted Stock Units (RSUs) \| Maximum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period		4 years
2015 Stock Incentive Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of shares available for grant (in shares) \| shares		7,700,000
Plans Other Than Twenty Fifteen Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of shares available for grant (in shares) \| shares		0
Tranche One \| Performance Stock Units
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Performance target term		1 year
Tranche Two \| Performance Stock Units
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Performance target term		1 year
Tranche Three \| Performance Stock Units
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Performance target term		1 year

Shared-based Compensation (Schedule of Allocation of Stock-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 59,142	$ 54,071	$ 50,149
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	44,159	44,454	38,292
Research and development expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	4,501	2,251	4,197
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 10,482	$ 7,366	$ 7,660

Shared-based Compensation (Summary of Activity Under Stock Incentive Plans) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Outstanding, beginning balance (in shares)		8,072,718	8,248,130	4,325,209
Granted (in shares)	1,000,000.0		971,590	5,288,675
Exercised (in shares)		(557)	(94,392)
Forfeited (in shares)		(125,739)	(605,737)	(623,987)
Expired (in shares)		(665,883)	(446,873)	(741,767)
Outstanding, ending balance (in shares)		7,280,539	8,072,718	8,248,130
Vested and expected to vest (in shares)		7,212,334
Exercisable (in shares)		5,003,163
Weighted Average Exercise Price
Outstanding, beginning balance (in dollars per share)		$ 20.62	$ 22.79	$ 41.70
Granted (in dollars per share)			7.55	10.42
Exercised (in dollars per share)		7.55	9.89
Forfeited (in dollars per share)		14.38	19.01	28.32
Expired (in dollars per share)		40.37	36.80	40.29
Outstanding, ending balance (in dollars per share)		18.93	$ 20.62	$ 22.79
Vested and expected to vest, end of period (in dollars per share)		19.00
Exercisable, end of period (in dollars per share)		$ 21.60
Weighted Average Remaining Contractual Term
Outstanding		6 years 3 months 18 days
Vested and expected to vest		6 years 3 months 14 days
Exercisable		6 years 25 days
Aggregate Intrinsic Value
Outstanding		$ 0
Vested and expected to vest		0
Exercisable		$ 0

Shared-based Compensation (Stock Option Assumptions) (Details) - Stock Options	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)		4 years	4 years
Risk-free interest rate		2.70%	1.70%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility		63.00%	58.00%

Shared-based Compensation (Summary of Restricted Stock Units and Performance Stock Units Activity) (Details) - Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Outstanding, beginning balance (in shares)	11,019,472	4,724,673	1,685,060
Granted (in shares)	6,687,695	5,609,561	4,168,477
LTCI modification (in shares)		2,989,965
Forfeited (in shares)	(918,425)	(753,653)	(552,981)
Vested (in shares)	(3,872,453)	(1,551,074)	(575,883)
Outstanding, ending balance (in shares)	12,916,289	11,019,472	4,724,673
Vested and expected to vest, end of period (in shares)	12,098,438
Aggregate Intrinsic Value
Outstanding, end of period	$ 60,577,395
Vested and expected to vest	$ 56,741,674

Other Expense (Income), Net (Details) - USD ($)		1 Months Ended	3 Months Ended								12 Months Ended
Other Expense (Income), Net (Details) - USD ($)	Jul. 03, 2017	Dec. 31, 2017	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Component of Operating Income [Abstract]
Net gain on sale of business and other assets			$ 3,300,000	$ 1,900,000	$ 2,500,000	$ (1,300,000)	$ 15,300,000	$ 2,900,000	$ 24,600,000	$ 2,400,000	$ (6,367,000)	$ (45,155,000)	$ (13,809,000)
Foreign currency gain, net											5,247,000	(3,762,000)	(2,801,000)
Net loss from our investments in the equity of other companies											2,346,000	3,444,000	898,000
Other miscellaneous, net											15,451,000	(6,480,000)	(1,311,000)
Other expense (income), net											16,677,000	(51,953,000)	(17,023,000)
Restructuring Cost and Reserve [Line Items]
Expenses			$ 19,400,000	$ 11,000,000.0	$ 2,100,000	$ 2,000,000.0	4,200,000	$ 4,000,000.0	$ 29,200,000	$ 49,000,000.0
Contract termination
Restructuring Cost and Reserve [Line Items]
Expenses											$ 17,500,000
2017 US generic pharmaceuticals restructuring
Restructuring Cost and Reserve [Line Items]
Expenses												20,384,000
Disposal group, disposed of by sale, not discontinued operations \| Huntsville, Alabama manufacturing and distributing facility \| 2017 US generic pharmaceuticals restructuring \| Facility closing
Restructuring Cost and Reserve [Line Items]
Net gain on disposal							$ 12,500,000					$ 12,500,000
Disposal group, disposed of by sale, not discontinued operations \| Litha Healthcare Group Limited
Restructuring Cost and Reserve [Line Items]
Gain on sale of business	$ 0	$ 10,100,000											$ 10,100,000

Income Taxes (Narrative) (10K) (Details) - USD ($)	12 Months Ended
Income Taxes (Narrative) (10K) (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
Provisional tax benefit related to Tax Cuts and Jobs Act of 2017			$ 36,200,000
Significant adjustments to the provisional amounts recorded	$ 0
Valuation allowance	9,828,959,000	$ 9,877,617,000
Increase (decrease) in valuation allowance	(48,700,000)	1,814,600,000
Undistributed earnings of foreign subsidiaries	1,092,000,000.0
Total unrecognized income tax benefits	530,191,000	479,400,000
Unrecognized tax benefits that would impact effective tax rate	320,300,000	304,300,000
Accrued interest and penalties	43,710,000	27,700,000
Interest and penalties	13,800,000	8,600,000	1,400,000
Current unrecognized tax benefit	486,481,000	$ 451,690,000	$ 415,951,000	$ 424,601,000
Minimum
Operating Loss Carryforwards [Line Items]
Statues of limitation		3 years
Maximum
Operating Loss Carryforwards [Line Items]
Statues of limitation		5 years
Accounts Payable and Accrued Liabilities
Operating Loss Carryforwards [Line Items]
Current unrecognized tax benefit	$ 6,800,000

Income Taxes (Components of Income Before Income Tax by Geography) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
U.S.	$ (688,224)	$ (1,342,860)	$ (1,866,222)
International	343,320	404,028	383,218
Total segment adjusted income from continuing operations before income tax	$ (344,904)	$ (938,832)	$ (1,483,004)

Income Taxes (Schedule of Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current:
U.S. Federal	$ 15,317	$ 6,236	$ (86,478)
U.S. State	(3,002)	2,864	(6,462)
International	8,926	8,278	(1,224)
Total current income tax	21,241	17,378	(94,164)
Deferred:
U.S. Federal	(515)	10,084	(124,682)
U.S. State	(482)	(778)	(3,225)
International	(4,564)	(3,749)	(28,222)
Total deferred income tax	(5,561)	5,557	(156,129)
INCOME TAX	$ 15,680	$ 22,935	$ (250,293)

Income Taxes (Schedule of Reconciliation of Income Tax at Federal Statutory Income Tax Rate To Total Income Tax Provision) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Notional U.S. federal income tax provision at the statutory rate	$ (72,430)	$ (197,155)	$ (519,051)
State income tax, net of federal benefit	(4,455)	494	(11,473)
U.S. tax reform impact	0	5,664	(36,216)
Uncertain tax positions	43,273	46,317	58,120
Residual tax on non-U.S. net earnings	(67,987)	(638,724)	(1,350,811)
Non-deductible goodwill impairment	27,493	109,189	60,808
Change in valuation allowance	30,123	748,562	1,644,879
Intra-entity transfers of assets	0	(63,335)	(53,509)
International Pharmaceuticals segment divestitures	0	0	(56,092)
Base erosion minimum tax	13,662	0	0
Non-deductible expenses	21,299	3,446	3,957
Executive compensation limitation	4,547	5,955	2,178
Other	20,155	2,522	6,917
INCOME TAX	$ 15,680	$ 22,935	$ (250,293)

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Accrued expenses and customer allowances	$ 112,489	$ 185,910
Deferred interest expense	317,997	240,736
Fixed assets and intangible assets	598,730	604,385
Loss on capital assets	61,971	62,033
Net operating loss carryforward	9,743,763	8,751,544
Other	89,501	65,266
Research and development and other tax credit carryforwards	16,620	9,551
Total gross deferred income tax assets	10,941,071	9,919,425
Deferred tax liabilities:
Other	(10,086)	(1,965)
Outside basis difference	0	(73,652)
Intercompany notes	(1,131,537)	0
Total gross deferred income tax liabilities	(1,141,623)	(75,617)
Valuation allowance	(9,828,959)	(9,877,617)
Net deferred income tax liability	$ (29,511)	$ (33,809)

Income Taxes (Operating Loss Carryforwards) (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Foreign \| Ireland
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 16,862
Foreign \| Luxembourg
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	9,336,611
Domestic
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	200,671
Domestic \| Capital Loss Carryforward
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	34,740
Domestic \| General Business Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	7,305
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	186,211
State and Local Jurisdiction \| Capital Loss Carryforward
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	26,459
State and Local Jurisdiction \| General Business Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 6,643

Income Taxes (Valuation Allowances) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Valuation Allowance [Line Items]
Valuation allowance	$ 9,828,959	$ 9,877,617
Foreign \| Ireland
Valuation Allowance [Line Items]
Valuation allowance	189,581
Foreign \| Luxembourg
Valuation Allowance [Line Items]
Valuation allowance	8,205,074
Domestic \| U.S.
Valuation Allowance [Line Items]
Valuation allowance	$ 1,430,762

Income Taxes (Schedule of Reconciliation of Change in Uncertain Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning balance	$ 451,690	$ 415,951	$ 424,601
Gross additions for current year positions	35,766	36,088	44,293
Gross reductions for prior period positions	(2,377)	(3,570)	(64,887)
Gross additions for prior period positions	880	7,950	22,765
Decrease due to lapse of statute of limitations	(1,006)	(2,129)	(13,151)
Currency translation adjustment	1,528		2,330
Currency translation adjustment		(2,600)
Unrecognized tax benefits, ending balance	486,481	451,690	$ 415,951
Accrued interest and penalties	43,710	27,700
Total UTB balance including accrued interest and penalties	$ 530,191	$ 479,400

Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Numerator:
Loss from continuing operations	$ (208,489)	$ (41,431)	$ (98,052)	$ (12,612)	$ (265,479)	$ (146,071)	$ (52,479)	$ (497,738)	$ (360,584)	$ (961,767)	$ (1,232,711)
Loss from discontinued operations, net of tax	(10,154)	(37,984)	(7,953)	(5,961)	(26,429)	(27,134)	(8,388)	(7,751)	(62,052)	(69,702)	(802,722)
NET LOSS	$ (218,643)	$ (79,415)	$ (106,005)	$ (18,573)	$ (291,908)	$ (173,205)	$ (60,867)	$ (505,489)	$ (422,636)	$ (1,031,469)	$ (2,035,433)
Denominator:
For basic per share data—weighted average shares (in shares)	226,787	226,598	226,221	224,594	224,353	224,132	223,834	223,521	226,050	223,960	223,198
Dilutive effect of ordinary share equivalents (in shares)									0	0	0
For diluted per share data—weighted average shares (in shares)	226,787	226,598	226,221	224,594	224,353	224,132	223,834	223,521	226,050	223,960	223,198

- Definition

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Savings and Investment Plan and Deferred Compensation Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Savings And Investment Plan And Deferred Compensation [Line Items]
Contributions towards defined contribution savings and investment plans	$ 7.4	$ 6.4	$ 9.4
Endo 401(k) Plan
Savings And Investment Plan And Deferred Compensation [Line Items]
Maximum annual contributions per employee (percent)	4.00%
Vesting period	2 years
Endo 401(k) Plan, Matching Tier One
Savings And Investment Plan And Deferred Compensation [Line Items]
Employer matching contribution (percent)	100.00%
Percentage of employees gross pay	3.00%
Endo 401(k) Plan, Matching Tier Two
Savings And Investment Plan And Deferred Compensation [Line Items]
Employer matching contribution (percent)	50.00%
Percentage of employees gross pay	2.00%

Quarterly Financial Data (Unaudited) (Schedule Of Quarterly Financial Data) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Quarterly Financial Data [Abstract]
TOTAL REVENUES, NET	$ 764,800	$ 729,426	$ 699,727	$ 720,411	$ 786,389	$ 745,466	$ 714,696	$ 700,527	$ 2,914,364	$ 2,947,078	$ 3,468,858
Gross profit	364,744	340,261	311,519	328,502	353,175	332,501	332,791	296,929
Loss from continuing operations	(208,489)	(41,431)	(98,052)	(12,612)	(265,479)	(146,071)	(52,479)	(497,738)	(360,584)	(961,767)	(1,232,711)
Discontinued operations, net of tax	(10,154)	(37,984)	(7,953)	(5,961)	(26,429)	(27,134)	(8,388)	(7,751)	(62,052)	(69,702)	(802,722)
Net loss	$ (218,643)	$ (79,415)	$ (106,005)	$ (18,573)	$ (291,908)	$ (173,205)	$ (60,867)	$ (505,489)	$ (422,636)	$ (1,031,469)	$ (2,035,433)
Continuing operations, basic (in dollars per share)	$ (0.92)	$ (0.18)	$ (0.43)	$ (0.06)	$ (1.18)	$ (0.65)	$ (0.23)	$ (2.23)	$ (1.60)	$ (4.29)	$ (5.52)
Discontinued operations, basic (in dollars per share)	(0.04)	(0.17)	(0.04)	(0.02)	(0.12)	(0.12)	(0.04)	(0.03)	(0.27)	(0.32)	(3.60)
Basic (in dollars per share)	(0.96)	(0.35)	(0.47)	(0.08)	(1.30)	(0.77)	(0.27)	(2.26)	(1.87)	(4.61)	(9.12)
Continuing operations, diluted (in dollars per share)	(0.92)	(0.18)	(0.43)	(0.06)	(1.18)	(0.65)	(0.23)	(2.23)	(1.60)	(4.29)	(5.52)
Discontinued operations, diluted (in dollars per share)	(0.04)	(0.17)	(0.04)	(0.02)	(0.12)	(0.12)	(0.04)	(0.03)	(0.27)	(0.32)	(3.60)
Diluted (in dollars per share)	$ (0.96)	$ (0.35)	$ (0.47)	$ (0.08)	$ (1.30)	$ (0.77)	$ (0.27)	$ (2.26)	$ (1.87)	$ (4.61)	$ (9.12)
Weighted average shares—Basic (in shares)	226,787	226,598	226,221	224,594	224,353	224,132	223,834	223,521	226,050	223,960	223,198
Weighted average shares—Diluted (in shares)	226,787	226,598	226,221	224,594	224,353	224,132	223,834	223,521	226,050	223,960	223,198
Acquisition-related and integration items, net	$ (19,100)	$ 16,000	$ (5,500)	$ (37,500)	$ 8,600	$ 1,300	$ 5,200	$ 6,800	$ (46,098)	$ 21,914	$ 58,086
Asset impairment charges	267,400	4,800	88,400	165,400	303,500	142,200	22,800	448,400	526,082	916,939	1,154,376
Restructuring charges	19,400	11,000	2,100	2,000	4,200	4,000	29,200	49,000
Litigation-related and other contingencies, net	15,300	(14,400)	10,300		(1,600)	(1,800)	19,600	(2,500)	(11,211)	(13,809)	(185,990)
Net gain on sale of business and other assets	$ (3,300)	$ (1,900)	$ (2,500)	$ 1,300	$ (15,300)	$ (2,900)	$ (24,600)	$ (2,400)	$ 6,367	$ 45,155	$ 13,809

SCHEDULE II--Valuation and Qualifying Accounts (Details) - Valuation Allowance for Deferred Tax Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 9,877,617	$ 8,062,975	$ 4,841,209
Additions, Costs and Expenses	299,372	2,569,175	3,811,982
Deductions, Write-offs	(9,078)	(2,259)	0
Other	(338,952)	(752,274)	(590,216)
Balance at End of Period	$ 9,828,959	$ 9,877,617	$ 8,062,975

Label	Element	Value
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	$ 2,328,764,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	487,956,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	(502,929,000)
Additional Paid-in Capital [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	8,743,240,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	8,791,170,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	8,855,810,000
AOCI Attributable to Parent [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	(353,434,000)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	(209,821,000)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	$ (229,229,000)
Common Stock [Member]
Shares, Issued	us-gaap_SharesIssued	222,954,175
Shares, Issued	us-gaap_SharesIssued	223,331,706
Shares, Issued	us-gaap_SharesIssued	224,382,791
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	$ 22,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	22,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	22,000
Retained Earnings [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	(6,061,106,000)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	(8,093,463,000)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	$ (9,129,578,000)
Euro Deferred Shares [Member]
Shares, Issued	us-gaap_SharesIssued	4,000,000
Shares, Issued	us-gaap_SharesIssued	4,000,000
Shares, Issued	us-gaap_SharesIssued	4,000,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	$ 42,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	48,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	$ 46,000